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Abstract 
Multiple sclerosis (MS) is a demyelinating neurodegenerative disease that typically has a 
relapsing-remitting pattern of progression superimposed on a gradual worsening of disease 
symptoms. Experimental autoimmune encephalomyelitis (EAE) is a model of MS where animals 
develop relapses, demyelination and accumulate neurological deficits. Studies using the EAE 
model have provided evidence that cannabinoids are beneficial in reducing disease symptoms 
and may impact long term neurodegeneration, but side-effects of exogenous cannabinoid 
receptor agonists may limit their potential as therapeutic agents for MS. Targeting enzymes 
involved in degradation of endocannabinoids such as the anandamide-degrading enzyme fatty 
acid amide hydrolase (FAAH) may be an attractive alternative strategy. 
Using experimental allergic encephalomyelitis (EAE) as a mouse model of MS, two 
complementary approaches were used to assess FAAH as a potential therapeutic target. The 
FAAH deficient (ABH.FAAH-/-) developed similar paralytic relapsing disease of similar severity of 
disease compared to the wild-type, but showed a poorer recovery following the acute phase. 
However, following a relapsing-remitting disease course, the FAAH deficient mice showed a 
substantial improvement in clinical score, improved motor control, and lost less neurofilament 
compared to wild-type mice. These findings indicate that fatty acid amides may be 
neuroprotective in EAE. Secondly, a selective FAAH inhibitor (PF-3845; 10 mg/kg) was used to 
treat mice during the relapse phase of the disease course. Treatment with PF-3845 caused an 
elevation of anandamide in the CNS. This treatment resulted in a small reduction in 
neurofilament loss, but no reduction in clinical score or improvement in motor control was 
observed compared to the vehicle treated group. 
To investigate at a cellular level how FAAH might affect disease progression in the EAE 
model, immunohistochemistry was used to analyse FAAH expression in the CNS. Employing 
novel antibodies to FAAH in combination with neuronal and glial cell markers, it was found 
that, in addition to previously reported neuronal expression of FAAH, FAAH is highly expressed 
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in oligodendrocytes, but not in other glial cell types. Thus, genetic deletion or pharmacological 
inhibition of FAAH may affect both neuronal activity and oligodendroglial function (e.g. 
myelination). 
The role of FAAH in oligodendrocytes was investigated in vitro. An oligodendrocyte 
precursor cell (OPC) monoculture was used to monitor differentiation, and a co-culture 
comprising neurons and OPCs was used to monitor myelination. During the differentiation of 
OPCs, FAAH expression was detected in the entire oligodendroglia lineage, but with high 
expression only in mature myelin basic protein (MBP) expressing cells. Treatment with the 
FAAH inhibitor PF-3845 (0.1 μM to 1 µM) increased differentiation of OPCs into mature 
oligodendrocytes. However, the same treatment of co-cultures had no effect on the 
myelination of neurites. 
In conclusion, this study has: i) obtained evidence that genetic deletion of FAAH is 
neuroprotective in a mouse model of MS and ii) provided new insights on FAAH expression in 
the CNS. Further investigation of FAAH, in particular its role(s) in oligodendrocytes, will be 
required to fully unlock the therapeutic potential of FAAH inhibition in the treatment of MS. 
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Chapter 1: An introduction to MS, cannabinoids and FAAH 
1.1 Multiple Sclerosis: A neurodegenerative disease 
Multiple sclerosis (MS) is primarily an inflammatory disorder of the central nervous system 
(CNS) that leads to demyelination of axons. Inflammation causes regional blood brain barrier 
perturbations, mononuclear cell infiltration and focal demyelination (Compston and Coles, 
2008). Clinically, this presents as a relapse with unpredictable episodes of neurological 
dysfunction from which the patient usually recovers (remission) (Compston and Coles, 2002). 
This inflammatory aspect of MS can be treated with disease modifying therapy (Table 1.1), 
reducing relapse rate and potentially slowing progression of disease in relapsing-remitting MS 
(RRMS) (Cohen et al., 2010; Polman et al., 2006). Over time, the clinical features of RRMS 
disease change to a more constant disease progression, called secondary progressive MS 
(SPMS) (see Figure 1.1). Progression of SPMS disease occurs independently from processes 
causing inflammatory-mediated relapses, and intriguingly the rate of progression is largely 
unrelated to the prior frequency and severity of relapses in the previous phase of disease 
(Confavreux et al., 2000; Confavreux and Vukusic, 2006; Leray et al., 2010). However, frequency 
of relapses early in disease is associated with a poor prognosis. SPMS has many similarities to 
primary progressive MS (PPMS), a form of the disease that affects 10 – 20 % of people where 
episodes of relapse and remission are rare or non-existent, and instead present with a constant 
progressively degenerative disease from onset. SPMS and PPMS have a similar rate of clinical 
disease progression with 39 years the average age of onset, although RRMS disease may start 
about 10 years earlier (Kremenchutzky et al., 2006). Currently, no therapies exist to treat this 
progressive pathology in SPMS and PPMS (Miller and Leary, 2007), and although a number of 
candidates are in clinical trial (Table 1.2), neuroprotective therapeutics are a great unmet need. 
MS affects the ability of neurons in the brain and spinal cord to propagate action potentials 
along axons. This is primarily due to the demyelination of axons, which results in deficits in 
saltatory conduction (Compston and Coles, 2002). Demyelinated axons are left vulnerable and 
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are placed under considerable stress, which leads to degeneration of the neurons. 
Demyelination and loss of axons are the principal neuropathological correlates of the multitude 
of persistent symptoms that people with MS suffer from, which include pain, tremor, spasticity, 
cognitive abnormalities and fatigue (Compston and Coles, 2002). A number of therapies do 
exist to treat some of these symptoms; however these can be ineffective or have intolerable 
side effects in some patients.  
There is a perceived benefit from the use of cannabis by people with MS for symptom relief 
(Consroe et al., 1997), and the development of a spray formula containing Δ9-
tetrahydrocannabinol (Δ9-THC) and cannabidiol, the major psychoactive and non-psychoactive 
cannabinoids in cannabis, respectively, which has been approved for clinical treatment of 
spasticity in MS (Kavia et al., 2010). There is evidence to suggest that cannabis can elicit a 
neuroprotective effect in people with MS, and this was recently assessed in a clinical trial 
(Cannabinoids in Progressive Inflammatory brain Disease (CUPID)). Despite the clinical trial 
failing to meet the specified endpoints in all patients, there was a trend of reduced progression 
in the cohort of early stage progressive MS patients (<6 on the Expanded Disability Status 
Scale score) treated with Δ9-THC (unpublished data, Zajieck 2012). In addition, evidence from 
animal models of neurodegeneration has shown that activation of the cannabinoid receptor 
type I (CB1 receptor) has a prominent mechanistic role in neuroprotection (Marsicano et al., 
2003; Pryce et al., 2003; Croxford et al., 2008). However, because of the side effect profile of 
Δ9-THC, in particular the induced psychoactivity (Curran et al., 2002), alternative strategies for 
activation of cannabinoid receptors may need to be employed for development of 
therapeutics. One such strategy would be to elevate endogenous CB1 receptor agonists 
(endocannabinoids) such as anandamide. Thus, the aim of this research project was to 
characterise the enzyme fatty acid amide hydrolase (FAAH), which degrades anandamide, as a 
potential therapeutic target for treatment of MS. 
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Figure 1.1. Disease course of relapsing-remitting MS to secondary progressive MS. 
 
This schematic is a representation of disease course progression over time from having many 
inflammatory relapses in RRMS, to the disease becoming predominantly neurodegenerative in 
SPMS (figure modified from Compston and Coles, 2002).  
 
1.1.1 Epidemiology and Aetiology of MS 
Incidence and Prevalence of MS 
Multiple sclerosis is one of the most common neurological diseases in young adults, with a 
reported ~2.5 million people diagnosed with MS (87.7 % of global population surveyed). The 
global median estimated prevalence is 30 per 100,000 people (range of 5 – 80 / 100,000) with 
the highest prevalence in Europe (80 per 100,000) (Dua and Rompani, 2008), notably in areas 
of Scotland with ~300 per 100,000 (Visser et al., 2012). MS usually appears in young adults with 
an average age of onset of 29.2 years, at a time when people are starting or supporting a family 
and are most economically active. MS is also more common in women, with two females to 
every male affected. Of concern are the reports of increasing incidence of MS in females in 30 
year longitudinal studies and the genetic and / or environmental cause of this has not been 
identified (Orton et al., 2006; Ramagopalan et al., 2010a; Maghzi et al., 2013).  
 
Genetic risk factors 
The risk of acquiring MS is higher in relatives of a person with the disease than in the 
general population, especially in the case of siblings, parents, and children. In the case of 
monozygotic twins, concordance occurs in about 25–40% of cases, and half-siblings have a 
lower risk than full siblings, indicating a polygenic origin (Willer et al., 2003; Islam et al., 2006; 
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Compston and Coles, 2008; Handel et al., 2010). In addition to the familial studies, specific 
genes have been linked with MS. Genome-wide association studies in patients with MS have 
identified over 50 genes encoding several human leucocyte antigen (HLA) and non-HLA 
susceptibility alleles (Booth et al., 2008; Ramagopalan et al., 2010b; Gourraud et al., 2012).  
Genetic variants in the HLA group of genes on chromosome 6 confers the greatest risk of 
developing MS, with the leading candidates including HLA-DR (DRB1*1501 allele has a disease 
risk odds ratio of 5.0), HLA-A and HLA-C (Lincoln et al., 2005; Prat et al., 2005; Barcellos et al., 
2006; Caillier et al., 2008). 
The non-HLA gene variants contributing to disease susceptibility can be categorised as 
inflammatory, neurological and genes with no obviously predictable role. The inflammatory 
gene variants include interleukin 2 (IL-2) receptor, IL-7 receptor, IL-10, IL-12, tyrosine kinase 2 
(TYK2), and cell adhesion molecules (CD58 and CD226), all of which play a role in T cell 
response pathways (Hafler et al., 2007; Ban et al., 2009; Fugger et al., 2009). The neurological-
disease associated gene variants include amiloride-sensitive cation channel (ACCN1), which is a 
proton-gated acid sensing ion channel (Bernardinelli et al., 2007), and kinesin family member 
1B (KIF1B), which is involved in axonal transport of mitochondria (Aulchenko et al., 2008).  
In conclusion, whilst there is evidence of a genetic basis for susceptibility to developing MS, 
a significant proportion of susceptible individuals (with familial and / or gene variant risks) 
remain healthy while others develop MS. Therefore, environmental risk factors are thought to 
interact with genetic factors in the causation of this disease. 
 
Environmental risk factors 
Multiple epidemiological studies on the incidence and geographic location, month of birth 
and dietary intake support the role of environmental factors in susceptibility to multiple 
sclerosis. MS was found to be more common in people who live farther from the equator, with 
decreased sunlight exposure generally being linked with a higher risk of MS (Islam et al., 2006, 
2007; Vukusic et al., 2007). This has been supported by studies on the month of birth, with 
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incidence correlating to the amount of maternal UV exposure during the gestation period (in 
the Northern hemisphere, May births have higher incidence compared to November births) 
(Willer et al., 2005; Ramagopalan et al., 2011). Decreased vitamin D production and dietary 
intake has been the main biological mechanism used to explain this higher risk (Munger et al., 
2004; Ramagopalan et al., 2010c). Many MS-susceptibility genes contain Vitamin D responsive 
promoters that may control expression levels, including HLA genes, and can influence the 
thymic selection of immune cells (Ramagopalan et al., 2009a; Disanto et al., 2013). 
Studies on migrant children (<15 years old) acquiring the incidence of their destination 
(moving from low to high incidence or vice versa) suggest environmental factors may also 
trigger development of disease (Elian et al., 1990; Dean and Elian, 1997; Hammond et al., 
2000). This includes the level of UV exposure, local dietary intake (including intake of vitamin D 
(Munger et al., 2004)) and there is evidence that local viral prevalence may play a role in 
development of disease (Giovannoni et al., 2006). Development of MS is also related to 
Epstein-Barr Virus (EBV) infection, with virtually all (99.5%) patients seropositive for EBV 
specific antibodies (compared to 90 % in general population) (Lossius et al., 2012). 
Furthermore, development of EBV-induced infectious mononucleosis after the age of 15 year 
old appears to substantially increase the risk of developing MS (Sumaya et al., 1980; 
Ramagopalan et al., 2009b; Handel et al., 2010). Other infections, including viral respiratory 
tract infections (Kriesel and Sibley, 2005) and increased levels of human endogenous retroviral 
(HERV) antigens have also been shown to increase the risk of developing MS (Perron et al., 
2009).  
Cohort and case-control studies of people with MS have also identified smoking, sex 
hormones and/or oral contraceptive pills, a stressful life event and excessive exposure to 
organic solvents as environmental risk factors (Handel et al., 2010).  
Three predominant risk factors for the development of MS have been identified with 
genetic variation, deficient vitamin D exposure and EBV infections all influencing the propensity 
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to develop MS. The exposure to these factors does appear to be age-dependent, with 
gestational and childhood vitamin D deficiency, and adolescent exposure to EBV, combined 
with familial genetics giving rise to disease in a ‘causal cascade model’ as proposed by Goodin 
(2009). 
MS has traditionally been thought of as an immune-mediated disease, with the immune 
system attacking the myelin sheaths of axons. This autoimmunity model supports RRMS, with 
the episodic relapses caused by inflammatory cells transgressing the blood brain barrier and 
infiltrating the CNS as observed in MS lesions. Secondary progressive and primary progressive 
MS, however, appear to be devoid of major lymphoid cell influx, yet with axons and neurons 
progressively degenerating. This aspect of the disease does not fully fit into this traditional 
dogma. This was further challenged by a seminal study that analysed lesions of patients who 
died during a relapse (Barnett and Prineas, 2004). Key to their new hypothesis was the 
observation that oligodendrocytes die at a very early stage of lesion formation, and it was 
postulated that this may be the initial pathological event as this occurs before the development 
of notable inflammation, although these lesions were associated with a microglia response. It 
has been postulated that the inflammatory response observed in RRMS could be in response to 
degeneration of the oligodendrocytes and demyelination.  
 
1.1.2 Pathology of MS 
Inflammatory Processes in MS 
One of the major pathologic hallmarks of the disease is inflammation. The inflammatory 
processes in MS are driven by T-lymphocytes, B-lymphocytes, macrophages, activated microglia 
and gliotic astrocytes. Exactly which sub-class of T-lymphocytes drives disease, or fails to 
suppress disease is the subject of much debate. T-lymphocytes, including Th-1 and Th-17 
lymphocytes (Langrish et al., 2005; Kebir et al., 2007) and CD8+ T-lymphocytes (Friese and 
Fugger, 2009) have all been implicated to drive inflammation. The suppressive T-lymphocytes 
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have also been implicated with Th2 lymphocytes (Kappos et al., 2000) and regulatory T-cells 
(Viglietta et al., 2004) unable to control the pro-inflammatory immunity. The T-lymphocytes are 
thought to be activated by CNS antigens, leading to autoimmune-type activation that targets 
myelin in the CNS. This process activates T-lymphocytes, B lymphocytes and macrophages in 
the periphery to infiltrate the CNS, leading to subsequent disease episodes (Navikas and Link, 
1996). This proposed ‘outside in’ model has been largely supported by animal models. In 
models such as experimental allergic encephalomyelitis (EAE), the disease is driven primarily by 
CD4+ T-lymphocytes as the disease is most commonly induced by immunisation with a myelin 
antigen, in combination with an adjuvant (see Chapter 2.1.3 for a more detailed description). 
This may account for the differences observed in the inflammatory processes between MS and 
EAE models (Korn et al., 2007). Although a number of causative antigens have been proposed 
as possible candidates including, αB-crystallin, a heat shock protein secreted by 
oligodendrocytes (van Noort et al., 1995; Ousman et al., 2007) and EBV antigens (Serafini et al., 
2007; Jilek et al., 2008; Farrell et al., 2009; Peferoen et al., 2010; Angelini et al., 2013), no 
antigen has yet been convincingly shown to be the causative trigger of autoimmunity in MS. In 
addition, the episodic nature of disease seen in RRMS requires a re-activation mechanism and 
this currently remains elusive (although re-activation of EBV antigens, or possibly HERV could 
fulfil this role). This absence of detection of a causative antigen has led to the suggestion that 
MS may not be a classical autoimmune disease triggered by an aberrant antigen. Instead, the 
inflammation observed may be as a consequence of a glia-degenerative or neurodegenerative 
event, with inflammation a secondary event – an ‘inside out’ model (Trapp and Nave, 2008). 
This may account for the differences observed in the inflammatory processes between MS and 
EAE models (Korn et al., 2007). This ‘inside out’ model is supported by histopathology in post-
mortem brains, particularly in early lesion formation where few T-lymphocytes are observed, 
and invasion of the lesion with macrophages and lymphocytes is predominantly after the initial 
degeneration of the myelin (Marik et al., 2007; Geurts et al., 2009; Henderson et al., 2009). This 
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may also be supported by the observation that T-lymphocyte immunotherapies have yet to 
make significant impact on MS, with the effective therapies all targeting B-lymphocytes 
(Giovannoni, 2011). 
 
Lesion Development 
Lesions appear to continuously form and regress during the course of MS, even at the end 
stages of the disease. Within each lesion, there seems to be a passage of progression from the 
early stages to the final scar formation. These are visually different on MRI and 
histopathologically they have a changing cellular composition. Biochemical analysis has also 
revealed progressive properties in the lesions. The lesions can be characterised into the 
following four categories, generally thought to progress in this order over the ‘life-cycle’ of the 
lesion. This was extensively reviewed in two recent papers (Prineas and Parratt, 2012a; van der 
Valk and Amor, 2009) but it should be noted that different categorisations of lesions do exist. 
Pre-active Lesion: An apoptotic depletion of oligodendrocytes is observed, without the 
presence of any immune infiltration from the periphery. The myelin appears paler than usual 
on a Luxol fast blue stain (Barnett and Prineas, 2004). These lesions appear to precede the 
detection of a lesion by gadolinium-enhancing MRI, but abnormalities in the tissue are 
detectable by MRI (Miller et al., 2003). Microglia clustering is observed, with an increase in 
HLA-DR expression reflecting an activated state (De Groot et al., 2001). 
Active Lesion: These lesions are highly inflammatory with infiltrating T-lymphocytes present, 
along with an abundance of infiltrating macrophages (in a 1:10 ratio) (Lassmann et al., 1998). 
The macrophages are laden with phagocytosed myelin debris and have the morphology of 
‘foam cells’ (Brück et al., 1995). These macrophages could be either the pathological drivers of 
myelin destruction, or they could be serving as scavenger cells by phagocytising degenerated 
myelin (Barnett et al., 2006). Interestingly, complement and immunoglobulins are deposited on 
degenerating myelin (Lucchinetti et al., 2004; Barnett et al., 2009). There is also a dramatic 
reduction in the number of oligodendrocytes. 
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Chronic Active Lesion: These are large lesions with an inactive hypocellular centre, with foamy 
macrophages around the edges of the lesion. Immune infiltrates can be seen in the area 
surrounding the perivascular space. There is also a presence of CNPase-positive 
oligodendrocytes, which may be engaged in remyelination of some axons (Bramow et al., 
2010). 
Inactive Lesion: There is a complete loss of myelin and oligodendrocytes, and substantial loss 
of axons, with remaining demyelinated axons embedded in the gliotic scar. The lesion is 
hypocellular with no immune infiltrates observed, and microglia density is reduced compared 
to surrounding tissue. Astrocytes appear to infiltrate the lesion with gliosis forming a ‘scar’-like 
structure over the lesion. The surrounding white matter appears normal, with no degenerative 
activity seen at the lesion border. 
Shadow plaques: These plaques are thought to be nascent lesions where remyelination is 
evident. Oligodendrocyte precursor cells (OPC) and immature oligodendrocytes populate the 
lesion, despite the presence of myelin-containing macrophages (Chang et al., 2002; Wolswijk, 
2002a). 
 
The blood brain barrier and compartmental inflammation 
The blood brain barrier (BBB) is a functional barrier and interface that separates the 
circulatory system from CNS, thereby maintaining the CNS as an immune privileged site (Amor 
et al., 2010). Disruption and damage to permeability of the BBB is another hallmark of MS, 
particularly in RRMS where damage to this barrier is profound, as seen by gadolinium-
enhanced MRI (Gaitán et al., 2011). This allows immune cells in the periphery to infiltrate the 
CNS giving rise to the infiltrates detected in active and chronic active lesions. BBB disruption 
appears to be milder in SPMS and PPMS, but leakage of serum proteins can be detected 
(Davalos et al., 2012). However, what is interesting is that adaptive immune cells can be 
observed in the CNS when the BBB in the localised tissue is intact. This is particularly pertinent 
in disease that progresses from RRMS to SPMS, where the humoral immune cells become 
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compartmentalised behind the BBB (Lassmann et al., 2007). These inflammatory cells are 
detected as prominent aggregates in the meninges. Remarkably, these cells appear to form 
lymphoid tissue-like structures and have been observed in the deep sulci of the cortex below 
the subarachnoid space (Serafini et al., 2004; Reynolds et al., 2011a). These inflammatory 
milleu structures appear to contain follicular dendritic cells, proliferating B-lymphocytes and 
plasma cells. Pro-inflammatory cytokines (TNFα and IFNγ) have been detected in the meninges 
and CSF in post-mortem brains that contain these structures, whereas this was not detected in 
brains without the inflammatory milleu (Magliozzi et al., 2010). 
 
1.1.3 Neurodegenerative processes in MS 
Demyelination 
Demyelination is the destruction of oligodendrocyte-myelin sheaths wrapped around 
axons. The principal cells involved in demyelination are phagocytising macrophages and 
microglia, with myelin-filled phagocytes observed in lesions. It is still debated whether the 
myelin phagocytosed by macrophages is myelin debris from dead oligodendrocytes, or whether 
macrophages cause the destruction of myelin directly (Barnett et al., 2006). Oligodendrocyte 
death is central to demyelination, with numerous mechanisms causing these cells to die. These 
include oligodendrocyte directed apoptosis, direct phagocytosis, C3 and C9 complement 
deposition and subsequent lysis by mononuclear cells, cytokine toxicity from nearby 
inflammation, viral infection, CD8+ lymphocyte-mediated cytotoxicity, antibody-mediated 
cytotoxicity from localised plasma cell, oxidative injury, hypoxic injury or deficient trophic 
support (Lassmann et al., 2012; Prineas and Parratt, 2012b). Recent evidence has shown that 
oligodendrocyte death, and the release of myelin antigens, fails to trigger CNS autoimmunity. 
This is despite the uptake of myelin debris by macrophages and myelin debris in the draining 
lymph nodes (Locatelli et al., 2012; Oluich et al., 2012). This again demonstrates how elusive 
the autoimmune antigen trigger is (“outside in” dogma), and how the initial neurodegenerative 
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event is still unidentified (“inside out” dogma). It has been suggested that a heterogeneity 
exists in MS lesions, and no single trigger or event may account for all the MS lesions observed, 
in a similar manner to the complex aetiology of the disease (Lucchinetti et al., 2000). 
Demyelination and the loss of oligodendrocytes are associated with damage to axons and 
loss of both axons and neurons. This neurodegeneration is another hallmark of MS (Trapp et 
al., 1998), and is seen in RRMS, SPMS and PPMS in both in the white and grey matter. 
 
White matter and grey matter atrophy 
MS has classically been called a white matter disease, with focal lesions most commonly 
involving white matter areas close to the ventricles of the cerebellum, brain stem, basal ganglia 
and spinal cord; and the optic nerve. These lesions are visible using conventional magnetic 
resonance imaging (MRI). The extent of axon loss in these lesions is correlated with the number 
of infiltrating inflammatory cells and activated microglia (Trapp et al., 1998; Kornek et al., 2000; 
Bjartmar et al., 2003). 
More recently, histopathological analysis of the grey matter has revealed significant 
demyelination in the cerebral cortex and spinal cord, and also in the cerebellar cortex and in 
the sulci of the deep grey matter (Bø et al., 2003; Gilmore et al., 2009). This demyelination is 
also associated with the loss of neurons, in the relative absence of immune infiltrates, although 
some T-lymphocytes are found in these lesions. Meningeal inflammation and the presence of 
B-lymphocyte follicles appear to contribute substantially to the degeneration of deep grey 
matter. This may be due to the density of cortical neurons, such as pyramidal cells, located in 
close proximity to the meningeal / subarachnoid space, and therefore exposed to the pro-
inflammatory cytokines and inflammatory cells originating from the inflammatory germinal 
follicles. The accumulation of lesions and atrophy of the grey matter, and the presence of B-
lymphocyte follicle-like germinal centres is correlated with the rate of clinical course in SPMS 
and PPMS (Howell et al., 2011; Reynolds et al., 2011b; Choi et al., 2012). 
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Normal appearing white matter (NAWM), as defined by conventional MRI, is the tissue 
surrounding the lesions. Changes in the NAWM are observed with histopathological 
techniques, and these include diffuse damage to axons and loss of neurons, activated microglia, 
diffuse astrocytic gliosis, and changes in myelination with altered Nodes of Ranvier and 
remyelination (Allen et al., 2001; Howell et al., 2010; Magliozzi et al., 2010).  
 
Mechanisms of axon loss and neuronal degeneration 
It is well documented that axon damage and loss of axons and neurons leads to the clinical 
deficit in all forms of MS. The cause and mechanisms of how the axons are injured and 
subsequently die are still being characterised. In an inflammatory active lesion many toxic 
molecules, including cytokines and reactive oxygen species, are released and this can cause 
bystander injury to axons. Substantial axonal transection and Wallerian degeneration is 
observed in active and chronic active lesions (Trapp et al., 1998).  
The chronic demyelination of axons also has a detrimental impact on axons, as seen in 
chronic inactive lesions (Kornek et al., 2000). Demyelination affects several pathways in the 
functionality of the axon that can lead to axonal vulnerability and death. The loss of trophic 
support provided by oligodendrocytes further contributes to axonal degeneration. These 
hypotheses come from transgenic mice with deficient myelin proteins (myelin-associated 
glycoprotein or 2′,3′-cyclic nucleotide 3′-phosphodiesterase) that produce compact, normal 
myelin structures, but the animals develop late age-dependent axonal degeneration. Therefore, 
removal of myelin and loss of supporting oligodendrocytes for considerable periods of time 
may also result in axonal degeneration in MS (Nave and Trapp, 2008). 
One of the principal roles of the myelin sheath is to facilitate saltatory conduction and help 
the axon conserve energy. An energy crisis is one of the prominent hypotheses contributing to 
the failure of axonal function and axonal death. This process also occurs via a number of 
interrelated pathways including increased energy demand to maintain polarisation required for 
axonal firing, in an environment that fosters dysfunctional mitochondria. A demyelinated axon 
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is unable to sustain saltatory conduction and to compensate there is an increase expression of 
voltage-gated sodium channels (particularly Nav1.2 and Nav1.6) on the axon and this is evident 
in MS lesions (Craner et al., 2004). This allows propagation of action potentials, but in an 
inefficient non-saltatory manner thus creating a higher demand for ATP. This creates a situation 
where an excessively high intracellular Na+ concentration and loss of ATP-dependant Na+ / Ca2+ 
exchanger function can cause an influx of Ca2+. This Ca2+ ion overload can then disrupt 
mitochondrial function and trigger apoptosis pathways (Dutta et al., 2006). 
Mitochondria dysfunctions appear to play a central role in axonal degeneration, 
particularly with the heightened demand for energy (Dutta et al., 2006; Mahad et al., 2009). 
Within an inflammatory lesion nitric oxide (NO) is elevated and with peroxynitrite (derivative of 
NO) can cause potent inhibition of complex IV of the respiratory chain (Smith et al., 2001a). 
Furthermore, prolonged exposure to NO and other reactive oxygen species generated by 
inflammatory cells has been shown to cause deletions in mitochondrial DNA in MS tissue. This 
is proposed to have an adverse effect on mitochondrial respiration, further contributing to an 
energy failure in the axon (Mahad et al., 2009; Campbell et al., 2012).  
In a neural circuitry depleted of axons, compensation by the remaining neurons is required 
with an increase in signalling activity. This can lead to excessive excitatory signalling, releasing 
excessive glutamate from the synapse into the extracellular space. The uptake of glutamate by 
astrocytes is ATP-dependent, and in an energy-deficient environment this mechanism fails, 
leading to elevated extracellular glutamate. Excessive glutamate is toxic to both axons and 
oligodendrocytes, inducing a cascade of signalling that releases Ca2+ from intracellular stores, 
which in turn can trigger apoptotic pathways in the neuron (Trapp and Nave, 2008). Elevated 
glutamate can be detected in lesions and NAWM by MRI (Srinivasan et al., 2005), and 
treatment with glutamate receptor antagonists reduce oligodendrocyte death and reduce 
axonal injury (Pitt et al., 2000a). Furthermore, excitatory glutamate signalling can be reduced 
indirectly by activation of the cannabinoid-type I receptor (CB1 receptor). This G protein-
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coupled receptor located on the pre-synaptic side of the synapse, initiates a signalling pathway 
that attenuates the release of glutamate (Pitt et al., 2000b; Wilson and Nicoll, 2001). This can 
be activated by an exogenous agonist (e.g. Δ9-THC), or by an endogenous endocannabinoid in a 
retrograde signalling feedback system. 
 
1.1.4 Experimental autoimmune encephalomyelitis as a disease model of MS 
The development of experimental autoimmune encephalomyelitis (EAE) was first 
discovered from observations of patients succumbing to symptoms of a neurological disease 
following a rabies vaccination (Baxter, 2007). The rabies vaccine was prepared in a rabbit spinal 
cord emulsion, and these were used to immunise humans against rabies virus. This occurred in 
1885 to 1887, and resulted in some patients developed early paralysis, followed by recovery, 
with some of the extreme cases developing further paralysis and eventually death. 
Pathologically, these cases were characterised by lymphocyte infiltrates and demyelination, 
distinct from the histology of rabies. This pathology was replicated using animal models, with 
the finding that the spinal cord emulsion (and not the rabies) was the cause of the 
encephalomyelitis, and hence the EAE model was established.  
The EAE disease in a mouse resembles many of the characteristics of MS from a 
pathological view. Axons in the CNS are demyelinated with multiple lesions, particularly in the 
spinal cord. The lesions progress from inflammatory foci, with considerable demyelination to 
form an astrocytic sclerotic plaque (Amor et al., 2005; Steinman and Zamvil, 2006). The EAE 
model has been used extensively to gain understanding of MS pathology, but it may also have 
overtly influenced the field to view MS as a CNS antigen-induced T-lymphocyte mediated 
inflammatory disease. The EAE model was instrumental in the pre-clinical development of 
disease modifying therapies including glatiramer acetate, mitoxantrone and natalizumab (Baker 
et al., 2011), despite all the criticism the model receives (Vesterinen et al., 2010).  
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Chronic Remitting EAE as a neurodegenerative model of MS 
Developing an experimental model of Multiple Sclerosis is a challenging task. This is 
because the disease has two interrelated pathologies with inflammatory and 
neurodegenerative components. In addition, the disease is multifocal and multiphasic in 
nature. The disease mechanisms of MS have been modelled in the experimental allergic 
encephalomyelitis (EAE) animal model. However, the pathogenesis of EAE varies dramatically 
depending on the species and strain of selected animal, and the choice of immunogen (van der 
Star et al., 2012a). An increasing majority of EAE studies are being performed on the C57BL/6 
mouse strain using the myelin oligodendrocyte glycoprotein peptide (MOG35-55) as the 
immunogen; this is because this genetic background is often used for transgenesis. Disease in 
this strain of mouse exhibits a severe inflammatory attack followed by a poor recovery 
(remission) due to nerve loss and often exhibits a highly variable disease course (Axtell et al., 
2010; Coquet et al., 2013). This may be reflective of a relatively EAE resistant genetic 
background and it was thought that C57BL/6 were not susceptible to EAE induction until it was 
found that they are susceptible to disease induction with MOG35-55 peptide (Mendel et al., 
1999). The model is limited to a chronic, monophasic disease, and this makes it difficult to 
dissociate neuroprotective versus immunological effects. 
The key clinical hallmarks of neurodegeneration observed in MS following repeated 
relapses, and in secondary progressive MS, include a multiphasic disease with progressive 
disability following each relapse and remission (Compston and Coles, 2008; Ferguson et al., 
1997; Trapp and Stys, 2009). The pathological hallmarks include multifocal and chronic 
demyelinated lesions, gliosis, limited remyelination and neurodegeneration including loss of 
axons and neuronal atrophy. Chronic models of EAE in rats (Kornek et al., 2000; Papadopoulos 
et al., 2006) and in mice (Baker et al., 1990; Wujek et al., 2002; Pryce et al., 2005; Hampton et 
al., 2008) provide some of the behavioural and histological features observed in progressive 
disease. 
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Figure 1.2. Representative disease course of CREAE in ABH mice. 
 
 
ABH mice were injected with spinal cord homogenate in complete Freund’s adjuvant on day 0 
and 7 (open inverse triangles) to induce an Acute Phase and again on day 28 to induce a 
Relapse Phase. The mean clinical score ± SEM is monitored daily; RotaRod is measured pre-
immunisation, Remission 1 and Remission 2. The neurofilament content of the spinal cord is 
removed and assayed on Remission 2 (Day 50). This image is modified from Al-Iziki et al. (2012). 
 
Induction of EAE in the Biozzi ABH mouse with spinal cord homogenate results in an 
inflammatory Acute Phase; with paralysis and weight loss (see Figure 1.2 for a schematic of the 
typical disease course). This is followed by a near full recovery (Remission 1) of motor function 
and weight. This phase is largely inflammatory with immune infiltration and animals 
accumulate limited demyelination and nerve loss (Baker et al., 1990; Al-Izki et al., 2012). Whilst 
in this strain relapses occur spontaneously (Baker et al., 1990), the induction of relapse with a 
further injection of antigen in adjuvant induces a more consistent relapse onset and the 
accumulation of nerve loss and an increase in residual motor control deficit during Remission 2 
(Al-Izki et al., 2012). 
The utilisation of spinal cord homogenate as the immunogen immunises against multiple 
CNS antigens. In MS the initiating auto-antigen is still unknown, and due to the inflammatory 
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attack and release of multiple antigens, epitope spreading is prevalent. Therefore, 
immunisation with a wide repertoire of antigens is a robust approach. Experimentally, this 
immunogen has been shown to generate a reproducible induction and clinical course of EAE 
over many years (Baker et al., 1990; Jackson et al., 2009; Al-Izki et al., 2012). The dominant 
immune response has been to the epitope proteolipid protein PLP 56-70 (Pryce et al., 2005). 
However, using this peptide alone in immunisations induces inconsistent disease (Smith et al., 
2005). As observed in MS, epitope spreading was evident in EAE with additional populations of 
reactive T-lymphocytes identified (Davies et al., 2005). 
The initial immunisations induce a CD4+ T-lymphocyte mediated inflammatory attack 
targeting CNS antigens. This inflammation is evident in the change in the behaviour of the 
animal with the onset of paralysis. The severity of the paralysis is correlated with the kinetics of 
leucocyte cell infiltration into the spinal cord (Allen et al., 1993). The accumulation of 
leucocytes was observed to be 8-fold higher during the peak of paralysis in both the acute 
phase and relapse phase. This infiltration resolves to near normal levels as the mice recover at 
remission. The majority of these cells were CD4+ T-lymphocytes and macrophages, with a small 
increase in B-lymphocytes and neutrophils (Allen et al., 1993). 
The relapse immunisation induces a primed adaptive immune response. This includes 
effector CD4+ lymphocytes that drive relapsing disease (Pryce et al., 2005), whilst CD8+ 
lymphocytes form a minor part of the immune infiltrate in the CNS. CD8+ T-lymphocyte 
depletion does not alter the disease course (O’Neill et al., 1993) and there is a limited B-
lymphocyte and antibody response (Allen et al., 1993; Morris-Downes et al., 2002). Relapses 
are also associated with blood brain barrier (BBB) dysfunction and infiltration of mononuclear 
cells (Baker et al., 1990; Butter et al., 1991; Allen et al., 1993; Al-Izki et al., 2012). Activated 
microglia and macrophages (with evidence of myelin phagocytosis) are also seen at the edges 
of lesions (Pryce et al., 2003, 2005). Following each relapse increasing demyelination, 
hypercellular lesions with gliosis and neurodegeneration are observed. The severity of the 
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inflammation is also important as it is correlated with the extent of demyelination (Bjartmar et 
al., 2000, 2003; Wujek et al., 2002). Demyelination leaves the axons vulnerable to excitotoxicity 
and exposure to free radicals (Smith et al., 2001b). The neurodegeneration is observed as loss 
of axons and depletion of neurofilaments (Petzold et al., 2003; Pryce et al., 2003; Croxford et 
al., 2008; Hampton et al., 2008; Anderson et al., 2008; Gnanapavan et al., 2012). Quantitation 
of the loss of axons correlates with the behaviour observed in CREAE and to that observed in 
human clinical cases. A loss of 10-20 % axonal content is undetectable with the behavioural 
scoring scale in EAE in SJL/J mice (Wujek et al., 2002), but minor motor deficits in Biozzi ABH 
mice can be detectable using open field activity chambers (Pryce et al., 2003) and RotaRod 
assays (Al-Izki et al., 2012). A 20 - 30 % axon loss in the spinal cord leaves the mice with 
permanent motor disability, and 40 – 60 % axon loss results in complete hind limb paralysis 
(Jackson et al., 2005a; Petzold et al., 2003; Pryce et al., 2003; Wujek et al., 2002). This loss of 
axons is broadly consistent with clinical and pathological analysis of relapsing remitting and 
secondary progressive MS patients (Kornek et al., 2000; Bjartmar et al., 2003). 
The CREAE mouse model, using the Biozzi ABH mouse strain with spinal cord homogenate 
as the immunogen, is a well-characterised animal model. The model is multiphasic, has 
pathological hallmarks of CNS lesions and represents the inflammatory and neurodegenerative 
processes of relapsing remitting MS. This can be used to dissociate immunosuppressive from 
neuroprotective effects of agents (Al-Izki et al., 2011, 2012) and therefore is an excellent model 
for the purposes of this study; to understand the influence of FAAH deficiency in inflammatory 
and, more importantly, neurodegenerative disease. 
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1.1.5 Treatment for MS is a multifactorial strategy 
A multitude of different drugs are licenced for the treatment of MS, which is a reflection of 
the complexity and multifactorial nature of the disease. Drugs are required to treat the acute 
relapse, the numerous symptoms arising from the neurological dysfunction and therapies now 
exist that alter the course of the disease. However, no licenced therapies currently exist that 
reduce the neurodegeneration in SPMS and PPMS, or contribute to the repair process in the 
early stages of disease. 
 
Management of acute relapses 
During episodes of relapse, administration of high doses of intravenous corticosteroids, 
such as methylprednisolone, prednisolone and dexamethasone, is the routine therapy for acute 
relapses (Dua and Rompani, 2008). The aim of this kind of treatment is to end the attack sooner 
and leave fewer lasting deficits in the patient. Although generally effective in the short term for 
relieving symptoms, long term use of corticosteroid treatments do not appear to have a 
significant impact on disease progression in the long-term (Ciccone et al., 2008). 
 
Treatment of neurological symptoms 
A patient with MS can suffer from neurological symptoms, with the most common 
presenting symptom being muscle weakness, dysfunction and / or spasticity, which is seen in 
over 50 % of patients. Sensory problems including changes in sensation and fatigue are 
common in 40 % of patients (Dua and Rompani, 2008). Numerous additional symptoms include 
difficulties with coordination and balance (ataxia); problems in speech or swallowing, visual 
problems (including optic neuritis), pain, and bladder and bowel difficulties. Cognitive 
impairment of varying degrees and emotional symptoms of depression or unstable mood are 
also common. Numerous licenced and off-label drugs are used to manage this plethora of 
symptoms (Compston and Coles, 2008; Thompson et al., 2010). 
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Disease modifying therapies 
To date, eight disease-modifying treatments (DMT) have been approved by regulatory 
agencies in Europe and North America for relapsing-remitting MS. The first DMT approved was 
interferon β-1b in 1993. Shortly after this, interferon β-1a was licenced in two different 
formulations; one for subcutaneous and the other for intramuscular administration. The fourth 
medication was glatiramer acetate, a random polymer of amino acids derived from myelin 
basic protein that acts as an immunomodulator. These first line treatments are effective in 
reducing relapse rate by approximately 30 %, but with marked variation in efficacy in different 
individuals due to the development of neutralising antibodies against interferon-β  and poor 
compliance due to the injectable route of administration (Farrell and Giovannoni, 2010; Creeke 
and Farrell, 2013). 
Natalizumab (Tysabri) is a monoclonal antibody drug that reduces infiltration of 
inflammatory cells across the BBB, was the fifth DMT to be licenced. This therapy was very 
effective in reducing relapse rate by 68 %, however this potent treatment was also associated 
with an increase in progressive multifocal leucoencephalopathy (PML) caused by infection of 
the brain with JC virus. This resulted in the death of about 23 % of people developing PML and 
was temporarily withdrawn from the clinic (Lindå et al., 2009; Ali et al., 2013). The risk of PML 
in JC sero-negative patients is about 1 in 14,000, but increases to about 1 in 94 in JC virus 
positive individuals treated for 2 years or more with prior exposure to immunosuppressive 
drugs. 
Fingolimod (Gilenya) was the first orally administered DMT for MS, approved for use as a 
second line treatment. The mode of action modulates sphingosine-1-phosphate receptors and 
this prevents chemotactic signalling in T- and B-lymphocytes, causing the cells to remain in the 
lymphoid tissue. This potent immunosuppressive therapy reduces relapse rate by 86 % in 
combination with a first line interferon-β therapy (Cohen et al., 2010; Kappos et al., 2010), and 
has been further investigated in animal models for both neuroprotection, with negative results 
31 
(Al-Izki et al., 2011), and in vitro remyelination properties with mixed results (Miron et al., 
2010; Jackson et al., 2011; Hu et al., 2011). 
Teriflunomide (Aubagio) was the second orally administrated DMT approved for first line 
treatment of RRMS (previously used in treatment of rheumatoid arthritis). The drug targets 
proliferating lymphocytes, thereby reducing the T-lymphocyte mediated inflammation (Ali et 
al., 2013). 
Recently in 2013, dimethyl fumarate (BG-12), another oral drug was approved for first line 
therapy in RRMS (previously used for treatment of psoriasis), with a comparable efficacy to 
fingolimod, but a reduced side effect risk (Gold et al., 2012). The mechanism of action is poorly 
understood, but appears to target T-lymphocytes by shifting the CD4+ cells towards a Th2 
lymphocyte phenotype. Neuroprotective effects have also been proposed by reducing oxidative 
stress via the nuclear factor like-2 activator (Nrf-2) anti-oxidant pathway (Ali et al., 2013). 
 
Table 1.1. Therapeutic drugs licenced for the treatment of relapsing-remitting MS 
Therapeutic         Date of Approval  Mechanism of Action 
Interferon beta-1b 1993    Anti-inflammatory cytokine 
Interferon beta-1a 1994    Anti-inflammatory cytokine 
Glatiramer acetate 1996    Random amino acid polymer 
Natalizumab  2004    α4-integrin adhesion molecule inhibitor  
Fingolimod  2010    Sphingosine-1-phosphate receptor modulator 
Teriflunomide  2012    Pyrimidine synthesis inhibitor 
Dimethyl fumarate 2013    Nuclear factor (erythroid-derived 2)-like 2 activator 
Drugs approved by the FDA and EMEA for the treatment of relapsing-remitting MS (RRMS) in 
the US and Europe (Ali et al., 2013). 
 
To date, all of the approved therapies for use in MS appear to act through 
immunosuppressive or anti-inflammatory pathways and thus are effective in reducing the rate 
of relapse in RRMS. However, no therapies have shown efficacy in reducing the rate of 
progressive neurodegeneration in SPMS or PPMS. The more recent therapies are highly 
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effective at reducing relapse rate and it will be interesting to see if these reductions in 
inflammatory events will positively impact the disease overtime, particularly the slowing or 
preventing subsequent development of SPMS. There is a number of therapeutics in clinical trial 
for SPMS and PPMS (Table 1.2) with primary endpoints measuring relative neurodegeneration 
(e.g. brain atrophy, new T2-weighted lesions on MRI) or clinical disease progression (e.g. 
Kurtzke's Expanded Disability Status Scale (EDSS)). Clearly more neuroprotective therapeutics 
are needed to treat SPMS and PPMS.  
 
Table 1.2. Therapeutic drugs in clinical trial for the treatment of secondary progressive 
and primary progressive MS. 
___________________________________________________________________________ 
Therapeutic          MS Sub-type  Clinical Trial Phase 
Lipoic Acid      SPMS   Phase 2 
RTL1000 (Recombinant T Cell Receptor Ligand)  SPMS   Phase 1 
Sunphenon EGCg (Epigallocatechin-Gallat)  SPMS & PPMS  Phase 2 
Fingolimod      PPMS   Phase 3 
Siponimod      SPMS   Phase 3 
BAF312       SPMS   Phase 3 
Simvastatin      SPMS   Phase 2 
Idebenone      PPMS   Phase 1 
Tcelna        SPMS   Phase 2 
Natalizumab      SPMS & PPMS  Phase 3 
Ocrelizumab      PPMS   Phase 3 
Hydroxyurea      PPMS   Phase 2 
Masitinib      SPMS & PPMS  Phase 2 
Amiloride      SPMS   Phase 2 
Riluzole       SPMS   Phase 2 
Ibundilast      SPMS   Phase 2 
Oxcarbazipine      SPMS   Phase 2 
 
Drugs in clinical trial for secondary progressive MS (SPMS) and primary progressive MS (PPMS). 
Data extracted from ClinicalTrials.gov, from within disease category ‘Multiple Sclerosis, Chronic 
Progressive’ with neuroprotection primary endpoints of. Data updated May 2013. 
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1.1.6 The use of cannabis as therapeutic strategy 
There is a prevalence of smoking the drug cannabis to alleviate symptoms in people with 
MS, and there is evidence to suggest that cannabis can control and relieve spasticity and 
spasms, tremor and pain, caused by MS (Kmietowicz, 2010; Zajicek and Apostu, 2011; Corey-
Bloom et al., 2012; Zajicek et al., 2012). To seek a scientific basis for these earlier reports in 
animals (Baker et al., 2000) reports a multicentre randomised placebo controlled trial was 
conducted in the UK in 2003 (Zajicek et al., 2003). Patients (n = 667) were treated with an orally 
administrated extract of Cannabis sativa, ∆9-THC or placebo, administered over a period of 15 
weeks. The outcomes of spasticity were measured primarily using the Ashworth scale and 
patient opinion. There was no significant improvement with either the C. sativa extract or ∆9-
THC compared to placebo using the Ashworth scoring, possibly due to the insensitivity and 
subjectivity of the Ashworth Scale as an output measurement. However, patients treated with 
either formulation improved in mobility (using a timed walk test) and reported a reduction in 
pain. Furthermore, at twelve month follow-up there was potential benefit seen in people taking 
Δ9-THC as assessed using the Ashworth scale (Zajicek et al., 2005) and this formed the basis for 
the CUPID study to investigate the neuroprotective effect of THC. The CUPID trial tested the 
efficacy of Δ9-THC (compared with placebo) on reducing disease progression in primary 
progressive MS. The trial was a 3 year long trial and recently completed with results indicating 
that Δ9-THC treatment failed to meet the endpoints of slowing disease progression (Expanded 
Disability Status Scale (EDSS), and the Multiple Sclerosis Impact Scale). However, patients with 
lower disability scores (< 6 EDSS score) showed a significant reduction in disease progression 
following treatment (P = 0.00014, ICRS2012 conference abstract, Zajicek, 2012) indicating that 
treating PPMS earlier may hold more benefit. These results may also be a reflection of the non-
linearity of the EDSS particularly in scores greater than 6 on the EDSS scale (online press release 
2013, John Zajicek, Plymouth University). 
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One of the more recent therapies for the management of spasticity is the oral spray 
formulation nabiximols (Sativex) containing ∆9-THC and cannabidiol. It has been approved for 
treatment of spasticity in MS (Kavia et al., 2010) and has been shown to be effective in reducing 
pain and spasticity in people with MS. 
 
Adverse effects of Cannabis use 
The use of cannabinoids for treatment is known to have adverse side effects. These include 
changes in perception (psychosis, blurred vision, visual hallucinations, tinnitus, disorientation, 
confusion and dissociation) (Martín-Sánchez et al., 2009), dysphoria and changes in motor co-
ordination and memory disorders (Wang et al., 2008). There is also concern that individuals 
requiring long-term treatment with cannabinoids may have an increased the risk of developing 
mental illness, such as schizophrenia and psychosis (Rice, 2008). 
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1.2 The Cannabinoid System 
1.2.1 Discovery of the cannabinoid system 
The cannabinoid system was discovered following the identification of Δ9-THC as the active 
compound in Cannabis sativa responsible for the psychoactive effects of cannabis observed in 
humans and animal models (Gaoni and Mechoulam, 1964; Mechoulam et al., 1970). The 
production of highly active synthetic cannabinoid compounds led to the realisation that 
cannabinoid effects were mediated by receptors and the first one to be discovered was the CB1 
receptor (Devane et al., 1988), followed by the molecular cloning of the Cnr1 gene (Matsuda et 
al., 1990). The CB2 receptor was identified based on significant amino acid sequence homology 
(44 %) shared with CB1 receptor (Munro et al., 1993). The CB2 receptor is found to be 
predominantly expressed on immune system cells, in contrast to the CB1 receptor that is highly 
expressed in neurons. 
 
1.2.1 The cannabinoid receptor 1 (CB1) 
Neuroanatomical distribution of the CB1 receptor 
The CB1 receptor is highly expressed in the mature brain and widely distributed (Howlett et 
al., 2002). The receptor is located in neurons, and at comparable levels to that seen for other 
neurotransmitter receptors including glutamate, GABAergic and dopamine receptors 
(Herkenham et al., 1990, 1991). Higher resolution immunogold staining with electron 
microscopy showed the CB1 receptors located on the pre-synaptic terminal of axons (Katona et 
al., 1999; Nyíri et al., 2005). The receptors are found in the synaptic terminals of GABAergic, 
glutamatergic, cholinergic, noradrenergic and serotonergic axons (Katona and Freund, 2008). 
The CB1 receptor is expressed at a high level in both the central nervous system and in the 
periphery. It is the most abundant G protein-coupled receptors in the brain, and located in the 
basal ganglia, neocortex, hippocampus, hypothalamus and cerebellum (Herkenham et al., 1990; 
Egertová et al., 1998; Tsou et al., 1998a; Egertová and Elphick, 2000). Analysis of the 
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distribution of the CB1 receptor in the spinal cord using immunostaining methods revealed 
prominent expression in the dorsal lateral funiculus, the superficial dorsal horn and lamina X 
(surrounding the central canal) (Farquhar-Smith et al., 2000) . Most of the staining appeared to 
be on interneurons, in fibers and axon terminals. Significant expression has also been detected 
on the dorsal root ganglion (DRG) neurons by immuno-staining and in situ hybridisation 
(Bridges et al., 2003; Agarwal et al., 2007; Hohmann and Herkenham, 1999). The distribution is 
functionally relevant, with CB1 receptor agonists inducing effects on behaviour that can be 
correlated with neuroanatomical expression. For example, high expression in the basal ganglia 
and cerebellum probably accounts for the decrease in motor control initiation and co-
ordination observed in rats treated with Δ9-THC (Herkenham et al., 1991). Many of the 
functional roles of the CB1 receptor were discovered through the genetic deletion of the gene 
in the mouse (Zimmer et al., 1999) and by the use of specific antagonists, in particular with 
SR141716 (Rimonabant) (Rinaldi-Carmona et al., 1994; Pertwee, 2009). 
There is also evidence that the CB1 receptor can be regulated by the cannabinoid receptor 
interacting protein 1a (CRIP1a) (Niehaus et al., 2007) although this is controversial (Saul, 2012). 
Activation of the CB1 receptor induces a tonic inhibition of voltage-gated Ca2+ channels, with 
this mechanism proposed to reduce glutamate excitotoxicity. In a primary cortical neuron 
neurotoxicity assay, the CB1 receptor agonist WIN55,212-2 was shown to be protective, with 
overexpression of CRIP1a suppressing this CB1 receptor activity (Stauffer et al., 2011). However, 
the functional activity of CRIP1a has not yet been determined in vivo. 
 
Expression pattern of CB1 receptor is altered in disease 
The distribution of the CB1 receptor in an EAE model reported a decrease in CB1 levels in 
specific regions of the brain (Berrendero et al., 2001). These included the basal ganglia (lateral 
caudate-putamen) and to a lesser extent the cerebral cortex (deep and superficial layers), 
whilst other regions of the brain were unchanged. Brain tissue was dissected at the peak of the 
acute phase / relapse 1 (13 days post-induction), reflecting an auto-inflammatory disease state. 
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A further study found a similar decrease in CB1 expression as the disease progressed. 
Endocannabinoid levels were also monitored and a decrease in the levels of AEA and 2-AG was 
found in the striatum and the mid-brain, motor function-related areas of the brain. The animals 
were also treated with Rolipram, a type IV phosphodiesterase (PDE4) that has anti-
inflammatory properties and capable of reducing and slowing development of EAE disability. 
This treatment also prevented the decrease in CB1 receptor expression in the basal ganglia 
compared to EAE rats un-treated with Rolipram (Cabranes et al., 2005), indicating a responsive 
activity of the CB1 receptor to the disease state. 
 
1.2.3 Discovery of the endocannabinoids anandamide and 2-AG 
The discovery of a receptor system responsive to an exogenous agonist (Δ9-THC), lead to 
the pursuit of the existence of endogenous ligands. It was predicted from the lipophilic nature 
of the Δ9-THC that the putative ‘endocannabinoids’ would be found in the lipid-soluble 
fractions of the brain. This lead to the discovery of N-arachidonoylethanolamine, which was 
also named anandamide due to the ‘inner bliss‘ (ananda in Sanskrit) reflecting the “high” 
experience elicited by cannabis. Anandamide is a partial agonist for CB1 and CB2 receptors, and 
found to have a relatively low concentration in brain tissue (pmol / g tissue) (Devane et al., 
1992; Pertwee et al., 2010). A second endocannabinoid, 2-arachidonoylglycerol (2-AG), was 
identified and discovered to be a low affinity, full agonist of the cannabinoid receptors 
(Mechoulam et al., 1995; Sugiura et al., 1995). This molecule also produces cannabimimetic 
effects in animal models, comparable to the effects elicited by Δ9-THC (Mechoulam et al., 
1995). 2-AG is found at much higher concentrations (μmol / g tissue) in the brain compared to 
anandamide (Stella et al., 1997). 
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Enzymatic control of endocannabinoid biosynthesis and degradation 
The key endogenous ligands for CB1 receptor are anandamide and 2-AG, and the 
biosynthesis and degradation of these messenger molecules are tightly controlled by substrate 
specific enzymes. 
Biosynthesis of both endocannabinoids is from de novo phospholipid precursors in the 
cellular membrane in an activity-dependent manner. Endocannabinoids do not appear to be 
stored and this ‘on-demand’ synthesis is somewhat unique for signalling molecules (Alger and 
Kim, 2011). The biosynthetic pathway for 2-AG is mediated by the α and β isoforms of 
diacylglycerol lipase (DAGLα and DAGLβ) (Bisogno et al., 2003), with the cleavage of the 
precursor 1,2-diacylglycerol (DAG). Genetic deletion of DAG lipases in mice has shown that 
DAGLα has the primary role of 2-AG biosynthesis in the brain, while DAGLβ generates 2-AG in 
peripheral tissues, particularly in the liver (Gao et al., 2010; Tanimura et al., 2010). 
The pathway of anandamide synthesis appears to be more diverse than the 2-AG / DAGL 
relationship, and is there is certainly less clarity on the actual biosynthetic pathway. A number 
of proposed pathways are detailed below, with data suggesting that anandamide is generated 
through a number of independent pathways.  
NAPE-PLD: Evidence suggests that N-acyl phosphatidylethanolamines (NAPE) are the key 
metabolic precursor to anandamide, catalysed by the NAPE-phospholipase D enzyme (NAPE-
PLD). The enzyme is activated by calcium, is specific to NAPE substrate and was shown to 
catalyse formation of anandamide in vitro (Okamoto et al., 2004). However, generation of 
NAPE-PLD knockout mice revealed no significant difference in brain anandamide content 
compared to wild-type mice (Leung et al., 2006), and therefore the contribution of NAPE-PLD to 
anandamide biosynthesis in the brain remains unclear. 
GDE1 and ABHD4: A second potential biosynthetic pathway was discovered by analysis of 
brain tissue from NAPE-PLD deficient mice. Glycerophosphodiesterase 1 (GDE1), a 
phosphodiesterase highly expressed in the CNS, was shown to generate anandamide from 
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glycerophospho-N-arachidonoylethanolamine (GP-anandamide) (Simon and Cravatt, 2008). A 
proteomic screen identified a serine hydrolase, α/β-hydrolase 4 (ABHD4), that generates GP-
anandamide from NAPE, providing an alternative 2-step pathway for anandamide synthesis in 
NAPE-PLD deficient mice (Simon and Cravatt, 2006). However, mice deficient in GDE1 showed 
no change in the basal level of anandamide in the brain (Simon and Cravatt, 2010a). Therefore, 
as with NAPE-PLD, the contribution of the GDE1-ABHD4 pathway to anandamide biosynthesis 
in the brain remains unclear. 
Lyso-PLD: A third proposed pathway for anandamide generation involves hydrolysis of 
lyso-NAPE by lyso-phospholipase D enzyme. Lyso-NAPE is generated from NAPE, by either 
phospholipase A2 or ABHD4, therefore providing another 2-step alternative pathway (Sun et 
al., 2004).  
PTPN22 and SHIP: Anandamide can be generated from phospho-anandamide by either the 
tyrosine phosphatase PTPN22 or inositol 5’-phosphatase (SHIP). Phospho-anandamide is 
generated from NAPE by phospholipase C (PLC)-like (PLC), providing another 2-step pathway 
for generating anandamide (Liu et al., 2006, 2008). 
Genetic deletion of these respective enzymes including NAPE-PLD-/- (Leung et al., 2006), 
GDE1-/- (Simon and Cravatt, 2010a), PTPN22-/- (Liu et al., 2008) does not appear to alter the 
basal level of anandamide in brain homogenates of these respective transgenic mice. 
Furthermore, the mice genetically deficient in both NAPE-PLD and GDE1 showed no conversion 
of NAPE to anandamide, with again no changes to basal levels of anandamide (Simon and 
Cravatt, 2010a). These findings indicate that the generation of anandamide is possible by 
multiple parallel pathways.  
Anandamide is degraded by fatty acid amide hydrolase (FAAH) (Cravatt et al., 1996), 
whereas 2-AG is catabolised by multiple enzymes, with the majority (~85 %) degraded by 
monoacylglycerol lipase (MGL) (Dinh et al., 2002), a minor component (~13 %) being degraded 
by α/β-hydrolase-6 (ABHD6) and α/β-hydrolase-12 (ABHD12) and a small (< 2 %) portion being 
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degraded by other enzymes including FAAH (Blankman et al., 2007; Marrs et al., 2010). 
Degradation of both anandamide and 2-AG release arachidonic acid, with either ethanolamine 
or glycerol, respectively. 
 
1.2.4 Retrograde synaptic signalling is mediated by endocannabinoids 
The activation of CB1 receptors with cannabinoid agonists results in attenuation of 
neurotransmitter release from the synapse, as was demonstrated with WIN 55,212-2 
decreasing γ-aminobutyric acid (GABA) release (Katona et al., 1999). Furthermore, antagonism 
of CB1 receptors was shown to block depolarisation-induced suppression of inhibition (DSI) at 
GABAergic hippocampal synapses (Wilson and Nicoll, 2001). In addition, CB1 receptor 
antagonists also block depolarisation-induced suppression of excitation (DSE) at excitatory 
synapses in the cerebellum (Kreitzer and Regehr, 2001). These short-term mechanisms of 
synaptic plasticity are primarily mediated by 2-AG, with genetic deletion of DAGLα causing 
abolition of DSI and DSE in the brain (Gao et al., 2010; Tanimura et al., 2010; Yoshino et al., 
2011), and genetic deletion of MGL inducing an enhanced synaptic depression (Pan et al., 2011; 
Straiker et al., 2011). These findings suggest that the degradation of 2-AG regulates 
mechanisms of short-term synaptic plasticity, while synthesis of 2-AG by DAGLα is essential for 
this retrograde signalling. Consistent with this notion, DAGLα is localised post-synaptically in 
dendritic spines that are apposed to CB1 receptor-expressing axon terminals (Yoshida et al., 
2006). 
Long term depression (LTD) is also regulated via the CB1 receptor (Gerdeman et al., 2002; 
Marsicano et al., 2002). However, anandamide has also been found to regulate LTD through an 
alternative pathway, by activating the transient receptor potential cation channel V 1 (TRPV1) 
post-synaptically (Chávez et al., 2010; Grueter et al., 2010).  
Synaptic plasticity of localised circuits is also maintained in a homeostatic manner by tonic 
retrograde endocannabinoid signalling. In a hippocampal slice culture with chronically altered 
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activity, anandamide levels were shown to be adaptive, with an up-regulation of FAAH, and a 
subsequent reduction in anandamide to reduce the synaptic tone (Kim and Alger, 2010). 
Thus, the CB1 receptor and the endocannabinoids anandamide and 2-AG are mediators of 
mechanisms of synaptic plasticity, providing activity-dependant retrograde inhibitory control of 
neurotransmitter release. The levels of each endocannabinoid are critical for this signalling and 
each is tightly regulated by distinct set of enzymes, as discussed below.  
 
Inhibition of FAAH or MGL: evidence of distinct functional roles for anandamide and 2-AG. 
Evidence from genetic deletion models and the use of selective pharmacological inhibitors 
has shown that the levels of anandamide and 2-AG are tightly regulated by FAAH, and MGL, 
respectively. Genetic (Cravatt et al., 2001) or pharmacological (Kathuria et al., 2003) disruption 
of FAAH activity leads to elevated levels (>10-fold in the CNS) of anandamide. Elevated 
anandamide was shown to induce CB1 receptor-dependant analgesia, in an analogous manner 
to Δ9-THC-induced analgesia (Cravatt et al., 2001; Lichtman et al., 2004a). Interesting, in FAAH 
deficient mice anandamide does not induce catalepsy, hypothermia or hypomotility, in contrast 
with the classically observed effects of Δ9-THC administration (Cravatt et al., 2001). A detailed 
analysis of the CB1 receptor in FAAH deficient mouse showed no changes in CB1 receptor 
density ([3H]CP55,940 autoradiographic binding), no changes in CB1 receptor gene expression 
(in situ hybridisation), and only a minor down-regulation in receptor signalling activity (WIN-
55,212-2-stimulated [35S]GTPγS autoradiographic binding) in the substantia nigra and 
cerebellum, but in no other brain (Cabranes et al., 2006; Pryce et al., 2013). These findings 
suggest that despite the 8-fold increase in AEA, a relatively normal neuronal circuitry exists in 
the adult mouse. 
Disruption of MGL by pharmacological (Long et al., 2009) and genetic (Chanda et al., 2010; 
Schlosburg et al., 2010) methods caused a substantial elevation (8-10 fold) in 2-AG levels in the 
CNS, without affecting levels of AEA or other N-acyl ethanolamines. Elevated 2-AG induced 
different behaviour compared to elevated anandamide. Acute inhibition of MAGL caused 
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analgesia, hypomotility and catalepsy (Long et al., 2009). More importantly, sustained 
elevations of 2-AG produced a ‘functional antagonism’ of endocannabinoid signalling with i) 
development of tolerance to the analgesic effects of acute MAGL inhibition; ii) development of 
cross-tolerance to the analgesic and hypothermic effects of exogenous CB1 receptor agonists; 
iii) reduction of CB1 receptor ligand binding; and (iv) reduction in CB1 receptor signalling 
(Schlosburg et al., 2010). Interestingly, prolonged use of Δ9-THC also leads to the development 
of tolerance (and dependency), indicating substantial down-regulation of CB1 receptor ligand 
binding and signalling in the CNS (Lichtman and Martin, 2005; Sim et al., 1996). 
These recent findings point towards anandamide and 2-AG having overlapping, yet distinct 
roles in signalling. 2-AG has a much broader role throughout the CNS, whereas the role of AEA 
may be more as a stress-responsive endocannabinoid (Schlosburg et al., 2010) consistent with 
FAAH deficient and FAAH inhibited mice exhibiting reduced pain (Lichtman et al., 2004b) and 
anxiety (Kathuria et al., 2003; Kinsey et al., 2011). This is important to consider with the 
translation of targeting these enzymes towards clinical treatment. The effectiveness of MGL 
inhibition and elevated 2-AG may be nullified by desensitisation and down-regulation of the 
CB1 receptor. Importantly, in the FAAH deficient mouse, the CB1 receptor system showed no 
changes in ligand binding, expression, and only a minor reduction in signalling in specific brain 
regions (Pryce et al., 2013). Therefore, a FAAH inhibitor could give sustained therapeutic 
activity, but without the undesirable side-effects associated with cannabis use. 
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1.3 Fatty acid amide hydrolase and the degradation of 
anandamide 
1.3.1 Discovery and properties of FAAH 
Amidohydrolase activity was detected in liver and brain tissue homogenates and cell 
cultures giving rise to the prediction of an enzyme with the role of degrading N-acyl 
ethanolamines (Schmid et al., 1985; Deutsch and Chin, 1993). In addition, a structurally related 
fatty acid primary amide, oleamide (cis-9,10-octadecenoamide) was also shown to be degraded 
by an amidohydrolase enzyme (Cravatt et al., 1995). This led to the isolation, expression and 
cloning of the enzyme named fatty acid amide hydrolase (FAAH) (Cravatt et al., 1996). FAAH is 
an integral membrane protein localised to post-synaptic somata and dendrites (Egertová et al., 
1998; Gulyas et al., 2004). This is an unexpected location considering the proposed function of 
anandamide and FAAH in retrograde signalling, where one would have expected FAAH to be co-
localised with CB1 receptor pre-synaptically in an analogous manner to MGL. FAAH is a ~60 kDa 
serine hydrolase, with a unique amidase signature in the active site. FAAH is the only amidase 
signature class of enzyme characterised in a mammalian system, with many examples of this 
enzyme class existing in prokaryote and eukaryote species (McKinney and Cravatt, 2005). A 
more unusual trait of FAAH is that it is the only AS enzyme that is an integral membrane 
enzyme, containing an N-terminal transmembrane domain. The X-ray crystal structure of FAAH 
(with N-terminal domain removed) in complex with MAFP was resolved to 2.8 Å (Bracey et al., 
2002). This has provided insights into the active site, the hydrophobic cap covering the active 
site, and channels that allow the entry and exit of FAA substrate and product. This has assisted 
in the design of selective FAAH inhibitor compounds (Ahn et al., 2009a; Seierstad and 
Breitenbucher, 2008). 
The activity of FAAH was further characterised with the genetic deletion of the Faah gene 
mice, confirming a role for FAAH in degradation of anandamide in vivo (Cravatt et al., 2001). 
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Anandamide in the brain was elevated (>10-fold), with wild-type levels of 2-AG and CB1 
receptor expression (Lichtman et al., 2002; Osei-Hyiaman et al., 2005). 
FAAH regulates the levels of anandamide ensuring tight spatial and temporal control of the 
signalling activity. This catabolic enzyme therefore has a functional role in a number of 
neurobehavioral processes including (but not limited to) pain and sleep in mammals. FAAH is a 
potential therapeutic target in a number of neurological processes, including analgesia (Cravatt 
et al., 2001; Lichtman et al., 2004c; Ahn et al., 2011), motility, cognition, appetite (Rodríguez de 
Fonseca et al., 2001), anxiety (Kathuria et al., 2003; Kinsey et al., 2011), sleep (Huitron-Resendiz 
et al., 2004), spasticity (Baker et al., 2001; Baker and Pryce, 2008; Pryce et al., 2013) and 
neuroprotection in an EAE model (Webb et al., 2008). Understanding the functional role of 
FAAH, its structural and enzymatic properties and anatomical expression pattern may allow 
FAAH inhibition to be successfully targeted for therapeutic applications. 
 
1.3.2 Functional role of FAAH in metabolism of fatty acid amides 
Spatial and temporal regulation of anandamide levels 
Anandamide was thought to have weak cannabinoid properties due to its weak affinity and 
rapid degradation. The affinity of anandamide for the CB1 receptor is approximately 100 times 
weaker than that of Δ9-THC. This was observed using SR141716A antagonism and CP 55,940 
agonism competition assays in brain homogenates (Adams et al., 1998). Anandamide affinity is 
in the range of 61 to 543 nM, whereas Δ9-THC is in the range of 5.05 to 80.3 nM (Pertwee, 
2005). 
Anandamide has a short half-life in vivo with the half-life proposed to be in the order of 
minutes (Beltramo et al., 1997a; Stella et al., 1997) due to rapid hydrolysis by FAAH (Cravatt et 
al., 1996), and potentially a rapid transport of anandamide into cells by a putative transport 
molecule. The transporter hypothesis was deduced from use of selective inhibitors of FAAH, 
including either 25 μM BTNT (E-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyran-2-
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one) (Beltramo et al., 1997b) or 15 μM Lyn-TFK (linoleyl trifluoromethyl ketone) in combination 
with a CB1 receptor antagonist (SR141716A). However, the compound N-(4-hydroxyphenyl) 
arachidonylamide (AM404) caused accumulation of anandamide in neurons and astrocytes in 
vitro. Based on the kinetic profile of anandamide in the presence of AM404, it was assumed 
that the process of anandamide disappearance in the presence of the FAAH inhibitors had to be 
driven by a carrier-mediated transporter. It should be noted that these FAAH inhibitors have 
questionable selectivity and have extremely short half-lives in vivo (Seierstad and 
Breitenbucher, 2008). Therefore, the physiological relevance of these in vitro experiments, 
using very high concentrations of inhibitor, is questionable. 
A putative anandamide transporter was recently identified as a truncated isoform of full 
length FAAH, termed FAAH-like anandamide transporter (FLAT) (Fu et al., 2011). FLAT is 
enzymatically inactive, and therefore acts as a shuttle transporter for the reuptake of 
anandamide. This discovery attempts to explain the extracellular actions of anandamide. 
However, reported findings of FLAT have not been replicated by other researchers, despite 
efforts to do so. Consequently, doubt has been cast on the innate existence of FLAT and its 
functional capabilities as a transporter of AEA (Fowler, 2013). 
 
Functional role of FAAH metabolism of non-cannabinoid fatty acid amides 
Anandamide is the only fatty acid amide (FAA) that binds the cannabinoid receptor (hence 
the endocannabinoid classification), but it is not the only FAA substrate of FAAH (Lambert and 
Di Marzo, 1999). However, FAAH appears to be the single enzyme controlling the degradation 
of FAAs, in contrast to other lipid signalling systems such as sphingosine 1-phosphate (S1P) and 
lysophospholipids that are degraded by several different enzymes (Deutsch et al., 2002).  
 
Fatty acid amide substrates 
There are two classes of FAAs that include the N-acyl ethanolamines (NAEs) and the fatty 
acid primary amides (FAPAs). The known NAEs found in mammalian tissues include 
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anandamide, N-palmitoyl ethanolamine (PEA), N-stearoyl ethanolamine (SEA), N-oleoyl 
ethanolamine (OEA), N-docosahexaenoyl ethanolamine (DHEA) and N-linoleoyl ethanolamine 
(LEA)(Bradshaw et al., 2009a). In addition, the biosynthetic precursor NAPEs are also 
considered NAEs, but as previously discussed, are not directly degraded by FAAH. From a 
chemical structural aspect, the NAEs consist of fatty acids conjugated to an amine by an amide 
bond. 
FAPAs are of a similar structure to NAEs, but only contain the fatty acid component with an 
amide group attached. The most well know of the FAPAs is 9-Z-octadecenamide (oleamide), a 
sleep inducing signalling molecule and the first identified substrate of FAAH (Cravatt et al., 
1996). There has been some suggestion that oleamide also binds the cannabinoid receptors 
(Leggett et al., 2004); however, this is controversial (or binding is at very low affinity) and it 
appears that oleamide may elicit some cannabimimetic activity by an entourage effect, or as an 
allosteric modulator in combination with anandamide or 2-AG (Lambert and Di Marzo, 1999). 
Importantly, many FAAH substrates activate receptors, other than the cannabinoid 
receptors. Oleamide has been shown to activate GABA(A) receptors via the β subunit to induce 
sleep (Lees et al., 1998; Yost et al., 1998). PAE is a ligand for transient receptor potential 
vanilloid type 1 (TRPV1) and proliferator-activated receptor alpha (PPARα) (Lo Verme et al., 
2005). OEA, a signalling lipid regulating satiety and inflammation is reported to be a ligand for 
TRPV1 (Movahed et al., 2005), PPARα (Fu et al., 2003), and the orphan G-protein coupled 
receptor, GPR119 (Overton et al., 2006). PAE and OEA have been shown to elicit anti-
inflammatory properties (carrageenan-induced paw oedema and phorbol ester-induced ear 
oedema mouse models) through the nuclear receptor PPARα (Fu et al., 2003; Hansen, 2010; Lo 
Verme et al., 2005). 
 
N-palmitoyl glycine 
PalGly is a relatively novel saturated fatty acid glycine, and it is upregulated in FAAH 
knockout mice and in URB597 treated mice, suggesting FAAH is the major enzyme in the 
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degradation pathway (Rimmerman et al., 2008). Transient receptor potential channel 5 (TRPC5) 
is activated by PalGly, a channel receptor capable of inducing nitric oxide release, calcium 
uptake and anti-inflammatory effects (Bradshaw et al., 2009b). In addition, PalGly was shown 
to activate the orphan G protein-coupled receptor (GPCR) GPR18, with anti-nociceptive and 
anti-inflammatory effects (Rimmerman et al., 2008). 
 
N-arachidonoyl taurine 
N-arachidonoyl taurine (NAT) has been shown to be significantly elevated, particularly in 
CNS tissue, following treatment with PF-3845 and in FAAH deficient mice. NAT was 
demonstrated to activate both TRPV1 and TRPV4 at concentrations equal to those observed in 
FAAH deficient mice (Long et al., 2011; Saghatelian et al., 2006). Although no nervous system 
effects were reported, anti-hypertensive effects of elevated NAT were blocked by AM251, a 
CB1 receptor antagonist. 
 
1.3.3 Anatomical distribution and physiological roles of FAAH 
The first anatomical analysis of FAAH expression in the rat CNS used in situ hybridisation 
targeting FAAH mRNA (Thomas et al., 1997). This revealed neuronal (cell body) expression in 
the neocortex, hippocampal formation, amygdala, and cerebellum. Interestingly, a weak signal 
was also detected in the corpus callosum and anterior commissure, suggestive of expression in 
oligodendrocytes. These findings were extended using a novel anti-FAAH antibody, reactive to 
a FAAH-GST fusion protein (Egertová et al., 1998). Immunostaining was observed in the 
cytoplasm of neuronal somata and dendrites, indicating transport of the protein from the 
cytoplasm to the dendrites. Prominent expression was observed in the neocortex, 
hippocampus and cerebellum, and to a lesser degree in other regions of the brain, consistent 
with the findings of Thomas et al. (1997). In these regions, staining was predominantly located 
in the principal neurons; pyramidal cells in the neocortex and hippocampus and Purkinjie cells 
in the cerebellum.  
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Complementary localisation of FAAH and CB1 receptor 
FAAH expression was also compared with the localisation of the CB1 receptor. 
Complementary localisation was observed with FAAH expressed in the cell bodies and 
dendrites, and CB1 receptor expressed pre-synaptically in axon terminals, indicating a 
functional role of FAAH in regulating anandamide signalling to the CB1 receptor (Egertová et al., 
1998). An additional study, using an antibody reactive to the C-terminal of FAAH (Tsou et al., 
1998b), showed an expression pattern consistent with previous in situ hybridisation and 
immunohistochemistry studies described above, and similar conclusions regarding the role of 
FAAH in regulating CB1 receptor signalling via anandamide.  
These studies were followed by an in depth anatomical analysis of FAAH expression in the 
mouse brain, with the use of FAAH-/- tissue to verify the specificity of the antibody (Egertová et 
al., 2003). Novel findings from this study included FAAH expression in non-neuronal cells. 
Oligodendrocytes (identified based on morphological criteria) and ependymal cells, lining the 
ventricles, were reported to express FAAH. A further study of the ependymal cells showed 
mutually exclusive patterns of expression in rat and mouse. No expression of FAAH was 
detected in rat ependymal cells but FAAH expression was detected in the epithelial cells of the 
choroid plexus in rat (Egertová et al., 2000). In contrast, in mouse, the FAAH expression in 
ependymal cells did not extend into the choroid plexus (Egertová et al., 2004). However, the 
functional significance of these differences in the patterns of FAAH expression in the mouse 
and rat brain are not known.  
 
FAAH expression in brain tissue from patients with Multiple Sclerosis 
FAAH expression has been analysed in post-mortem CNS tissue from patients with multiple 
sclerosis using immunohistochemistry (Benito et al., 2007). Immunostaining was detected in 
cortical neuronal cells (but not in subcortical white matter neurons) in both normal and MS 
tissue. Plaques from multiple sclerosis pathology were specifically analysed, and 
immunostaining was only detected in active plaques. In addition to neuronal expression, FAAH-
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immunoreactivity was also detected in hypertrophic astrocytes in the active plaques. The FAAH 
immunostaining co-localised with glial fibrillary acidic protein (GFAP) staining indicative of 
astrocytes, and was described as abundant within the plaques, with strong immunoreactivity in 
the cell bodies but weak in the processes. The mechanism and functional significance of this 
increased expression of FAAH in astrocytes in pathological tissue is unknown, but it is 
corroborated by detection of FAAH in astrocytes in Alzheimer’s disease samples (Benito et al., 
2003) and in a macaque EAE model (Benito et al., 2005). 
Further investigation of the distribution of FAAH expression in the CNS is required to 
identify cell types expressing FAAH, both in health and disease. In the context of EAE as a model 
of MS, as reported in this thesis, identification of cell types expressing FAAH may assist 
interpretation of phenotypes observed in the EAE disease model using FAAH deficient mice 
(Chapter 2) and treated with the FAAH inhibitor PF-3845 (Chapter 3). Therefore, one of the 
aims of this study was to perform a high resolution analysis of FAAH expression in different CNS 
cell types in the mouse (Chapter 4). 
 
1.3.4 FAAH inhibitors as research tools and potential therapeutics 
As described previously, FAAH is a serine hydrolase, with a Ser217-Ser241-Lys252 catalytic 
triad (amidase signature). This differentiates FAAH from the more common serine hydrolases 
with a Ser-His-Asp triad (Ahn et al., 2008). Serine hydrolase inhibitors are notoriously 
promiscuous, with complex off target activity. The unique amidase signature gives an 
advantage to medicinal chemists in designing a highly selective compound that binds FAAH 
with minimal off target activity. The design of FAAH inhibitors and the breadth of existing 
compounds are described at length in Chapter 3 (section 3.1) as a basis for justification of the 
selection of PF-3845 in the FAAH inhibition studies reported in Chapter 3. 
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1.3.5 FAAH as a potential therapeutic target for MS 
Despite the promising evidence that cannabis use can control some of the symptoms of MS 
(Kmietowicz, 2010; Zajicek and Apostu, 2011; Corey-Bloom et al., 2012; Zajicek et al., 2012), the 
drug has undesirable psychoactive effects at doses inducing more effective treatment (Curran 
et al., 2002; Corey-Bloom et al., 2012). In rodent models, Δ9-THC treatment elicits a “tetrad” 
response including catalepsy, hypomotility, analgesia and hypothermia via the CB1 receptor 
(Pertwee, 1997; Varvel et al., 2005). A strategy to circumvent the undesirable side effects 
would be to target the endocannabinoid signalling system by elevating the levels of 
anandamide and / or 2-AG as agonists for CB1 receptor. As describe previously, elevation of 2-
AG also induces some of the undesirable effects of the tetrad response in rodents, whereas in 
the elevation of anandamide this is not apparent. This elevation in anandamide causes CB1 
receptor-dependent analgesia, but notably, no catalepsy, hypothermia or hypomotility is 
observed in rodents (Cravatt et al., 2001), and no significant side effects were observed in 
humans in clinical trials of a FAAH inhibitor (Huggins et al., 2012; Li et al., 2012). 
With respect to multiple sclerosis, FAAH inhibition could play a role in reducing 
neurodegeneration. An interesting EAE experiment was performed using the FAAH deficient 
mouse (C57BL/6.FAAH-/-) (Webb et al., 2008). The disease scoring showed no difference in 
inflammation, but did show a difference in recovery, with the FAAH deficient animals having 
significantly less disability compared to wild-type. This indicated a neuroprotective effect 
elicited from lack of FAAH activity during the disease course. 
The authors of this study stained for myelin and immune infiltrates with no significant 
differences found between the wild-type and knockout mice, although a minor reduction 
(statistically insignificant) in demyelination in the FAAH deficient animals was observed. It 
would be interesting to see if these neuroprotective effects can be repeated in a more robust 
model of EAE, such as the chronic relapsing EAE (CREAE) disease using the Biozzi ABH strain.  
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The neurodegenerative effects seen in this study are proposed to arise from the increase in 
anandamide levels, following the deletion of its degradative enzyme. This increase in 
anandamide could provide an increase in CB1 receptor stimulation, and thereby reduce the 
excitotoxic effects caused by the CREAE disease. This conceptual strategy is outlined in Figure 
1.3. 
 
Figure 1.3. FAAH inhibition as a neuroprotective strategy to reduce excitoxicity 
 
This schematic is a conceptual pathway of FAAH inhibition-mediated neuroprotection in a 
disease setting. In a neurodegenerative disease such as CREAE of progressive MS, 
demyelination and loss of axons can cause an overstimulation of axon potentials in a subset of 
axons. This causes excessive synaptic glutamate release, and consequently excitoxicity 
pathways are initiated. This signalling process is tempered by endocannabinoid retrograde 
signalling. In a therapeutic strategy, this retrograde signalling can be enhanced by using either 
FAAH inhibitors with elevated anandamide activating CB1 receptor, or from exogenous sources 
(e.g. Δ9-THC). CB1 receptor signalling inhibits Ca2+ influx, thereby reducing glutamate release 
and preventing intracellular Ca2+ overloading.  
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1.4 Aims and Objectives 
The literature review above has revealed preliminary evidence indicating that CB1 receptor 
activation by the endocannabinoid, anandamide may have a neuroprotective effect in 
progressive MS. The aims of the studies reported in this thesis were to investigate FAAH 
inhibition as a therapeutic strategy for progressive MS. This investigation has four main 
objectives: 
1. To investigate FAAH as a potential therapeutic for progressive MS by investigating 
the effect of FAAH-knockout on disease development in a chronic relapsing EAE 
model in the Biozzi ABH mouse. 
 
2. To investigate FAAH as a potential therapeutic for progressive MS by investigating 
the effect of a FAAH inhibitor on disease development in a chronic relapsing EAE 
model. 
 
3. To identify cell types that express FAAH expression in the mouse CNS to provide a 
neuroanatomical basis for interpretation of effects of FAAH knockout and FAAH 
inhibition in mice. 
 
4. To investigate the effects of FAAH inhibition in an in vitro model of oligodendrocyte 
differentiation and myelination. 
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Chapter 2: Effects of genetic deletion of FAAH in a relapsing 
remitting EAE model 
2.1.1 Phenotype of the FAAH knockout mouse 
FAAH knockout mice were first generated in the 129SvJ mouse strain by deleting 2.5 kb of 
DNA, including Exon 1 (amino acids 1-65) and the upstream promoter region (Cravatt et al., 
2001). Chimeric mice were generated from stem cell clones on a C57BL/6 strain background, 
and subsequently backcrossed to generate homozygous FAAH knockout mice.  
Analysis of brain NAE revealed increased levels of anandamide (>10-fold), N-oleoyl and N-
palmitoyl ethanolamine (Cravatt et al., 2001), but maintained wild-type 2-AG levels (Osei-
Hyiaman et al., 2005) and CB1 receptor expression (Lichtman et al., 2002; Pryce et al., 2013). 
Furthermore, the FAAH hydrolytic activity of brain extracts was significantly reduced with 
C57BL/6.FAAH-/- mice hydrolysis of anandamide and oleamide being 50–100-fold slower than 
brain extracts from wild-type mice (Cravatt et al., 2001). C57BL/6.FAAH-/- mice were sensitive to 
administration of anandamide producing the classic “tetrad” effect including hypomotility, 
analgesia, catalepsy and hypothermia. These effects disappeared within 4 hours. No differences 
were observed in general appearance, body weight, locomotion, or overt behaviour (Cravatt et 
al., 2001). In behavioural investigations it has been reported that these mice have reduced pain 
sensitivity (Cravatt et al., 2001; Kinsey et al., 2011; Lichtman et al., 2004b), reduced anxiety 
(Kinsey et al., 2011), increased preference and consumption of ethanol (Basavarajappa et al., 
2006; Blednov et al., 2007), increased susceptibility to induced seizures (Clement et al., 2003), 
and improvements in sleep (Huitron-Resendiz et al., 2004). No motor or cognitive defects have 
been observed in the FAAH knockout mouse (Ahn et al., 2008). All these characterisations were 
performed in the original C57BL/6.FAAH-/- mouse, however one would assume similar 
phenotypes would persist in the ABH.FAAH-/-. Consistent breeding of the homozygous 
ABH.FAAH-/- was problematic, and this is may be due to FAAH deficiency affecting fertility 
(Maccarrone et al., 2002; Sun et al., 2009) and miscarriage (Maccarrone et al., 2000). During 
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the handling of naïve and diseased animals, FAAH-/- mice were indistinguishable from wild-type 
littermates. 
 
2.1.2 Genetic deletion of FAAH shows neuroprotection in EAE model 
Induction of EAE disease in the C57BL/6.FAAH-/- mouse showed no impact on the 
inflammatory condition of the disease, but interestingly genetic deletion of FAAH did improve 
recovery from a mono-phasic EAE disease (Webb et al., 2008). In contrast a subsequent report 
indicated that disease was delayed in onset with a reduced mean severity of disease (Rossi et 
al., 2011), which may implicate a small diminution of the inflammatory response that drives the 
attack. The former results support the hypothesis of raised anandamide from FAAH deletion 
producing an improved recovery following disease. The EAE disease used in these studies was 
an acute monophasic disease that primarily assesses influences of T-lymphocyte mediated 
inflammatory processes.  
These data provided insight into the potential of FAAH deletion as a neuroprotective 
target; however the result was limited due to the apparent inconsistencies in this monophasic 
disease model. Multiple Sclerosis is usually multiphasic in nature, with the major 
neurodegenerative processes occurring in the later phases of disease. 
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2.2 Aims and Objectives 
Aims 
i) To investigate the effect of FAAH deletion in EAE disease.  
Objectives 
i) To analyse the effect of FAAH deficiency in the C57BL/6 mouse in monophasic EAE 
disease, investigating behavioural clinical deficits.  
ii) To analyse the effect of FAAH deficiency in chronic relapsing EAE disease, investigating 
behavioural clinical deficits and motor control, and molecular neurofilament levels. 
 
2.3 Methods and Materials 
2.3.1 Maintenance of Mouse Colony 
Adult male and female mice were bred from stock at Queen Mary, University of London 
and housed in a 12 h: 12 h light: dark cycle with controlled temperature and humidity. The mice 
were fed RM-1E diet and water ad libitum. All procedures were approved by ethical review in 
accordance to UK Home Office project licence issued to Professor David Baker (PPL 70/7124) 
under the Animals (Scientific Procedures) Act 1986. The mice were housed and used as 
reported previously, in accordance to the ARRIVE guidelines (Al-Izki et al., 2012). 
 
Generation of ABH.FAAH-/- mice colony 
C57BL/6/129.FaahTm1Crv mice (Cravatt et al., 2001), termed C57BL/6.FAAH-/- were obtained 
from Prof. Benjamin Cravatt, Scripps Institute, La Jolla, CA, USA. These had been backcrossed 
with C57BL/6 mice for 4 generations at the time of arrival. Heterozygous mice were crossed to 
produce C57BL/6.FAAH+/+ and C57BL/6.FAAH-/- litter mates. In addition, C57BL/6.FAAH-/- were 
backcrossed for at least 11 generations prior to inter-crossing with ABH mice to produce 
ABH.FAAHTm1Crv mice termed here, ABH.FAAH-/-. Offspring were genotyped for the FAAH 
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deletion, displayed enhanced responsiveness to anandamide dosing and had elevated 
anandamide in spinal cord tissue (Figure 2.3, Pryce et al., 2013). 
 
Measurement of Endocannabinoids 
To assess the effect of FAAH genetic deletion on spinal cord levels of the endocannabinoids 
anandamide and 2-AG levels, liquid chromatography mass spectrometry was used. Spinal cord 
tissue from ABH.FAAH-/- and ABH.FAAH+/+ was expelled from the spinal column using 
hydrostatic pressure and frozen in liquid nitrogen within 60s from death, as described 
previously (Bisogno et al., 1999). This work was done by Gareth Pryce and Tiziana Bisogno 
(Institute of Biomolecular Chemistry, CNR, Pozzuoli, Naples, Italy). 
 
2.3.2 Experimental Allergic Encephalomyelitis Mouse Model 
Induction of Experimental Autoimmune Encephalomyelitis 
Preparation of the spinal cord homogenate consisted of killing 20-50 animals, typically ex-
breeders by CO2 overdose. The head was removed using scissors and the spinal column was 
severed at the level of the pelvis. A 20 gauge needle attached to 20 ml syringe filled with 
distilled water was inserted into the spinal column. The spinal cord was expelled using 
hydrostatic pressure from the cervical end. The pooled spinal cords were homogenised in a 
glass hand homogeniser. Homogenate was frozen at -80 °C overnight and placed in a freeze 
dryer (Edwards, Crawley, UK) and dried for 24-48 h. The dried spinal cord homogenate was 
placed on foil and diced to a fine dust with a single edged razor blade. The homogenate was 
stored -20 °C (Al-Izki et al., 2012). 
Complete Freund’s adjuvant was prepared by mixing 15.5 ml Incomplete Freund Adjuvant 
(Difco, Becton Dickinson, Oxford, UK), 16 mg Mycobacterium tuberculosis H37Ra and 2 mg M. 
butyricum (Difco, Becton Dickinson, Oxford, UK), in a 5 ml sterile Bijou (Sterilin, Caerphilly, UK). 
The inoculum was prepared in 20ml syringes (Becton Dickinson, Oxford, UK) with the syringe 
plunger removed, and the barrel plugged with a stopper cap (Scientific Laboratory Supplies, 
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Nottingham, UK). 5 ml sterile PBS plus 33 mg of dried spinal cord homogenate (6.6 mg/ml) was 
mixed and then 5 ml of Complete Freund’s adjuvant (see above) was added. The syringe was 
sealed with Parafilm and vortexed, followed by 10 min sonication in a water bath sonicator 
(Bransonic Ultrasonicator, Sigma, UK) The adjuvant was vortexed and placed on ice to cool. A 1 
ml syringe was inserted into the 20 ml syringe and the adjuvant was pumped for 20 min. until it 
had thickened sufficiently that the solution did not disperse when a drop was added to water. 
The inoculum was transferred into 1 ml syringes by placing a long (6 cm) large bore needle into 
the 20 ml syringe and filling the syringes from the needle end. Once filled the 1 ml syringes 
were fitted with 16 mm 25 gauge needle (Becton Dickson, Oxford, UK). 
Immunisation of the mice was performed by holding the mouse at the nape of the neck 
between thumb and forefinger, placed on the top of a wire mouse cage. The tail was held with 
the right hand with thumb and forefinger (tips facing the head) The skin of the dorsal surface of 
the flank was lifted with thumb and forefinger (left hand) and the needle was inserted (facing 
towards the head) subcutaneously into the mouse. 0.15ml of adjuvant was injected into the 
right flank and another 0.15ml was injected into the left flank. Mice were immunised on Day 0, 
and the procedure was repeated with fresh inoculum one week later (Day 7) with injections 
below (more posterior) to the original injection sites. In the relapsing-remitting model, the 
Relapse Phase was induced by re-immunisation using the same procedure at Day 28 in mice 
with remission (score ≤ 0.5) (Al-Izki et al., 2012). 
 
Clinical disease scoring 
Body weight and clinical disability signs were assessed daily for the development of 
relapsing-remitting paralysis using the neurological scoring system, as described previously 
(O’Neill et al., 1992) and illustrated in Figure 2.2. 
 
 
58 
Figure 2.2. The clinical assessment of chronic relapsing experimental allergic 
encephalomyelitis. 
 
0 - normal 
1 - loss of tail tone. Tail is completely paralysed. If the tail 
has some tone, but does not lift, this equates to 0.5 score 
which is typical for Acute Phase remission. 
2 - impaired righting reflex. If the animal slowly rights 
itself, this equates to 1.5 score. 
3 - partial hind limb paralysis, with 1 limb completely 
paralysed. If the animal has gait disturbance, this 
equates to 2.5 score 
4 - complete hind limb paralysis, with both hind limbs 
paralysed. If there is partial movement in one of the 
hind limbs, this equates to 3.5 score. 
5 - moribund. If the fore limbs become paralysed, the 
animal was euthanised. If the animal lost 35 % of pre-
immunisation weight, the animals was euthanised. If the 
animals lose the ability to thermo-regulate and appear 
cold to touch, the animals were euthanised. 
* - Relapse was defined as a change in clinical score of at 
least 1 point, and loss of weight (> 5 %), while remission 
was defined as the resolution of clinical paralysis and 
weight gain 
 
This assessment was performed on a daily basis from Day 10 post-immunisation. This image 
was modified with the kind permission of David Baker. 
 
 
RotaRod activity monitoring 
Motor control, coordination and fatigue were assessed on an accelerating (4 – 40 rpm) 
RotaRod (ENV-575M. Med Associates Inc, St. Albans, VT, USA). During the remission phase 
activity was assessed over an observation period of 5 minutes. Assessment ended when the 
mouse either fell from the spindle or if the mouse held onto the spindle rod for two 
consecutive revolutions, indicating failed tolerance for the speed of the revolving drum (Al-Izki 
et al., 2012). 
 
Neurofilament ELISA assay 
To assess neurodegeneration in the CREAE mice, the spinal cord content of phosphorylated 
heavy chain neurofilament was measured using an enzyme linked immunosorbent assay (ELISA) 
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as previously described (Jackson et al., 2005a; Petzold et al., 2003). The whole spinal cord was 
extracted from mice using hydrostatic pressure. The spinal cord was rapidly frozen in liquid 
nitrogen. The samples were homogenised in T-PER buffer (T-PER Tissue Protein Extraction 
Reagent plus Halt Protease Inhibitor Cocktail (EDTA-Free) (Fisher Scientific UK Ltd, UK) plus 8 M 
urea (Sigma), with a glass homogeniser. In addition, samples were triturated through a 23 
gauge needle / 1ml syringe on ice. The samples were centrifuged at 13,000 g at 4 °C, and the 
supernatant was collected for analysis. A 96 well plate (Nunc Maxisorp 96-well microplate, 
Fisher Scientific UK Ltd, UK) was coated overnight at 4 °C with capture antibody (anti-
neurofilament HSMI-35 antibody, 1:5000, Covance Inc., Cambridge Bioscience, Cambridge, UK) in 
carbonate coat buffer (pH 9.6). Following a single wash in wash buffer (PBS + 0.1 % Tween 20, 
Sigma, pH 7.4), non-specific binding was blocked by incubation with 5 % bovine serum albumin 
in wash buffer for 1 h at room temperature. Following a wash step, samples and standards 
(Bovine neurofilament heavy chain, Sigma, Poole, UK) were diluted in diluent buffer (PBS, 0.1 % 
BSA, 0.1 % Tween 20, pH 7.4) and incubated in the plate for 2 h at room temperature. 
Following 3 wash steps, the detector antibody was applied (rabbit anti-NF200, 1:1000, Sigma) 
and incubated for 1 h at room temperature. Following three washes, a reporter antibody 
(horseradish peroxidase-conjugated anti-rabbit antibody, 1:1000, DAKO, Glostrup, Denmark) 
was subsequently applied. Following a final 5 washes, the tetramethylbenzidine (TMB) 
chromogenic reagent system (R & D Systems, Abingdon, UK) was applied. Signal development 
was halted by addition of 2N HCl (Sigma), and the coloured reaction product was measured at 
450 nm using a Synergy HT ELISA plate reader (BioTek, Vermont, USA). 
Total protein of the individual samples (diluted 1:10) was measured in triplicate using the 
bicinchoninic acid (BCA) protein assay (Pierce, Fisher Scientific UK Ltd, UK). The absorbance of 
samples was measured at 270 nm in in a Synergy HT ELISA plate reader (BioTek, Vermont, USA), 
and sample protein concentrations were calculated relative to the BSA standard curve. 
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2.3.3 Statistical Analysis 
The primary outcome was to compare the groups at Remission 2 (Day 50). Power analysis, 
using G*Power software version 3.1.3 (Erdfelder et al., 1996), indicates that groups sizes of n = 
11 at Day 50 has over 80 % power to detect statistically accurate therapeutic effects 
(Vesterinen et al., 2010). Using this protocol, there is an attrition rate of animals that are non-
responders, moribund or fail to recover after Acute Phase (to 0.5 clinical score), and this was 
factored into animal number requirements. 
The differences in clinical scores and the day of onset of EAE between the groups were 
assessed using non-parametric statistics using SPSS version 20 (IBM SPSS Statistics, IBM Inc, 
USA). The Group Score represents the maximal clinical grade ± standard error of the mean 
(S.E.M.) developed by all animals within the group. The EAE score represents the maximal 
clinical grade ± S.E.M. developed only by animals that relapsed and the day of onset ± standard 
deviation (S.D.) represents the day of the first increase of clinical signs. 
RotaRod (mean ± S.E.M.) and neurofilament (mean ± S.E.M.) data were analysed using 
student’s t-tests incorporating a test for normality and equality of variance using SPSS version 
20. 
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2.4. Results 
2.4.1 FAAH deficient mice have elevated levels of anandamide in spinal cord 
The AEA levels in the spinal cords of both wild-type (ABH.FAAH+/+) and FAAH knockout mice 
(ABH.FAAH-/-) was analysed by liquid chromatography mass spectroscopic analysis (Baker et al., 
2001; Bisogno et al., 1999). An 8-fold increase in AEA was observed, while levels of 2-AG were 
unchanged (Figure 2.3).This is broadly consistent with the brain levels of AEA observed in the 
original C57BL/6.FAAH-/- mice where levels increased 15-fold compared to wild-type animals 
(Cravatt et al., 2001). 
 
Figure 2.3. Levels of endocannabinoids in the spinal cord of ABH.FAAH-/- mice. 
 
The spinal cord levels of anandamide are significantly raised in the FAAH-/- mouse compared to 
the wild-type mice (Left). No difference was detected in 2-AG levels (Right) (Student’s t-test; *P 
< 0.05, **P < 0.01, ***P < 0.001). This work was done by Gareth Pryce (QMUL) and Tiziana 
Bisogno (Institute of Biomolecular Chemistry, CNR, Pozzuoli, Naples, Italy). 
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2.4.2 FAAH deficient C57BL/6 mice show a reduced neurological deficit in 
behavioural assays (Unpublished study performed by Gareth Pryce). 
EAE was induced in the C57BL/6.FAAH-/- mice with MOG35-55. In this strain of mouse 
(C57BL/6) this typically induces a monophasic chronic disease, with an acute inflammatory 
attack (acute phase), followed by a poor recovery (remission) (Jones et al., 2008; Soulika et al., 
2009). 
In this strain of mice following immunisation with MOG peptide the onset of disease in 
wild-type and knockout animals was highly variable from day 13 to day 25 post-inoculation. 
Therefore, the disease in susceptible animals was plotted from day of onset. The 
C57BL/6.FAAH-/- mice had a comparable incidence, severity (maximal EAE score) and time of 
onset with C57BL/6.FAAH+/+ mice, indicating that FAAH knockout had no significant impact on 
inflammation in this model of EAE (Figure 2.4). FAAH knockout did have an effect on the 
recovery of these animals, with a significant reduction in the clinical scores of the 
C57BL/6.FAAH-/- mice compared to the wild-type mice. This indicates a reduced 
neurodegeneration sustained during the acute phase inflammatory attack or enhanced 
recovery of neuronal activity (Baker et al., 2011; Jackson et al., 2005b) due to the abolition of 
FAAH activity and elevated EAE.  
  
63 
Figure 2.4. Genetic deletion of FAAH limits the accumulation of disability in EAE. 
 
EAE was induced in C57BL/6 wild-type and FAAH deficient mice with MOG35-55 in complete 
Freund’s adjuvant on day 0 and 7. The mean ± SEM daily clinical scores demonstrate that 
C57BL/6.FAAH-/- mice (filled circles) show improved recovery from paralysis compared to wild-
type mice (open circles) (Mann Whitney U test; *P < 0.05, **P < 0.01, ***P < 0.001). This work 
was done by Gareth Pryce. 
 
 
2.4.3 Genetic deletion of FAAH in the ABH mouse shows reduced 
neurological deficit in behavioural assays 
The Biozzi ABH mouse is a more robust mouse model for assessing relapsing remitting EAE 
disease. The disease is multiphasic with the mice being able to sustain multiple inflammatory 
attacks, followed each time with a remission phase (Amor et al., 2005; Baker et al., 1990). 
The impact of FAAH deletion (ABH.FAAH-/- mice) on the disease course was assessed in 
three separate behavioural studies. These include a ‘Pilot study’, ‘Study 2’ and ‘Study 3’ and 
which were analysed separately. An identical protocol was maintained for each experiment; 
this enabled combining the data from the three studies into a final ‘Combined Studies’ analysis.  
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All the analyses include a full table of data. The ‘Group Score’ represents the maximal 
clinical grade (mean ± S.E.M.) developed by all animals within the group, including non-
responders. The ‘EAE Score’ represents the maximal clinical grade (mean ± S.E.M.) developed 
only by animals that relapsed. The ‘Day of Onset’ (mean ± standard deviation (S.D.)) represents 
the day of the first observation of clinical signs, and this event corresponds with a loss of 
weight (data not shown).  
The analysis was split to independently assess the Acute Phase and the Relapse Phase. This 
is important to assess the impact of FAAH deficiency on inflammatory processes of each phase 
of disease. Furthermore, animals that did not fully recover at Remission 1 (clinical score > 0.5) 
were excluded from the remainder of the study. Only animals that recovered were re-
immunised at Day 28 to ensure a consistent baseline of prior disease.  
 
Genetic deletion of FAAH in the ABH mouse shows a variable decrease in recovery following 
the Acute Phase in CREAE 
The pilot study showed a typical disease course for ABH CREAE, with a high frequency of 
disease incidence (26 / 31 animals) and equivalent EAE score between the groups (Table 1). Of 
interest is the early onset of disease in the FAAH deficient group. There were no differences 
between groups at Remission 1 in the clinical scores, but there was a significant, albeit minor, 
less decrease in RotaRod performance in the FAAH knockout group (Figure 2.5) (a baseline pre-
immunisation RotaRod score was not available). This study was done with the assistance of 
Gareth Pryce.  
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Table 2.1: Acute Phase data from ‘Pilot Study’ CREAE Behavioural Experiment 
Acute Phase 
___________________________________________________________________________ 
Strain  No. EAE/ Group Score EAE score Day of Onset 
     Total     ± SEM    ± SEM    ± SD 
___________________________________________________________________________ 
ABH  9/10  3.6 ± 0.4 4.0 ± 0.1  15.8 ± 0.7 
 
ABH.FAAH-/- 17/21  3.2 ± 0.4 4.0 ± 0.1  14.8 ± 1.9* 
___________________________________________________________________________ 
Remission 1 
___________________________________________________________________________ 
Strain   No. RM1  Group Score 
     n      ± SEM 
___________________________________________________________________________ 
ABH   8   0.5 ± 0.0 
ABH.FAAH-/-  15   0.5 ± 0.0 
___________________________________________________________________________ 
RotaRod Performance 
___________________________________________________________________________ 
Strain       Remission 1 
   Time (s) ± SEM 
___________________________________________________________________________ 
ABH      157 ± 14 
ABH.FAAH-/-     167 ± 20* 
___________________________________________________________________________ 
*P < 0.05, **P < 0.01, ***P < 0.001 
 
EAE was induced in ABH wild-type and FAAH deficient mice with SCH on day 0 and 7. The data 
reflects maximal clinical score of the group, maximal clinical score of animals that developed 
EAE (mean ± S.E.M.) and the day of onset of EAE symptoms (mean ± S.D.) (Mann Whitney U 
test; *P < 0.05, **P < 0.01, ***P < 0.001). RotaRod scores reflect time of latency to fall (mean ± 
S.E.M.). (Student’s t-test; *P < 0.05, **P < 0.01, ***P < 0.001) 
 
 
The Study 2 experiment again showed a typical Acute Phase disease course, with a high 
frequency of EAE incidence (58 / 60 animals) (Table 2.1). In contrast to the Pilot Study, there 
was no difference in disease onset between the groups (Figure 2.5 C). There was also no 
significant difference in maximal clinical scores between the group, although there does appear 
to be differences. Unfortunately, and only in this experiment, the FAAH deficient group had a 
high rate of mortality or animals requiring culling due to endpoints (see Table 2.1, difference 
between No. EAE and No. RM1). There was a significant difference in clinical scores, with the 
wild-type animals recovering better than the FAAH deficient animals. This was also reflected in 
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the RotaRod scores, with the wild-type animals performing better than the FAAH knockout 
animals (Figure 2.5 D). However, it should be noted that the baseline score was lower in the 
FAAH deficient mice prior to immunisation.  
 
Table 2.2: Acute Phase data from ‘Study 2’ CREAE Behavioural Experiment 
Acute Phase 
___________________________________________________________________________ 
Strain  No. EAE/ Group Score EAE score Day of Onset 
     Total     ± SEM    ± SEM    ± SD 
___________________________________________________________________________ 
ABH  20/20  4.1 ± 0.1 4.1 ± 0.1  13.8 ± 1.3 
 
ABH.FAAH-/- 38/40  4.0 ± 0.2 4.2 ± 0.1  14.2 ± 1.0 
___________________________________________________________________________ 
Remission 1 
___________________________________________________________________________ 
Strain   No. RM1  Group Score 
      n      ± SEM 
___________________________________________________________________________ 
ABH   18   0.6 ± 0.1 
ABH.FAAH-/-  24   1.0 ± 0.1* 
___________________________________________________________________________ 
RotaRod Performance 
___________________________________________________________________________ 
Strain   Pre-Immunisation      Remission 1 
     Time (s) ± SEM   Time (s) ± SEM 
___________________________________________________________________________ 
ABH      264 ± 11      229 ± 19 
ABH.FAAH-/-     235 ± 8*      161 ± 21* 
___________________________________________________________________________ 
*P < 0.05, **P < 0.01, ***P < 0.001 
 
EAE was induced in ABH wild-type and FAAH deficient mice with SCH on day 0 and 7. The data 
reflect maximal clinical score of the group, maximal clinical score of animals that developed 
EAE (mean ± S.E.M.) and the day of onset of EAE symptoms (mean ± S.D.) (Mann Whitney U 
test; *P < 0.05, **P < 0.01, ***P < 0.001). RotaRod scores reflect time of latency to fall (mean ± 
S.E.M.). (Student’s t-test; *P < 0.05, **P < 0.01, ***P < 0.001). 
 
 
Due to the variability observed between the Pilot Study and Study 2, a third study was 
performed to investigate the discrepancies. In particular, the aim was to validate the early 
onset of disease (also seen in the Relapse Phase of Pilot Study, but not in Study 2 – see Figure 
2.5) in the ABH.FAAH-/- group. Variability was also seen in the Remission 1 scores and RotaRod 
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scores between the two studies. Thus, Study 3 was required to investigate if FAAH deficiency 
did indeed cause early disease onset, and whether this group does have a worse recovery 
compared to wild-type. 
The Study 3 experiment showed a typical Acute Phase disease course, but the incidence of 
disease in FAAH deficient animals was lower (35 / 43) than previously but still within a normal 
range (Al-Izki et al., 2012). This is reflected in the lower Group Score, but importantly, there 
was no difference in the EAE Score, indicating a relatively equal severity of inflammation 
between the two groups.  
There was a difference in disease onset between the groups (Table 2.3, Figure 2.5 E), but in 
contrast to the Pilot Study, this time the FAAH deficient group had a later onset of disease. 
Consistent with the Pilot Study, there was no significant difference in the Remission 1 scores, 
although there does appear to be a delay in the time course of the recovery, and this is 
concurrent with the later onset of disease. There was no significant difference in the RotaRod 
scores, although the FAAH deficient group did have a lower performance (Figure 2.5 F), in a 
similar manner to Study 2. 
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Table 2.3: Acute Phase data from ‘Study 3’ CREAE Behavioural Experiment 
Acute Phase 
___________________________________________________________________________ 
Strain  No. EAE/ Group Score EAE score Day of Onset 
     Total     ± SEM    ± SEM    ± SD 
___________________________________________________________________________ 
ABH  27/28  3.9 ± 0.2 4.1 ± 0.1  15.1 ± 1.7 
 
ABH.FAAH-/- 35/43  3.0 ± 0.3** 3.7 ± 0.2  16.8 ± 1.7*** 
___________________________________________________________________________ 
Remission 1 
___________________________________________________________________________ 
Strain   No. RM1  Group Score 
      n      ± SEM 
___________________________________________________________________________ 
ABH   19   0.7 ± 0.1 
ABH.FAAH-/-  27   1.2 ± 0.2 
___________________________________________________________________________ 
RotaRod Performance 
___________________________________________________________________________ 
Strain   Pre-Immunisation      Remission 1 
     Time (s) ± SEM   Time (s) ± SEM 
___________________________________________________________________________ 
ABH      255 ± 14      197 ± 21 
ABH.FAAH-/-     242 ± 11      152 ± 21 
___________________________________________________________________________ 
*P < 0.05, **P < 0.01, ***P < 0.001 
 
EAE was induced in ABH wild-type and FAAH deficient mice with SCH on day 0 and 7. The data 
reflects maximal clinical score of the group, maximal clinical score of animals that developed 
EAE (mean ± S.E.M.) and the day of onset of EAE symptoms (mean ± S.D.) (Mann Whitney U 
test; *P < 0.05, **P < 0.01, ***P < 0.001). RotaRod scores reflect time of latency to fall (mean ± 
S.E.M.). (Student’s t-test; *P < 0.05, **P < 0.01, ***P < 0.001). 
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Figure 2.5. Variation in the accumulation of disability in repeated studies of FAAH 
knockout mice in the acute phase of EAE. 
 
EAE was induced in ABH wild-type and FAAH deficient mice with spinal cord homogenate in 
complete Freund’s adjuvant on day 0 and 7. The mean ± SEM daily clinical scores demonstrate 
that ABH.FAAH-/- mice (filled circles) show no difference in recovery from paralysis (A and E) 
and a decrease in recovery from paralysis (C) compared to wild-type mice (open circles). The 
mean ± SD day of onset was increased (A), showed no difference (C) and was decreased (E) in 
the ABH.FAAH-/- mice compared to wild-type (Mann Whitney U test; *P < 0.05, **P < 0.01, ***P 
< 0.001). The mean ± SEM motor control performance on an accelerating RotaRod pre-
immunisation and at remission 1 indicated that ABH.FAAH-/- mice had an improved recovery 
(B), a decline in recovery (D), and no change in performance compared to wild-type. (Student’s 
t-test; *P < 0.05, **P < 0.01, ***P < 0.001) 
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The variability and contrasting findings observed in these three experiments prompted the 
results to be combined from the three studies. All three studies were performed under the 
same conditions and the only difference was the time of year that they were done, and since 
the environmental conditions were maintained constant in the facility throughout the year, this 
was not seen as a confounding influence on any of the studies.  
Combining data from the three studies produced a large n number and reduced the 
variability. There was no significant difference between the groups in the Group Score, EAE 
Score or the Day of Onset (Table 2.4). However, at Remission 1, the FAAH deficient group 
shows a significantly slower recovery in clinical score and has a lower performance in the 
RotaRod test at Day 50 (Figure 2.6 A and B), indicating that FAAH deficiency adversely affects 
the recovery of this strain compared to wild-type following an acute phase disease insult. 
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Table 2.4: Acute phase data from a combination of the Pilot Study, Study 2 and Study 3 
CREAE behavioural experiments. 
 
Acute Phase 
___________________________________________________________________________ 
Strain  No. EAE/ Group Score EAE score Day of Onset 
     Total     ± SEM    ± SEM    ± SD 
___________________________________________________________________________ 
ABH  56/58  3.9 ± 0.1 4.1 ± 0.1  14.7 ± 1.6 
 
ABH.FAAH-/- 90/104  3.4 ± 0.2 3.9 ± 0.1  15.3 ± 1.9 
___________________________________________________________________________ 
Remission 1 
___________________________________________________________________________ 
Strain   No. RM1  Group Score 
     n      ± SEM 
___________________________________________________________________________ 
ABH   45   0.6 ± 0.0 
ABH.FAAH-/-  66   0.9 ± 0.1** 
___________________________________________________________________________ 
RotaRod Performance 
___________________________________________________________________________ 
Strain   Pre-Immunisation      Remission 1 
     Time (s) ± SEM   Time (s) ± SEM 
___________________________________________________________________________ 
ABH      259 ± 9      203 ± 12 
ABH.FAAH-/-     239 ± 7      159 ± 12* 
___________________________________________________________________________ 
*P < 0.05, **P < 0.01, ***P < 0.001 
 
EAE was induced in ABH wild-type and FAAH deficient mice with SCH on day 0 and 7. The data 
reflects maximal clinical score of the group, maximal clinical score of animals that developed 
EAE (mean ± S.E.M.) and the day of onset of EAE symptoms (mean ± S.D.) (Mann Whitney U 
test; *P < 0.05, **P < 0.01, ***P < 0.001). RotaRod scores reflect time of latency to fall (mean ± 
S.E.M.). (Student’s t-test; *P < 0.05, **P < 0.01, ***P < 0.001). 
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Figure 2.6. Genetic deletion of FAAH increases the accumulation of disability in the Acute 
Phase of CREAE. 
 
 
EAE was induced in ABH wild-type and FAAH deficient mice with spinal cord 
homogenate in complete Freund’s adjuvant on day 0 and 7 in three separate 
studies. The combined mean ± SEM daily clinical scores demonstrate that 
ABH.FAAH-/- mice (filled circles) show a decrease in recovery from paralysis (A) 
compared to wild-type mice (open circles). No difference in the day of onset 
(mean ± SD) was observed in the ABH.FAAH-/- mice compared to wild-type (Mann 
Whitney U test; *P < 0.05, **P < 0.01, ***P < 0.001). The mean ± SEM motor 
control performance on an accelerating RotaRod pre-immunisation and at 
remission 1 indicated that ABH.FAAH-/- mice had a decrease in recovery (B) 
compared to wild-type. (Student’s t-test; *P < 0.05, **P < 0.01, ***P < 0.001). 
 
 
Genetic deletion of FAAH in the ABH mouse shows a reduced neurological deficit following 
the relapse phase in CREAE 
It is important to note that animals that did not fully recover at Remission 1 (clinical score > 
0.5) were excluded from the remainder of the study as part of protocol. Only the animals that 
recovered were re-immunised at Day 28 to ensure a consistent baseline of prior disease to 
ensure rigour in the Relapse Phase analysis. The analysis reflects only the animals included in 
this phase of disease, and as such, the Remission 2 RotaRod data are compared to only the 
included Pre-immunisation and Remission 1 animals. 
The pilot study Relapse Phase showed a typical disease course for ABH CREAE, with an 
adequate frequency of disease relapse (18 / 24 animals) (Al-Izki et al., 2012) and equivalent 
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Group and EAE score between the groups (Table 2.5, Figure 2.7 A). As observed in the Acute 
Phase of this study (Table 2.1, Figure 2.5 A), there was also an early onset of relapse in the 
FAAH-deficient group. The FAAH deficient animals recovered significantly faster and with an 
improved clinical score than the wild-type group. However, this was not reflected in the 
RotaRod performance, with both groups showing no difference in motor control. An analysis of 
the total neurofilament (phosphorylated heavy chain) content was also assessed, with an 
increase in the ABH.FAAH-/- group, but with no statistical difference detected between the 
groups (Figure 2.7 C). As a reference guide, neurofilament content ranges from ~10 to 20 μg 
per mg of protein in naïve wild-type Biozzi ABH mice (Al-Izki et al., 2012).  
The Study 2 Relapse Phase showed a less typical disease course, with an immediate 
increase of symptoms observed following immunisation (Day 29 to Day 33). Following these 
initial symptoms, the disease course followed a more typical pattern (Day of Onset was scored 
from the prominent rise in symptoms). There was an adequate incidence of relapse (24 / 29), 
and equivalent Group and EAE score between the groups (Table 2.6, Figure 2.7 D). There was a 
significantly lower clinical score in the FAAH deficient group at Remission 2. The RotaRod scores 
also showed an increase in motor ability, although no statistical significance was observed 
(Figure 2.7 E). This may be due to this subset of animals (animals conforming to the re-
immunisation criteria) showing a distorted baseline, with the FAAH knockout group starting 
with a reduced motor ability pre-immunisation. 
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Table 2.5: Relapse Phase data from ‘Pilot Study’ CREAE Behavioural Experiment 
Relapse Phase 
___________________________________________________________________________ 
Strain  No. EAE/ Group Score EAE score Day of Onset 
     Total     ± SEM    ± SEM    ± SD§ 
___________________________________________________________________________ 
ABH     7/9  2.9 ± 0.6 3.8 ± 0.2  8.4 ± 1.3 
ABH.FAAH-/-    11/15  3.0 ± 0.5 4.1 ± 0.1  6.8 ± 0.9* 
Remission 2 
___________________________________________________________________________ 
Strain   No. RM2  Group Score 
     n      ± SEM 
___________________________________________________________________________ 
ABH   7   3.0 ± 0.1 
ABH.FAAH-/-  10   2.3 ± 0.2*** 
RotaRod Performance 
___________________________________________________________________________ 
Strain  Pre-Immunisation     Remission 1     Remission 2 
    Time (s) ± SEM   Time (s) ± SEM  Time (s) ± SEM 
___________________________________________________________________________ 
ABH            157 ± 14     93 ± 14 
ABH.FAAH-/-           167 ± 20     86 ± 21 
Neurofilament Content 
___________________________________________________________________________ 
Strain             Remission 2 
   (μg/mg protein) ± SEM 
___________________________________________________________________________ 
ABH    3.3 ± 0.4 
ABH.FAAH-/-   4.4 ± 0.5 
___________________________________________________________________________ 
§Day of Onset is post-immunisation at Day 28; *P < 0.05, **P < 0.01, ***P < 0.001 
 
CREAE was re-induced in ABH wild-type and FAAH deficient mice with SCH on day 28 in animals 
with a remission score ≤ 0.5. The data reflects maximal clinical score of the group, maximal 
clinical score of animals that developed a relapse (mean ± S.E.M.) and the day of onset of 
relapse symptoms (mean ± S.D.) (Mann Whitney U test; *P < 0.05, **P < 0.01, ***P < 0.001). 
RotaRod score reflects the time of latency to fall (mean ± S.E.M.) and neurofilament content 
(μg per mg of total protein) reflects the remaining nerve content in the spinal cord. (Student’s 
t-test; *P < 0.05, **P < 0.01, ***P < 0.001). 
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Table 2.6: Relapse Phase data from ‘Study 2’ CREAE Behavioural Experiment 
Relapse Phase 
___________________________________________________________________________ 
Strain  No. EAE/ Group Score EAE score Day of Onset 
     Total     ± SEM    ± SEM    ± SD§ 
___________________________________________________________________________ 
ABH     14/17     3.3 ± 0.4 4.0 ± 0.1  6.8 ± 1.4 
 
ABH.FAAH-/-    10/12     3.2 ± 0.4 3.7 ± 0.2  7.0 ± 1.0 
Remission 2 
___________________________________________________________________________ 
Strain   No. RM2  Group Score 
     n      ± SEM 
___________________________________________________________________________ 
ABH   12   2.7 ± 0.2 
ABH.FAAH-/-  10   1.9 ± 0.1* 
RotaRod Performance 
___________________________________________________________________________ 
Strain  Pre-Immunisation     Remission 1     Remission 2 
    Time (s) ± SEM   Time (s) ± SEM  Time (s) ± SEM 
___________________________________________________________________________ 
ABH     265 ± 12      229 ± 23     53 ± 15 
ABH.FAAH-/-    222 ± 13*      219 ± 28     96 ± 18 
§Day of Onset is post-immunisation at Day 28; *P < 0.05, **P < 0.01, ***P < 0.001 
 
CREAE was re-induced in ABH wild-type and FAAH deficient mice with SCH on day 28 in animals 
with a remission score ≤ 0.5. The data reflects maximal clinical score of the group, maximal 
clinical score of animals that developed a relapse (mean ± S.E.M.) and the day of onset of 
relapse symptoms (mean ± S.D.) (Mann Whitney U test; *P < 0.05, **P < 0.01, ***P < 0.001). 
RotaRod score reflects the time of latency to fall (mean ± S.E.M.) and neurofilament content 
(μg per mg of total protein) reflects the remaining nerve content in the spinal cord. (Student’s 
t-test; *P < 0.05, **P < 0.01, ***P < 0.001). 
 
The Relapse Phase in Study 3 showed a typical disease course for ABH CREAE, with a low 
incidence of relapse (21 / 33 animals). However, this low incidence was consistent in both 
groups and may have been due to using a new batch of SCH and adjuvant. This was reflected in 
the low Group Scores, but importantly, the EAE Score was within normal range, with no 
significant difference between the groups (Table 2.7, Figure 2.7 F). There was also no significant 
difference in Day of Onset of disease, despite this being observed in this study’s Acute Phase 
and in the Pilot Study Relapse Phase. The Remission 2 clinical score showed a significant 
improvement in the FAAH deficient group compared to wild-type, consistent with the Pilot 
Study and Study 2 Remission 2 clinical observations. In addition, there was a significantly 
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improved RotaRod performance and higher neurofilament content in the FAAH deficient group 
compared to the wild-type (Table 2.7., Figure 2.7 G and H). This correlates well with the clinical 
scoring observations, indicating that FAAH deficiency reduces the neurodegeneration 
associated with relapse in CREAE. 
 
Table 2.7: Relapse Phase data from ‘Study 3’ CREAE Behavioural Experiment 
Relapse Phase 
___________________________________________________________________________ 
Strain  No. EAE/ Group Score EAE score Day of Onset 
     Total     ± SEM    ± SEM    ± SD§ 
___________________________________________________________________________ 
ABH     11/15  2.7 ± 0.4 3.5 ± 0.2  8.3 ± 1.9 
ABH.FAAH-/-    10/18  1.7 ± 0.3* 2.9 ± 0.2  9.0 ± 1.7 
Remission 2 
___________________________________________________________________________ 
Strain   No. RM2  Group Score 
     n      ± SEM 
___________________________________________________________________________ 
ABH   11   1.9 ± 0.3 
ABH.FAAH-/-  8   0.9 ± 0.2* 
RotaRod Performance 
___________________________________________________________________________ 
Strain  Pre-Immunisation     Remission 1     Remission 2 
    Time (s) ± SEM   Time (s) ± SEM  Time (s) ± SEM 
___________________________________________________________________________ 
ABH     244 ± 20      255 ± 23     103 ± 23 
ABH.FAAH-/-    245 ± 17      231 ± 23     210 ± 32* 
Neurofilament Content 
___________________________________________________________________________ 
Strain             Remission 2 
   (μg/mg protein) ± SEM 
___________________________________________________________________________ 
ABH    5.4 ± 0.4 
ABH.FAAH-/-   6.9 ± 0.5* 
§Day of Onset is post-immunisation at Day 28; *P < 0.05, **P < 0.01, ***P < 0.001 
 
CREAE was re-induced in ABH wild-type and FAAH deficient mice with SCH on day 28 in animals 
with a remission score ≤ 0.5. The data reflects maximal clinical score of the group, maximal 
clinical score of animals that developed a relapse (mean ± S.E.M.) and the day of onset of 
relapse symptoms (mean ± S.D.) (Mann Whitney U test; *P < 0.05, **P < 0.01, ***P < 0.001). 
RotaRod score reflects the time of latency to fall (mean ± S.E.M.) and neurofilament content 
(μg per mg of total protein) reflects the remaining nerve content in the spinal cord. (Student’s 
t-test; *P < 0.05, **P < 0.01, ***P < 0.001). 
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Figure 2.7. Genetic deletion of FAAH reduces the accumulation of disability following a 
relapse in CREAE. 
 
EAE was induced in ABH wild-type and FAAH deficient mice with SCH on day 0 and 7. A relapse 
was induced on Day 28, only in animals with a remission 1 score of ≤ 0.5. The combined mean ± 
SEM daily clinical scores demonstrate that ABH.FAAH-/- mice (filled circles) show an improved 
recovery from paralysis compared to wild-type mice (open circles) in all three studies (A, D, F). 
The day of onset (mean ± SD) was later in FAAH knockout animals compared to wild-type in 
Study 1 (A), but no difference was observed in Study 2 (D) and Study 3. (Mann Whitney U test; 
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*P < 0.05, **P < 0.01, ***P < 0.001). The mean ± SEM motor control performance on an 
accelerating RotaRod at Remission 2 indicated that ABH.FAAH-/- mice had an improved recovery 
compared to wild-type in Study 3 (G), whilst no difference was observed in Study 1 (B) and 
Study 2 (E). The mean ± SEM Neurofilament Heavy content of the spinal cord at Remission 2 
was higher in ABH.FAAH-/- mice compared to wild-type in Study 3 (H), while no difference was 
detected in Study 1 (C). (Student’s t-test; *P < 0.05, **P < 0.01, ***P < 0.001). 
 
 
As discussed previously, the data from all three studies were combined in an attempt to 
reduce the observed variability by increasing the overall n numbers. Combining all the Relapse 
data produces a classic disease course with moderate incidence (60 / 86), consistent in both 
groups of animals. There were no significant differences observed between the groups in the 
Group Score, maximal clinical score, or the onset time of disease (Table 2.8, Figure 2.8). 
Importantly, and this was consistently observed in the individual studies, there was a 
significantly improved clinical score in the FAAH deficient group. This was also reflected by the 
improved RotaRod performance and increased levels of nerve content in the FAAH deficient 
animals following the disease course. All three outcomes of disease indicate a reduced 
neurological deficit in the FAAH deficient animals compared to the wild-type group. This was 
seen in all three studies, providing strong evidence that FAAH deletion is neuroprotective 
during the Relapse Phase of disease. 
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Table 2.8: Relapse Phase data from the combined Pilot, 2 and 3 studies of CREAE 
Behavioural Experiment. 
Relapse Phase 
___________________________________________________________________________ 
Strain  No. EAE/ Group Score EAE score Day of Onset 
     Total     ± SEM    ± SEM    ± SD§ 
___________________________________________________________________________ 
ABH     31/41  3.0 ± 0.2 3.8 ± 0.1  7.7 ± 1.7 
 
ABH.FAAH-/-    29/45  2.5 ± 0.2 3.6 ± 0.1  7.5 ± 1.5 
Remission 2 
___________________________________________________________________________ 
Strain   No. RM2  Group Score 
     n      ± SEM 
___________________________________________________________________________ 
ABH   30   2.5 ± 0.2 
ABH.FAAH-/-  28   1.8 ± 0.1*** 
RotaRod Performance 
___________________________________________________________________________ 
Strain  Pre-Immunisation     Remission 1     Remission 2 
    Time (s) ± SEM   Time (s) ± SEM  Time (s) ± SEM 
___________________________________________________________________________ 
ABH     244 ± 20      225 ± 23     103 ± 23 
ABH.FAAH-/-    245 ± 17      231 ± 23     210 ± 32** 
Neurofilament Content 
___________________________________________________________________________ 
Strain   No. RM2           Remission 2 
      n  (μg/mg protein) ± SEM 
___________________________________________________________________________ 
ABH   16            4.5 ± 0.4 
ABH.FAAH-/-  14            5.9 ± 0.5* 
§Day of Onset is post-immunisation at Day 28; *P < 0.05, **P < 0.01, ***P < 0.001 
 
CREAE was re-induced in ABH wild-type and FAAH deficient mice with SCH on day 28 in animals 
with a remission score ≤ 0.5. The data reflects maximal clinical score of the group, maximal 
clinical score of animals that developed a relapse (mean ± S.E.M.) and the day of onset of 
relapse symptoms (mean ± S.D.) (Mann Whitney U test; *P < 0.05, **P < 0.01, ***P < 0.001). 
RotaRod score reflects the time of latency to fall (mean ± S.E.M.) and neurofilament content 
(μg per mg of total protein) reflects the remaining nerve content in the spinal cord. (Student’s 
t-test; *P < 0.05, **P < 0.01, ***P < 0.001). 
 
  
80 
Figure 2.8. Genetic deletion of FAAH reduces the accumulation of disability following a 
Relapse in Relapsing Remitting EAE in all studies. 
 
EAE was induced in ABH wild-type and FAAH deficient mice with spinal cord homogenate in 
complete Freund’s adjuvant on day 0 and 7. A relapse was induced on Day 28, only in animals 
with a remission 1 score of ≤ 0.5, in three separate studies. (A) The combined mean ± SEM daily 
clinical scores demonstrate that ABH.FAAH-/- mice (filled circles) show an improved recovery 
from paralysis compared to wild-type mice (open circles). No difference in the day of onset 
(mean ± SD) was observed in the ABH.FAAH-/- mice compared to wild-type (Mann Whitney U 
test; *P < 0.05, **P < 0.01, ***P < 0.001). (B) The mean ± SEM motor control performance on 
an accelerating RotaRod at Remission 2 indicated that ABH.FAAH-/- mice had an improved 
recovery compared to wild-type. (C) The mean ± SEM Neurofilament Heavy content of the 
spinal cord at Remission 2 was higher in ABH.FAAH-/- mice compared to wild-type. (Student’s t-
test; *P < 0.05, **P < 0.01, ***P < 0.001). 
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2.5 Discussion 
2.5.1 FAAH deficiency raises anandamide levels in the ABH mouse 
The genetic deletion of FAAH, the catabolic enzyme of anandamide, causes a constitutively 
higher level of anandamide in the spinal cord tissue of ABH mice (8-fold higher compared to 
wild-type). This rise in anandamide is consistent to the heightened levels observed in the 
C57BL/6 mouse strain (>10-fold higher than wild-type) (Cravatt et al., 2001). This enhanced 
level of anandamide in the FAAH deficient mice provides a potential mechanism of action for 
the neuroprotective effects observed following EAE disease. Increased anandamide could 
provide an enhanced level of agonist for the CB1 receptor. This increased activation of the CB1 
receptor could be neuroprotective by causing a reduction in glutamate release at excitatory 
synapses. This could act as a “synaptic brake,” (Katona and Freund, 2008) potentially reducing 
glutamatergic excitotoxic events that may occur during disease, particularly in demyelinated 
axons (Marte et al., 2010; Pitt et al., 2000b; Sattler and Tymianski, 2001). Consistent with this 
notion, elevation of anandamide in the FAAH deficient mice appears to reduce the loss of 
neurons in the EAE disease model. 
 
2.5.2 Neuroprotective effect of FAAH in EAE Disease 
Monophasic disease EAE shows improved outcome in FAAH deficient mice 
The FAAH deficient C57BL/6 mice showed an improved recovery following monophasic 
EAE. This was consistent with the results reported by Webb et al. (Webb et al., 2008), but 
inconsistent with data reported by Rossi et al. (Rossi et al., 2011). However, based on some 
variability in individual experiments a delay in onset could be seen in ABH.FAAH-/-, but likewise 
an early onset was seen in other experiments and overall the data indicate that there is no 
marked influence of FAAH gene deletion on the development of EAE. These data indicate the 
value of reproducibility of results. Our observations in the C57BL/6.FAAH-/- reported here 
(Figure 2.4) confirm the results presented by Webb et al. (2008). However, it was found that 
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disease is inconsistent in C57BL/6 mice following induction of EAE with the MOG35-55 peptide. 
This is a consistent finding in many laboratories (Axtell et al., 2010; Coquet et al., 2013). In 
comparison to SJL/J and ABH mice, C57BL/6 mice are relatively EAE resistant and this genetic 
resistance to disease may account for variable disease onset (Levine and Sowinski, 1973; Baker 
et al., 1990). Furthermore, this may relate to the use of MOG35-55 peptide for immunization. 
MOG35-55 was first found to induce EAE in Biozzi ABH mice where it induces chronic EAE, in 
comparison to MOG8-22 that induces relapsing disease (Amor et al., 1994, 2005). However the 
MOG35-55 is a sub-dominant epitope compared to MOG8-22 in ABH mice and it induces 
inconsistent disease incidence (Amor et al., 1994). Likewise, it has been reported that MOG35-55 
is also sub-dominant to MBP119-132 (Shetty et al., 2012) and may contribute to this inconsistency. 
A reduction of clinical severity of EAE is usually associated with a failure of inflammatory cells 
to accumulate in the CNS (Allen et al., 1993). This is usually a consequence of peripheral 
immunosuppression. That FAAH-knockout mice developed disease with a comparable 
incidence and severity as wild-type mice and this indicates that there is essentially no 
immunosuppressive action of FAAH deletion as found by Webb et al. (2008). Therefore, 
comparable effects have been found on two distinct genetic backgrounds. The lack of overt 
immunosuppression was an important criterion when attempting to measure a 
neurodegenerative effect, because immunosuppression would clearly cause neuroprotection 
due to a failure of pathogenic cells to accumulate in the CNS. A recent study, also using the 
C57BL/6.FAAH-/- mice, showed that the FAAH deficient group had a late onset of disease and 
significantly reduced severity of disease (Rossi et al., 2011). Oddly, the authors claimed that the 
attenuation of EAE disease was consistent with those reported by Webb et al. (2008). 
Furthermore, using animals from those EAE experiments, the authors describe a mechanism of 
CB1 receptor mediated neuroprotection (Rossi et al., 2011). As the animals had an attenuated 
inflammatory attack, one assumes they will obviously have less neuronal damage, therefore 
questioning the neuroprotective properties of the intervention (Baker et al., 2011). This may 
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support the claim that anandamide may modulate the immune response in multiple sclerosis 
(Chiurchiù et al., 2013), although there is no good evidence to suggest that cannabinoids induce 
immunosuppression at physiological doses (Croxford et al., 2008). It is also interesting to note 
the variability in EAE disease course between Rossi et al., Webb et al and our findings when 
using the same knockout mouse strain. This probably reflects the limited usefulness of C57BL/6 
mouse strain in neuroprotection studies, in addition to the many subtle and un-reported 
differences in behavioural experimentation protocols including gender, weight and age 
distribution, cage dynamics and environmental enrichment, and reliance on subjective 
outcome measures (Baker and Amor, 2010; Kilkenny et al., 2010). Using the Biozzi ABH strain, 
here the initial findings of Webb et al. (2008) were confirmed and expanded upon by 
demonstration of robust neuroprotection in a relapsing remitting EAE model. 
 
A variable and slower acute phase recovery in FAAH deficient mice in CREAE 
There were some consistent and some variable observations in the three acute phase EAE 
behavioural studies. Both strains of ABH mice have a consistent incidence across the three 
studies, but there was an inconsistent time of disease onset. This was particularly noticeable 
when comparing the Pilot Study and Study 3, where both experiments showed statistically 
significant, but probably biologically irrelevant, differences in disease onset between the 
strains, but with opposite results. In the Pilot Study, there was an early onset, whilst in Study 3 
there was a late onset in the FAAH deficient animals (Figure 2.5). Overall, when combining all 
the data, including the neutral Study 2, showed no significant difference in onset between the 
strains. (Figure 2.6). 
The other variability in the data was with the outcome of Remission 1. All three of the 
studies had consistent inflammatory attack data (mean maximal EAE score) between the wild-
type and knockout strains. Despite this, the recovery to Remission 1 was similar, yet statistically 
different between the strains in Study 2, but not in the Pilot Study or Study 3 (Figure 2.5). 
Furthermore, the RotaRod data from the different studies concurred with their respective 
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clinical score data. Study 1 showed no difference between the strains, Study 2 showed a 
reduced clinical recovery and reduced RotaRod performance (albeit with a reduced pre-
immunisation baseline), whilst the Pilot Study showed no difference, and the Study 3 showed a 
reduced performance (but statistically insignificant). The combination of all three data sets 
showed a significant difference in Remission 1 in both the clinical score and RotaRod (Figure 
2.6).  
These ABH Acute Phase results are in contrast to the outcomes reported using the C57BL/6 
models both by Webb et al. (2008) and our own results presented in this Chapter (Figure 2.4), 
where the C57BL/6.FAAH-/- animals had an improved recovery. Yet we have seen a difference in 
the acute phase of the ABH model with the FAAH deficient animals worse off. Both models are 
essentially a monophasic disease. This may be a reflection of the response of the C57BL/6 
strain to the inflammatory assault, causing full blown neurodegenerative damage to the CNS. 
Whereas, in the ABH model, the inflammatory attack is more of a leucocyte infiltration causing 
paralysis, with FAAH deficiency possibly delaying the egress of these leucocytes out of the CNS 
(Allen et al., 1993). In another scenario, the data recorded from this set of animals may have 
been imprecise due to novice technique (particularly with the Study 2 experiment) and the 
combined ‘significant’ difference is a statistical anomaly. 
 
FAAH deletion has a neuroprotective effect in the relapse phase of CREAE 
There was low variability in most aspects of the data in the relapse phase (compared to the 
Acute Phase), with all three experiments showing the same trends. Some variability exists in 
the Study 2, particularly with the small rise in clinical scores immediately following 
immunisations (Day 28 – Day 31). This was probably a data artefact due to my personal 
inexperience of scoring EAE mice. There is a subtle difference in scoring in the acute phase 
compared to the relapse phase. In the acute phase, the first sign of disease is loss of tail tone 
(score 1), whereas in the relapse, the first sign of disease is more likely to be limb paresis (score 
2.5) (the tail has already lost some of its tone), so the distinction is much more difficult and less 
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linear than in the acute phase. The protocol used for the relapse phase requires all animals to 
be in remission (clinical score ≤ 0.5). Due to the ABH.FAAH-/- mice having a poor recovery 
following the acute phase, this resulted in considerable number of mice being removed prior to 
the relapse phase. There is a possibility that this may bias the relapse phase towards selection 
of individual animals that are able to better recover following disease. However, exclusion of 
these animals are still necessary, as the protocol requires, ensuring all mice begin the relapse 
phase with the same clinical score. 
The overall outcome of the relapse phase experiments, and this is more clearly evident in 
the combination of the three data sets, was a neuroprotective effect in disease at remission 2. 
This was consistent in all three of the outputs at Remission 2, including the clinical scores, 
RotaRod performances and the levels of spinal cord neurofilament (Figure 2.7 and 2.8). These 
results support our hypothesis that FAAH inhibition causing an elevation in AEA, with this in 
turn activating the CB1 receptor pathways, protects vulnerable neurons during CREAE disease. 
However, the involvement of other N-acylethanolamines acting via non-CB1 receptor mediated 
mechanism cannot be ruled out, as discussed below. 
 
2.5.3 Is neuroprotection driven by anandamide? 
The spectrum of altered fatty acid amide metabolism 
It is possible that the neuroprotective effect observed in these EAE studies was mediated 
by other substrates of FAAH, rather than AEA. FAAH elicits broad hydrolase specificity for a 
number of substrates in addition to anandamide. Genetic deletion of FAAH therefore raises all 
of these substrates including NAE (PAE, SEA and OEA) (Cravatt et al., 1995; Kathuria et al., 
2003; Long et al., 2011), FAPA (oleamide (Cravatt et al., 1996)), N-acyl glycines (N-oleoyl 
glycine (OlGly), N-stearoyl glycine and N-palmitoyl glycine (PalGly) (Bradshaw et al., 2009a)) and 
N-Acyl taurines (Long et al., 2011). None of these molecules bind to the CB1 receptor, and it is 
therefore of interest that in contrast to the neuroprotection seen with enhanced 
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endocannabinoid levels, this complement the previous observations that CB1 receptor 
deficiency is associated with enhanced neurodegeneration (Pryce et al., 2003). 
There is also the possibility of a FAA ‘entourage effect’ with the genetic deletion of FAAH. 
All of the FAAs described above require micromolar concentrations of ligand to activate their 
respective receptors. FAA at this concentration, in the tissue of FAAH inhibitor treated or FAAH-
/- tissue, has not been reported (with the exception of NAT). Although these FAA can activate 
these different receptors, it is probable that they require a high localised concentration. This 
may occur when a combination of FAAs, all at elevated concentration (due to FAAH deletion / 
inhibition), could synergistically activate these receptors (Bradshaw et al., 2009a; Ho et al., 
2008). 
 
Additional non-CB1 receptor effects of raised anandamide 
Anandamide is an agonistic ligand for the CB1 receptor, but not exclusively as it also 
interacts with other protein targets. These include the CB2 receptor, G-protein coupled 
receptor 55 (GPR55) (Lauckner et al., 2008), TRPV1 (Chávez et al., 2010; Tognetto et al., 2001; 
Zygmunt et al., 1999) and PPARα (O’Sullivan, 2007). Activation of these receptors could 
mediate some of the effects observed in the CREAE behavioural study. For example, activation 
of PPAR receptors can modulate aspects of EAE (Racke et al., 2006; Xu et al., 2006). Likewise, 
TRVP1 may have immunosuppressive potential as shown by receptor agonism (Tsuji et al., 
2010) and thus would be associated with immunosuppression which was not seen here. 
However, due to the noxious nature of these chemicals, such immunosuppression is likely to be 
due to a stress response to adverse effects of TRPV1 agonism, as was found with high doses of 
CB1 receptor agonism (Croxford et al., 2008). It is of interest therefore, that TRPV1 deficient 
mice have no influence of susceptibility to EAE (Croxford et al., 2008). In contrast, GPR55 
knockout mice exhibit a mild immunosuppressive phenotype (S. Sisay, unpublished), which 
would therefore suggest that anandamide is not working via this mechanism as GPR55 agonism 
who induce a worse phenotype. 
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In summary, FAAH deficient mice have elevated anandamide and it is hypothesised that 
this causes enhanced activation of CB1 receptors resulting in neuroprotective effects during 
CREAE disease. However, as described, AEA is not the only substrate for FAAH, and does not 
exclusively bind to the CB1 receptor. Therefore, the effects of FAAH deficiency reported here 
may also be explained by the elevation of other FAA catabolised by FAAH, and the actions of 
their downstream signalling pathways. In addition, the non-CB1 receptor activation by AEA also 
needs to be considered. It is important to note that there was no difference in the 
inflammatory component of the EAE disease (no difference in mean maximal clinical scores). 
There were also no differences observed in the relative satiety or sleepiness between the 
groups. Overall, these observations support our hypothesis of these results indicating a 
neuroprotective role of FAAH inhibition and elevated AEA. 
 
Developmental effects of FAAH genetic deletion on neuronal circuitry 
It is possible that FAAH deletion may alter the development of neuronal circuitry in the 
transition from synaptogenesis to a functioning synapse in the developing brain. 
Endocannabinoids and the CB1 receptor provide a retrograde signalling pathway to tune 
synaptic development (Bernard et al., 2005; Berghuis et al., 2007), progenitor proliferation, 
pyramidal specification (Mulder et al., 2008) and axonal navigation (Díaz-Alonso et al., 2012). 
This is evident with the expression of the cannabinoid system (including CB1 / CB2 receptors, 
FAAH and DAGL) in embryonic (Begbie et al., 2004; Watson et al., 2008) and adult neurogenesis 
(Goncalves et al., 2008). A genetic deletion would perturb this feedback pathway from the 
embryogenesis stage. On one hand, it would be surprising that an 8-fold increase in AEA 
signalling from the post-synaptic neuron would not have a profound effect on circuitry. On the 
other hand, neurodevelopment has evolved multiple feedback systems to control events such 
as differentiation and neurite outgrowth. Firstly within the cannabinoid system, 2-AG plays a 
dominant role in the endocannabinoid feedback with a magnitude higher level and stronger 
agonism for CB1 receptor than anandamide. These levels of 2-AG are unaffected by the 
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deletion of FAAH (Figure 2.3), leaving this system to still function in some (if not full) capacity as 
a retrograde feedback on circuitry.  
Secondly, several other systems also provide feedback during synaptogenesis and neural 
development including the Wnt family ligands (Ahmad-Annuar et al., 2006), glutamate release, 
and the brain-derived neurotrophic factor (BDNF) / TrkB pathway (Harkany et al., 2008).  
The ABH FAAH knockout mice appear to have a relatively normal adult motor co-ordination 
function on a behavioural level (e.g. pre-immunisation RotaRod analysis) and CNS neuronal 
organisation (see Chapter 4). These phenotypic and anatomical aspects, however, were not 
explored in detail. As described in Chapter 1.2.4, the ABH FAAH knockout mice showed no 
changes in CB1 receptor density, CB1 receptor gene expression, and minor downregulation in 
receptor signalling activity in the substantia nigra and cerebellum, but in no other regions of 
the brain (Cabranes et al., 2006; Pryce et al., 2013), indicating that a generally normal CB1 
receptor system is present in the adult mouse, despite the 8-fold elevation in anandamide. 
 
2.3.4 FAAH as a neuroprotective pharmacological target in MS 
There is now an exciting body of evidence that demonstrates FAAH deficiency reduces 
neuronal loss in an EAE model, performed in different mouse strains, with a high number of 
repeats and in different research groups.  
Based on these animal studies, there is potential to target pharmacologically to reduce 
neurodegeneration in MS. This is particularly pertinent as FAAH deficiency and raised 
anandamide is efficacious without the undesirable cannabimimetic effects (Cravatt et al., 
2001). Elevation of anandamide presents a major step forward in targeting the CB1 receptor 
pathway for therapy. Previous attempts using exogenous cannabinoid agonists, such as THC 
and R(+)WIN-55,212-2, can present with undesirable tetrad effects in rodent models (Baker et 
al., 2001; Croxford et al., 2008, 2008) and psychoactive effects in clinical treatment (Corey-
Bloom et al., 2012; Zajicek et al., 2003). Another plausible strategy is to target MAGL inhibition, 
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with 2-AG as the CB1 receptor agonist. However, one speculates that prolonged treatment with 
a MAGL inhibitor, although it may be effective as a CB1 receptor agonist, will also present 
undesirable cannabimimetic effects, and downregulation of the CB1 receptor system as 
demonstrated in MAGL deficient mice and chronically dosed mice with the MAGL inhibitor 
JZL184 (Schlosburg et al., 2010).  
The targeting of FAAH inhibition, raising anandamide as a CB1 receptor agonist appears to 
circumvent both of these issues. No cannabimimetic effects were observed in FAAH knockout 
mice despite the 8-fold higher anandamide levels. In addition, analysis of the CB1 receptor 
system in ABH.FAAH-/- showed that the CB1 receptor signalling system has a threshold that can 
tolerate an 8-fold increase in anandamide (Pryce et al., 2013).  
Translating these findings into a treatment strategy, elevation of anandamide is a 
promising way to achieve CB1 receptor activation and achieve efficacy without perturbing the 
system and causing a downregulation. Although a FAAH deficient mouse is an excellent tool for 
validating FAAH as a target, a gene knockout model is limited for translation to the clinic. 
Therefore, further EAE studies are required using a pharmacological approach, and with the 
availability of potent, selective inhibitors with durable pharmacokinetics (Ahn et al., 2009b, 
2011) this is now a worthy opportunity, and the focus of Chapter 3. 
 
2.3.5 Future Experiments 
To gain a greater understanding of the mechanism of action, and to identify whether 
increased CB1 receptor agonism by raised levels of anandamide is indeed the mechanism of 
action, one could block this receptor. Treatment of ABH.FAAH-/- mice with a CB1 receptor 
antagonist, such as Rimonabant (SR141617A), during a CREAE disease course may reduce the 
efficacy of FAAH deficiency, if this were the sole mechanism of action. A similar experiment 
could be designed by crossing the ABH.FAAH-/- mice with the ABH.Cnr1-/- to create a double 
knockout. However, difficulties exist with this approach as ABH.Cnr1-/- mice are vulnerable to 
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neurodegeneration. The neurons degenerate with ageing faster than in wild-type mice, and in 
addition, during an EAE experiment the mice undergo significant neurodegeneration in the 
acute phase, with a poor recovery at remission 1. This makes the more disease relevant 
relapsing-remitting model (CREAE) difficult to execute. However, should the FAAH deletion 
(and elevated AEA) benefit these animals (reduce the neurodegeneration), then one would 
reject the hypothesis that this is a CB1 receptor mediated effect. From the practical experience 
of measuring these somewhat subtle end points in EAE, one would be concerned with the 
difficulty in observing a significant difference from either of the CB1 receptor antagonist, or the 
FAAH::CB1 receptor double knockout mice in a CREAE experiment. 
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Chapter 3: Effects of pharmacological inhibition of FAAH in a 
  relapsing remitting EAE model 
The experimental work reported in this chapter builds upon the promising neuroprotection 
observed in the FAAH deficient mice in the CREAE model, as reported in Chapter 2. Translation 
of FAAH deficiency into a therapeutic model requires a pharmacological approach. Here, the 
properties of FAAH inhibitor compounds are explored, with the most promising available 
compound (PF-3845) being tested in the CREAE model. In addition, the effect of this compound 
on anandamide levels in the CNS was investigated. 
 
3.1.1 FAAH Inhibitor compounds 
FAAH is a serine hydrolase, with an amidase signature (McKinney and Cravatt, 2005). The 
enzyme is embedded in the internal membrane of the cell, with an exposed catalytic site. The 
hydroxyl group of Ser241 is the principal amino acid involved in the hydrolysis reaction 
involving a proton exchange between Lys142 and Ser217 to Ser241. This leads to the formation 
of a tetrahedral intermediate with the corresponding group in the carbonyl of anandamide and 
Ser241. Ser241 is the nucleophile, and is therefore the target of inhibitor binding to prevent 
this intermediate from forming with the enzyme, or being released from the enzyme (Ahn et 
al., 2008). 
Numerous inhibitors of FAAH have been generated by medicinal chemists due to the 
promising analgesic properties of elevated anandamide induced by FAAH inhibition (Cravatt et 
al., 2001; Seierstad and Breitenbucher, 2008). FAAH inhibitors are conventionally divided into 
two groups, reversible and irreversible inhibitors according to their half-life inside the catalytic 
site. Amongst the reversible inhibitors, the main structural class are α-ketoheterocycles. The 
irreversible inhibitors include carbamate and urea structural classes. Other important 
irreversible inhibitors are fluorophosphonates, such as methoxy arachidonoyl 
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fluorophosphonate (MAFP), which was incorporated in the first atomic resolution crystal 
structure of FAAH (Bracey et al., 2002). 
 
Alpha-ketoheterocycles-based compounds 
This class of compounds were designed to mimic the arachidonic part of AEA and were the 
first class of FAAH inhibitors (1994 – 2005). This class of compounds include CAY10402, 
CAY10400, and OL-135 and all are reversible inhibitors of FAAH (Boger et al., 2000; Lichtman et 
al., 2004c; Pryce et al., 2013). Proteomic studies have shown OL-135 to be highly selective for 
FAAH. In addition, in vivo administration of the OL-135 causes an elevation of anandamide, and 
induces analgesia in pain assays (Boger et al., 2005; Chang et al., 2006; Lichtman et al., 2004c). 
However, the alpha-ketoheterocycle compounds, despite their potency and selectivity, cause 
only transient increases in anandamide in vivo and therefore they have poor efficacy (Pryce, 
2010), by comparison with the FAAH deficient mouse (Lichtman et al., 2004a). The poor 
pharmacokinetics of alpha-ketoheterocycle compounds is probably the explanation behind the 
lack of efficacy observed in vivo as a >85% inhibition of FAAH is required to constitutively 
elevate anandamide (Fegley et al., 2005). 
 
Carbamate-based compounds 
The next class of compounds to be designed were based upon a replacement of the amide 
group of anandamide with a carbamate group. The carbamate moiety binds irreversibly to the 
nucleophile Ser241 residue producing a potent inhibitor of FAAH. This class of compounds 
includes URB597, a potent (IC50 = 4.6 μM; kinact/Ki = 800 M-1s-1) and well characterised FAAH 
inhibitor (Fegley et al., 2005; Kathuria et al., 2003). This compound binds covalently to the 
active site of FAAH, as demonstrated in the crystal structure of FAAH::URB597 (Mileni et al., 
2010), and displays promising pharmacokinetics (Piomelli et al., 2006), with complete recovery 
of FAAH activity only occurring >24 h after administration of URB597 (Seierstad and 
Breitenbucher, 2008). However, the selectivity of this compound is questionable from activity-
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based activity profiling (Zhang et al., 2007) and there is evidence that some of its effects are 
independent of FAAH inhibition (Pryce, 2010; Bosier et al., 2012) For example, a dose of 5 
mg.kg-1 URB597 inhibited spasticity in a CREAE mouse, but at this dose the same effect was 
observed in both wild-type and in FAAH deficient mice (Pryce, 2010). These findings indicate 
that this compound has additional off-target effects. This further demonstrates the importance 
of the using knockout mice in validating targets for therapy. 
 
Figure 3.1. URB597 inhibition in CREAE was observed in wild-type and FAAH deficient 
mice. 
 
ABH.FAAH-/- or ABH.FAAH+/+ mice were injected with 5 mg.kg-1 i.v. URB597 in Ethanol: 
Cremophor: PBS (1:1:18) and the resistance to hind limb flexion was assessed using a strain 
gauge at baseline and following administration of drug. To facilitate visualisation of differences 
between groups, results are expressed as the mean ± SEM percentage change in the resistance 
to hind limb flexion compared to baseline. The data was compared to baseline and assessed 
using a paired t test (*** P <0.001). This work was published by G. Pryce (2010). 
  
94 
Urea-based compounds 
The recent development of FAAH inhibitors has delivered more sophisticated compounds 
that were rationally designed by substituting the amide group of anandamide (or the 
carbamate group of URB597) with a urea moiety. This series of compounds includes the 
Johnson and Johnson compound JNJ-1661010 (Karbarz et al., 2009), and Pfizer compounds PF-
750 (Ahn et al., 2007), PF-3845 (Ahn et al., 2009b) and PF-04457845 (Johnson et al., 2011). 
 
PF-3845 
PF-3845 is a piperidine urea compound that covalently carbamylates the active serine 
(Ser241) forming a stable urea complex within the active site of the hydrolase. This inhibits 
FAAH activity with high potency (Ki = 0.23 ± 0.03 μM) and displays high selectivity. PF-3845 has 
a promising pharmacodynamic and pharmacokinetic profile in mice. Administration of PF-3845 
(10 mg.kg-1) raised AEA levels over 10-fold higher than baseline at a peak of 5 h post-injection. 
This elevation persisted for 24 h, but with a declining level over time compared to baseline (< 2-
fold). In addition, the PF-3845 compound was reported to be detectable in the brain 12 h after 
treatment (Ahn et al., 2009b). 
The selectivity of FAAH inhibition was designed with the assistance of activity-based 
protein profiling. This highly sensitive method allows the visualisation of compound binding to 
entire serine hydrolase proteome (Simon and Cravatt, 2010b). PF-3845 and the clinical PF-
04457845 compounds were both rationally designed and the selectivity for FAAH was guided 
by this analysis.  
PF-3845 has shown efficacy in pain and anxiety models; a reduction in inflammatory pain 
(Ahn et al., 2009b), neuropathic pain (Kinsey et al., 2010) and allodynia (Booker et al., 2011) 
was reported in rat models in a CB1 receptor-dependent manner. Administration of PF-3845 
was shown to reduce anxiety in a rat marble burying assay at doses that did not affect 
locomotor activity. Interestingly, the compound JZL-184, a MAGL inhibitor, produced similar 
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results indicating that the probable mechanism of action was CB1 receptor activation caused by 
elevation of either AEA or 2-AG (Kinsey et al., 2011). 
PF-04457845 
An additional compound in this series, PF-04457845, was produced for clinical applications 
(Johnson et al., 2011). This is an orally administered inhibitor with high potency, “exquisitely 
selective” as determined by activity-based protein profiling (Simon and Cravatt, 2010b) and 
mass spectrophotometry (Rakers et al., 2011), and promising pharmacodynamics with a 1 mg 
/kg dose increasing AEA levels for > 24 h duration. Notably, treatment of mice with PF-
04457845 at a higher dose of 10 mg/kg elicited no effect in body temperature, motility and 
body temperature (Ahn et al., 2011). This compound was recently in a phase II clinical trial for 
treatment of pain, indicating that this novel class of compound has passed initial safety trials in 
humans. However, the compound did not show efficacious pain relief and the trial did not 
progress beyond a Phase II trial. Despite these disappointing results, the positive aspect is that 
the drug passed safety trials in humans, with no significant adverse effects observed in both the 
Phase I and Phase II trials (Ahn et al., 2011; Huggins et al., 2012; Li et al., 2011). 
The brief history of FAAH inhibitors has provided valuable information about FAAH activity 
in vivo. The pharmacological data generated to date supports the hypothesis that inhibition of 
FAAH causes elevation of AEA and activation of the CB1 receptor. Furthermore, this has is the 
basis of a therapeutic strategy for reducing pain and anxiety (Roques et al., 2012). For this 
study, the same FAAH inhibition strategy was employed, with the objective being to assess 
whether treatment with a FAAH inhibitor can replicate the neuroprotective effects of FAAH 
deletion observed in the CREAE model, as reported in Chapter 2. The urea-based compounds 
were selected as the pharmacological agent of choice based on the superior selectivity, long 
half-life and ability to induce a sustained increase in AEA levels in the CNS. Due to intellectual 
property restrictions at the time of the study, the only urea-based compound available was PF-
3845, and this was used in all of the experiments described in this chapter.  
96 
3.2 Aims and Objectives 
Aims 
i) To investigate the effect of pharmacological FAAH inhibition in EAE disease.  
 
Objectives 
i) To analyse the effect of FAAH inhibitor treatment in chronic relapsing remitting EAE 
disease, investigating behavioural clinical deficits and motor control, and molecular 
neurofilament levels. 
 
ii) To analyse the anandamide levels in the CNS following FAAH inhibitor treatment. 
 
 
3.3 Methods and Materials 
3.3.1 FAAH Inhibitors 
The PF-3845 compound used in this study was a kind gift from Professor Ben Cravatt (The 
Skaggs Institute, La Jolla, CA, USA) and Dr. James Pearson (Ironwood Pharmaceuticals, Inc., 
Cambridge, MA, USA), which was used in the respective ‘Daily’ and ‘Twice Daily’ EAE 
behavioural studies. The original source of both batches was the Cayman Chemical Company 
(Ann Arbor, MI, US). 
 
Formulation and administration of PF-3845 
The PF-3845 compound was solubilised in ethanol: cremophor: saline in a 1:1:18 ratio and 
in that order, as described in Long et al. (2009). The compound was easily solubilised, some 
vortexing was required to mix the cremophor, but no sonicating or heating was required. 
Vehicle was mixed in the same formula, without addition of the PF-3845 compound. Both 
formulas were aliquotted and frozen, with a single aliquot thawed prior to every treatment. 
Vehicle and PF-3845 were colour coded so that the experimenter who administered the 
injections and scored the animals (R. Graves) was blind with respect to treatments. Animals 
were tail marked according to blinded colour code for treatments. ABH mice were administered 
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either 10 mg.kg-1 PF-3845 (100 μl of 2.5 mg.ml-1) or vehicle via an intraperitoneal injection once 
daily in the 24 h Study, or twice daily (7 am and 7 pm) in the 12 h Study.  
 
3.3.2 Chronic relapsing EAE behavioural protocol 
Wild-type ABH mice were immunised and assessed for clinical score using the same 
protocol as previously described (Chapter 2.2.3). At Remission 1 (Day 28), the animals’ motor 
skills were assessed by RotaRod and randomised into two groups of equal scores. Both groups 
were immunised with the same batch of immunogen at Day 28, as described previously 
(Chapter 2.2.3.1). Animals were clinically scored based on a disability scale as previously 
described (Chapter 2.2.3.2). At Day 33, treatment with vehicle or PF-3845 was initiated with a 
single injection in a blinded manner. In separate studies, treatments were administered either 
once daily (every 24 h) (Results 3.4.1) or twice daily (every 12 h) (Results 3.4.3). All animals 
were assessed daily for clinical score. At Remission 2 (Day 50) the animals were assessed by 
RotaRod, and subsequently the animals were culled and the spinal cords removed for analysis 
of neurofilament content as described previously (Chapter 2.2.3.3 and 2.2.3.4). 
 
3.3.3 Quantitation of Fatty Acid Amides (FAA) 
Mice were individually anaesthetised in CO2 until breathing stopped. The abdomen cavity 
was opened, the heart cut and the blood was extracted using a glass Pasteur pipette. The blood 
was placed into lithium heparin tubes (BD Becton-Dickinson, Oxford, UK) and gently mixed to 
minimise clotting. The blood was centrifuged to separate the plasma. The plasma was removed 
and placed into a labelled tube and frozen immediately on dry ice. 
Immediately following the blood extraction, the head was removed, the skull opened and 
the brain removed and placed into a labelled 5 ml bijoux container (Sterilin, Caerphilly, UK), and 
flash frozen in liquid nitrogen. Both of these procedures were performed in less than 1 min 
from anaesthetisation. Samples were analysed by Dr. Stacy Arnett (Ironwood Pharmaceuticals 
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Inc.) using liquid chromatography mass spectrometry techniques with both the type of 
treatment and mouse strain details blinded from the experimenters. 
 
3.3.4 Statistical Analysis 
Statistical methods used to assess CREAE behavioural studies 
The primary outcome of these studies was to compare the treatment groups at Remission 
2 (Day 50) as an indicator of neurodegeneration following a CREAE disease course. Power 
analysis, using G*Power software version 3.1.3 (Erdfelder et al., 1996), of previous CREAE 
experiments (e.g. Chapter 2.4) indicates that groups sizes of n = 11 at Day 50 has over 80 % 
power to detect statistically accurate therapeutic effects (Vesterinen et al., 2010). There is an 
attrition rate of animals that are non-responders, moribund or fail to recover after Acute Phase 
(to 0.5 clinical score), and this was factored into animal number requirements. 
The scores were analysed using the same method as described in Chapter 2.3.3. Briefly, the 
differences in clinical scores and the day of onset of EAE between the treatment groups were 
assessed using non-parametric statistics using SPSS version 20 (IBM SPSS Statistics, IBM Inc., 
USA). The Group Score represents the maximal clinical grade ± standard error of the mean 
(S.E.M.) developed by all animals within the group. The EAE score represents the maximal 
clinical grade ± S.E.M. developed only by animals that relapsed and the day of onset ± standard 
deviation (S.D.) represents the day of the first increase of clinical signs. RotaRod (mean ± 
S.E.M.) and neurofilament (mean ± S.E.M.) data were analysed using student’s t-tests 
incorporating a test for normality and equality of variance using SPSS version 20. 
 
Statistical methods for assessing the quantitation of anandamide. 
The mean AEA levels of the different treatment and strain groups were compared using a 
one-way analysis of variance followed by a Bonferroni's Multiple Comparison Test using 
GraphPad Prism 5 (GraphPad Software, Inc., USA). 
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3.4 Results 
3.4.1 Daily treatment with PF-3845 shows no improvement in neurological 
  deficit in CREAE behavioural assays 
This study, incorporating daily treatment, showed a typical disease course for ABH CREAE, 
with high frequency of disease incidence (28 / 31 animals), and also a robust inflammatory 
attack with many of the animals reaching a maximal clinical score of 4. Of note, and potentially 
a weakness of this study, was the poor recovery from the acute phase with only 6 (out of 28) 
animals reaching the ideal ≤0.5 clinical score which is usually the inclusion criteria for such a 
study. In the interests of animal preservation, the study was continued with the animals divided 
into two groups based on equivalent RotaRod scores. The data presented in the Table 3.1 only 
reflects those animals that completed the entire 50 day study. Hence, the Remission 1 RotaRod 
data presented are the mean scores of those 22 animals, and not the equivalent scores from 
the original 28 animals. As a consequence, there is an unbalanced baseline at Remission 1. 
The relapse phase followed a typical disease course with, again, a robust inflammatory 
attack. The treatment, initiated on Day 33, showed no impact on the Day of Onset of the 
relapse or the EAE relapse score (Table 3.1, Figure 3.2). There was a sustained recovery 
following the relapse, with the PF-3845 treated group showing a more rapid recovery, however 
there was no significant difference in the clinical scores at Remission 2 (Day 50). This 
observation was further endorsed by the RotaRod performance, with no statistically significant 
difference detected in the motor abilities between the two treatment groups at Remission 2 
(Figure 3.2 B). As mentioned previously, the Remission 1 RotaRod data have mismatched 
baseline scores due to the loss of non-responding (clinical score ≤ 0.5) and moribund (clinical 
score >4) animals during the relapse phase. These results were further confirmed on a 
molecular level with the analysis of spinal cord neurofilament heavy chain content. No 
significant difference in spinal cord neurofilament was detected in the ELISA between the 
treatment groups (Figure 3.2 C).  
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Table 3.1: Daily Treatment with PF-3845 in CREAE Behavioural Experiment 
Acute Phase 
Treatment      n   EAE score  Day of Onset 
         ± SEM     ± SD 
Vehicle      10   3.9 ± 0.1   15.4 ± 0.3 
PF-3845     12   3.7 ± 0.1   15.5 ± 0.4 
Remission 1 
Treatment  No. RM2  EAE Score 
     n      ± SEM 
Vehicle   10   1.7 ± 0.3 
PF-3845  12   1.7 ± 0.2 
 
Relapse Phase 
___________________________________________________________________________ 
Treatment  No. EAE/  EAE score  Day of Onset 
      Total      ± SEM     ± SD§ 
___________________________________________________________________________ 
Vehicle      10/14   4.0 ± 0.1   7.8 ± 1.7 
PF-3845     12/14   3.9 ± 0.1   6.7 ± 2.1 
Remission 2 
Treatment  No. RM2  EAE Score 
     n      ± SEM 
Vehicle   10   3.1 ± 0.1 
PF-3845  12   2.7 ± 0.1 
RotaRod Performance 
Treatment      Remission 1     Remission 2 
    Time (s) ± SEM  Time (s) ± SEM 
___________________________________________________________________________ 
Vehicle       157 ± 21     41 ± 9 
PF-3845      121 ± 17     49 ± 9 
Neurofilament Content (μg / mg protein) 
Treatment    n            Remission 2 
     (μg/mg protein) ± SEM 
Vehicle   10   3.4 ± 1.2 
PF-3845  11   4.7 ± 1.4 
§Day of Onset is post-immunisation at 28; *P < 0.05, **P < 0.01, ***P < 0.001 
 
EAE was induced in ABH wild-type mice with SCH on day 0 and 7. The data reflect maximal 
clinical score of the animals that developed EAE (mean ± S.E.M.) and the day of onset of signs 
of EAE (mean ± S.D.). CREAE was re-induced in ABH wild-type with SCH on day 28 in animals 
with a remission score ≤ 0.5. All animals were untreated in Acute Phase and randomised into 
treatment groups at Remission 1. Animals excluded from the Relapse Phase (e.g. non-
responders) were retrospectively excluded from the Acute Phase analysis. Animals were 
treated daily from Day 33 onwards with either vehicle or PF-3845 (10 mg.kg-1) by 
intraperitoneal injection. The data reflects maximal clinical score of the group, maximal clinical 
score of animals that developed a relapse (mean ± S.E.M.) and the day of onset of relapse 
symptoms (mean ± S.D.) (Mann Whitney U test; *P < 0.05, **P < 0.01, ***P < 0.001). RotaRod 
score reflects the time of latency to fall (mean ± S.E.M.) and neurofilament content (μg per mg 
of total protein) reflects the remaining nerve content in the spinal cord. (Student’s t-test; *P < 
0.05, **P < 0.01, ***P < 0.001). 
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Figure 3.2. Daily treatment with FAAH inhibitor PF-3845 shows no improvement in 
neurological recovery in CREAE disease. 
 
EAE was induced in ABH wild-type with SCH in complete Freund’s adjuvant on day 0 and 7. At 
day 28, the animals were divided into equivalent groups and re-immunised with SCH. (A) The 
combined mean ± SEM daily clinical scores show no difference between vehicle (open circles) 
or 10 mg.kg-1 PF-3845 (filled circles) daily treated mice in the recovery from the relapse (Mann 
Whitney U test; *P < 0.05, **P < 0.01, ***P < 0.001). (B) The mean ± SEM motor control 
performance on an accelerating RotaRod showed no difference at remission 2 between the 
vehicle (open bars) or PF-3845 (filled bars) treated groups. (C) The mean ± SEM neurofilament 
content of the spinal cord showed no difference at remission 2 between the vehicle (open bars) 
or PF-3845 (filled bars) treated groups. (B & C; Student’s t-test; *P < 0.05, **P < 0.01, ***P < 
0.001). 
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3.4.2 Pharmacodynamics of anandamide following PF-3845 treatment 
A 5-fold increase in brain anandamide levels was detected in the FAAH deficient mice 
compared to baseline (untreated wild-type mice). However, no significant difference in 
anandamide levels was observed when comparing vehicle and PF-3845 treated FAAH deficient 
animals. Importantly, this demonstrates that PF-3845 treatment in the FAAH deficient mouse 
has no effect on anandamide levels, indicating that PF-3845 is indeed increasing anandamide 
level via FAAH, and is not acting through an off-target mechanism (Figure 3.3). 
In wild-type mice treated with PF-3845, there was a significant 4-fold rise in anandamide 
levels 1 h following treatment, compared to vehicle treated animals. This confirms that in our 
hands this dosage of PF-3845 treatment elevates AEA in the brain of the ABH mouse. It should 
be noted, however, that the baseline AEA levels were an order of magnitude lower than AEA 
levels measured in FAAH knockout mice. 
The anandamide levels 24 h after PF-3845 treatment were substantially reduced compared 
to after 1 h treatment with no significant difference in AEA levels for vehicle or PF-3845 treated 
mice. This indicates that the anandamide levels in the brain returns close to baseline 24 h 
following PF-3845 treatment. These results , in addition to the kinetic profile reported by Ahn 
et al., 2009, prompted a change in the PF-3845 treatment regime in the CREAE disease model 
to treated every 12 h, instead of 24 h.  
 
Effects of FAAH inhibition on other fatty acid amides 
As discussed extensively in Chapter 1 (section 1.3.2) the disruption of FAAH activity 
increases levels of a spectrum of FAAs. A substantial elevation (4 to 6 fold above baseline) of 
PEA, OEA and DHEA (docosahexaenoyl ethanolamide) was detected in brains from FAAH 
knockout mice, with no difference between the vehicle and PF-3845 treated mice. In brain 
samples from wild-type mice, a significant elevation in PEA, OEA and DHEA was also measured 
1 hour after treatment with PF-3845. A sustained elevation of PEA and DHEA was detected in 
the wild-type brains 24 hour after treatment with PF-3845 (data not shown). 
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Figure 3.3. The pharmacodynamic profile of brain anandamide following treatment with 
the FAAH inhibitor PF-3845. 
 
ABH wild-type and FAAH deficient mice were administered a single dose of vehicle or PF-3845 
(10 mg.kg-1) by intraperitoneal injection. At 1 h or 24 h time points the animals were culled, and 
brain tissue rapidly removed. The data points represent the level of AEA in individual mice. 
Statistical comparisons were one way ANOVA analysis of the mean AEA level of the group, with 
a Bonferroni's Multiple Comparison Test (*P < 0.05, **P < 0.01, ***P < 0.001). 
 
 
3.4.3 Twice-daily treatment with PF-3845 shows no improvement in  
  neurological deficit in CREAE behavioural assays. 
This study, incorporating twice-daily treatment with PF-3845, showed a typical disease 
course for ABH CREAE, with a predictable Acute Phase inflammatory attack and Day of Onset. 
The recovery from the acute phase into Remission 1 was also typical; with a total of 24 animals 
reaching the ideal ≤ 0.5 clinical score (Figure 3.4 A). These animals were randomised into two 
groups based on the RotaRod performance. The data presented in the Table 3.2 and Figure 3.4 
only reflect those animals that completed the entire 50 day study (13 out of 22). Hence, the 
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Remission 1 RotaRod data presented are the mean scores of these 13 animals. However, they 
show near identical mean RotaRod scores at Remission 1, giving the study a balanced baseline. 
The relapse phase followed a typical disease course, with a poor incidence (13 / 24). 
Treatment was initiated on Day 33 with twice daily injections. This treatment (vehicle or PF-
3845) showed no impact on the Day of Onset or the EAE relapse score (Table 3.2, Figure 3.4 A). 
It should be noted that the relapse EAE score was higher than usual with nearly all the animals 
(12 / 13) gaining full hind limb paralysis and many for 5 days. This inflammatory attack was 
more severe than typical disease, but within the protocol guidelines and with no animals 
reaching a moribund state. There was a sustained recovery following the relapse in both 
treatment groups, with no significant difference in the clinical scores at Remission 2 (Day 50). 
This observation was further backed up by the RotaRod performance, with near identical mean 
RotaRod scores between the two treatment groups at Remission 2 (Figure 3.4 B). The analysis 
of nerve content, however, showed a significantly lower reduction in the neurofilament heavy 
chain content in the PF-3845 treated group with a mean ± S.E.M. of 7.8 ± 0.9 μg / mg protein 
compared to 5.0 ± 0.2 μg / mg protein in the vehicle treated group (Figure 3.4 C). For reference, 
naïve mice have a neurofilament content of 10 – 20 μg / mg protein (Al-Izki et al., 2012). There 
was no difference observed in the behavioural outputs in this study, but a significant difference 
was detected at the molecular level in neurofilament levels, indicating that twice daily 
treatment with PF-3845 may be protecting the nerve content during the neurodegenerative 
phase of EAE disease. 
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Table 3.2: Twice Daily Treatment of PF-3845 in CREAE Behavioural Experiment 
Acute Phase 
Treatment      n   EAE score  Day of Onset 
         ± SEM     ± SD 
Vehicle      7   3.8 ± 0.1   15.2 ± 2.2 
PF-3845     6   4.0 ± 0.0   14.8 ± 1.4 
Remission 1 
Treatment  No. RM2  EAE Score 
     n      ± SEM 
Vehicle   7   1.0 ± 0.3 
PF-3845  6   1.0 ± 0.3 
 
Relapse Phase 
Treatment No. EAE/ Group Score  EAE score Day of Onset 
     Total     ± SEM     ± SEM    ± SD§ 
Vehicle     7/12  3.3 ± 0.4  3.8 ± 0.1  7.8 ± 1.7 
PF-3845    6/12  3.6 ± 0.4  4.0 ± 0   6.7 ± 2.1 
Remission 2 
Treatment  No. RM2  EAE Score 
     n      ± SEM 
Vehicle   7   2.5 ± 0.4 
PF-3845  6   2.1 ± 0.4 
RotaRod Performance 
Treatment      Remission 1     Remission 2 
    Time (s) ± SEM  Time (s) ± SEM 
Vehicle       190 ± 29     139 ± 32 
PF-3845      189 ± 19     138 ± 41 
Neurofilament Content (μg / mg protein) 
Treatment    n            Remission 2 
     (μg/mg protein) ± SEM 
Vehicle   7   5.0 ± 0.2 
PF-3845  6   7.8 ± 0.9** 
§Day of Onset is post-immunisation at 28; *P < 0.05, **P < 0.01, ***P < 0.001 
 
EAE was induced in ABH wild-type mice with SCH on day 0 and 7. The data reflects maximal 
clinical score of the animals that developed EAE (mean ± S.E.M.) and the day of onset of EAE 
symptoms (mean ± S.D.). CREAE was re-induced in ABH wild-type and FAAH deficient mice with 
SCH on day 28 in animals with a remission score ≤ 0.5. All animals were untreated in Acute 
Phase and randomised into treatment groups at Remission 1. Animals excluded from the 
Relapse Phase (e.g. non-responders) were retrospectively excluded from the Acute Phase 
analysis.. Animals were treated twice daily from Day 33 onwards with either vehicle or PF-3845 
(10 mg.kg-1) by intraperitoneal injection. The data reflects maximal clinical score of the group, 
maximal clinical score of animals that developed a relapse (mean ± S.E.M.) and the day of onset 
of relapse symptoms (mean ± S.D.) (Mann Whitney U test; *P < 0.05, **P < 0.01, ***P < 0.001). 
RotaRod score reflects the time of latency to fall (mean ± S.E.M.) and neurofilament content 
(μg per mg of total protein) reflects the remaining nerve content in the spinal cord. (Student’s 
t-test; *P < 0.05, **P < 0.01, ***P < 0.001). 
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Figure 3.4. Twice daily pharmacological treatment with FAAH inhibitor PF-3845 shows no 
improvement in the neurological recovery of CREAE disease. 
 
EAE was induced in ABH wild-type with SCH in complete Freund’s adjuvant on day 0 and 7. At 
day 28, the animals were divided into equivalent groups and re-immunised with SCH. (A) The 
combined mean ± SEM daily clinical scores show no difference between vehicle (open circles) 
or PF-3845 (10 mg.kg-1) (filled circles) twice daily treated mice in the recovery from the relapse 
(Mann Whitney U test; *P < 0.05, **P < 0.01, ***P < 0.001). (B) The mean ± SEM motor control 
performance on an accelerating RotaRod showed no difference at remission 2 between the 
vehicle (open bars) or PF-3845 (filled bars) treated groups. (C) The mean ± SEM neurofilament 
content of the spinal cord showed no difference at remission 2 between the vehicle (open bars) 
or PF-3845 (filled bars) treated groups. (B & C; Student’s t-test; *P < 0.05, **P < 0.01, ***P < 
0.001). 
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3.5 Discussion 
3.5.1 Treatment with PF-3845 did not significantly improve the behavioural 
  outcomes following CREAE disease. 
This study demonstrated that neither daily nor twice daily treatment with PF-3845 
inhibited the incidence or severity of EAE. This confirms previous observations in FAAH 
deficient mice. This suggests that FAAH inhibition does not exert overt immunosuppressive 
activity. Furthermore, in contrast with findings from genetic deletion of FAAH (Chapter 2), 
pharmacological inhibition of FAAH did not detect a marked improvement in the behavioural 
outcomes in EAE. However measurement of neurofilament levels suggests a potential 
neuroprotective effect of PF-3845, which may be mediated by elevation of anandamide and / 
or other fatty acid amides.  
 
A diminished therapeutic window in the daily PF-3845 treatment study 
A rigorous analysis of the relapse phase and recovery in the ‘Daily’ treatment study 
shows that the study was non-optimal, as the mice were induced with a heightened level of 
paralysis. The Remission 1 mean clinical scores of 1.7 in both groups were higher than the 0.5 
clinical score used in the standardised CREAE protocol. Although both treatment groups had an 
equivocal starting point at the induction of the relapse, the therapeutic window was 
diminished. These animals always have an increased disability following a relapse and therefore 
the maximal mean recovery possible was > 1.7, leaving two points on the clinical scoring scale 
to differentiate an effective treatment. In this study, there was a trend towards an improved 
recovery in the PF-3845 treated group; however there was not enough statistical power to 
confirm this difference. This could be due to the non-optimal experimental conditions and 
subsequently the therapeutic window is too small to measure a difference on the clinical score 
scale currently used. The data, however, are consistent with the previously reported findings 
that daily administration of a FAAH inhibitor (URB597, 1mg.kg-1 i.p. daily) did not affect the 
clinical score in EAE (Webb et al., 2008). This is in contrast to that achievable with exogenous 
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CB1 receptor agonism, such as the use of THC (Croxford et al., 2008, G. Pryce unpublished 
observations). 
 
A delayed clinical recovery in the twice-daily PF-3845 treatment study 
Both of these studies produced a maximal EAE score higher than in previous experiments 
(see Chapter 2.4). Following a severe bout of disease, it is probable that the mice take longer to 
recover. This is particularly noticeable in the ‘Twice Daily’ study, with the increased gradient of 
the line graph in the treated group compared to the vehicle group (Figure 3.4 A). In previous 
experiments this begins to plateau in the region of Day 46 to Day 48 (Chapter 2, Figures 2.7 and 
2.8; Croxford et al., 2008; Al-Izki et al., 2012; Pryce et al., 2003). In the ‘Twice Daily’ study, the 
vehicle group is beginning to plateau and the treatment group is still on a downward trajectory. 
Since we used a standard protocol ending the study at Day 50, we may not have observed the 
full recovery of these mice. One could speculate that if the study was prolonged for 2 to 5 more 
days, including continued treatment, then we may have been able to compare the full recovery 
of both treatment groups. Altering the experimental protocol in this relapsing remitting EAE 
model is a difficult judgement to make as the mice will begin to spontaneously enter a second 
relapse phase at any day following Day 50 (Al-Izki et al., 2012; Pryce et al., 2005). If any mice do 
enter this phase, due to the effects of the onset of paralysis and infiltrating inflammatory cells, 
this renders the RotaRod and neurofilament analysis meaningless should these mice relapse. 
 
Twice daily treatment with PF-3845 reduced the loss of nerve content. 
The ‘Twice Daily treatment’ study showed an increase in the spinal cord neurofilament 
levels in the PF-3845 treatment group (Figure 3.4 C). This finding is inconsistent with the clinical 
score and RotaRod scores in the ‘Twice Daily’ study, and inconsistent with the findings from the 
‘Daily treatment’ study. It is possible that higher frequency of PF-3845 injections does confer an 
effect on reducing neuronal loss during disease. One could again speculate that treatment had 
no observable effect in the behavioural analyses because the animals were still recovering from 
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the paralysis. The inflammatory processes may have restricted the ability of mice in both 
groups to perform in the tests, whereas, at the cellular level, the neuronal cells in these mice 
may have indeed been protected by the treatment, and this was detectable. Future 
experiments could take a more detailed analysis of the spinal cord nerve content by staining 
cervical and lumbar sections for neurofilament, and other axonal markers (Jackson et al., 2009). 
Although substantially more time consuming, this would give both a quantitative and 
qualitative understanding of the amount of nerve degeneration. 
 
Therapeutic potential of PF-3845 in EAE 
In summary, this discussion outlines reasons as to why no therapeutic effect was observed. 
A therapeutic effect may be seen in a CREAE study using larger numbers of mice because it 
would allow more rigour in the selection of recovered Remission 1 animals for induction, and a 
reduction in the extreme variability (e.g. the heightened relapse inflammatory attack). Indeed, 
the treatment may be working at the cellular level (less nerve loss) more effectively than at the 
behavioural level providing some hope of efficacy. However, the statistical FA factor needs to 
be considered; if a significant therapeutic effect exists with PF-3845 treatment and if this 
efficacy is going to be successfully translated to humans, then a much greater difference 
between the treatment groups is required than was observed in these two studies. 
 
3.5.2 Treatment with PF-3845 elevates anandamide in the brain 
Levels of anandamide in brain tissue from FAAH deficient mice. 
The increase of AEA levels in brains from FAAH deficient mice were at a lower level relative 
to baseline (4-fold increase) compared to previous experimental results, where an 8-fold 
increase was observed (Chapter 2.4.1, Figure 2.3). There are several potential explanations for 
this difference. The first is the data was generated from brain tissue, whereas the data reported 
in Chapter 2 were from spinal cord tissue. Both analyses were done by different collaborators, 
but utilising the same liquid chromatography mass spectrometry technique. However this 
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technique is reported to be extraordinarily sensitive and therefore subtle technique differences 
are accentuated particularly the baseline readings (personal communication Dr. Jim Pearson, 
Ironwood Pharmaceuticals, Inc.).  
 
PF-3845 treatment induces an elevation of AEA for less than 24 h 
The increase in AEA levels achieved with a single dose of PF-3845 (10 mg.kg-1) in wild-type 
ABH mice in the experiments reported here were 4-fold above baseline. Previous reports 
describe an increase of > 10-fold (Ahn et al., 2009b). The key difference between these data is 
the time that tissue was collected after administration of PF-3845; our data was from tissue 
collected 1 h after treatment, whereas in the study by Ahn et al. (2009) the 10-fold increase 
was a peak level at 3 h post-treatment. In the Ahn et al. (2009) study there appears to be an 
increase of ~5-fold at 1 h post-treatment (from the dose response curve), consistent with the 4-
fold increase observed here. The AEA levels at 24 h post-treatment are also different; no 
difference in AEA levels were detected in this study, whereas Ahn et al. (2009) reported a 
significant difference, although at a much reduced level (<2-fold increase) compared to 1 h and 
3 h. 
In summary, the focus of these pharmacological studies was to investigate the 
neuroprotective effect observed in the FAAH deficient mice in CREAE disease, and attempt to 
replicate these effects using a pharmacological inhibitor of FAAH. The FAAH inhibition achieved 
pharmacologically with the potent inhibitor PF-3845 did not raise AEA levels to levels seen in 
FAAH deficient mice. The PF-3845 treatment also does not induce a clinical neuroprotective 
effect comparable to that seen in the FAAH deficient mice following CREAE. This heightened 
level of AEA in the FAAH knockout animals may be crucial in driving CB1 receptor activation, 
thereby giving rise to the behavioural and cellular neuroprotection observed in the CREAE 
disease model. 
 
 
111 
3.5.3 Future Experiments 
Treatment with the clinical FAAH inhibitor PF-04457845 
The PF-04457845 compound recently used in clinical trials for pain is now available for 
research purposes from chemical supply companies (e.g. Cayman Chemical Company (Ann 
Arbor, MI, US)). This compound has a superior pharmacology profile compared to PF-3845, the 
compound used in this study. PF-04457845 has higher potency, longer pharmacokinetics, and 
pharmacodynamics of FAAs, is more selective and has a safe profile for use in humans. PF-
04457845 is a highly potent inhibitor of FAAH (k inact/K i = 40,300 ± 11,500 M-1s-1), some 3 orders 
of magnitude more potent than PF-3845 (k inact/K i = 12,600 ± 3000 M-1s-1) and 25-fold higher 
than URB597 (k inact/K i = 1590 M-1s-1) (Ahn et al., 2011). This compound has an improved 
pharmacokinetic and pharmacodynamic profile, where a 4 mg dose in human adults induces > 
97 % FAAH inhibition and elevated AEA within 2 h of treatment. The elevated anandamide 
levels only returned to normal levels > 7 days following cessation of treatment (Huggins et al., 
2012; Li et al., 2012). This was similar in the mouse, where brain anandamide was elevated 4 to 
5-fold higher than baseline with a treatment of a 0.1 mg.kg-1 to 10 mg.kg-1 dose, respectively. 
This level of anandamide is still not the increase seen in the genetic deletion of FAAH. However, 
and of significant note, was the endurance of anandamide elevation, with anandamide still 
elevated at this level 24 h post-treatment (Ahn et al., 2011).  
This compound was not available when these behavioural studies were undertaken. The 
PF-04457845 has improved pharmacological characteristics compared to PF-3845. In particular, 
due to high potency of the drug, selectivity and low toxicity it would be interesting to do a 
dose-response experiment in the CREAE model with a moderate 1 mg.kg.-1 dose and high dose 
(> 10 mg.kg-1) to see if neuroprotective efficacy is attainable. However, one would continue to 
be cautious regarding the translation of results observed in a mouse CREAE experiment to 
human trials for MS. This interspecies disconnect was witnessed in the PF-04457845 pain 
clinical trial (Huggins et al., 2012). 
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Gene silencing of FAAH in CNS tissue as a therapeutic approach 
There exists a gulf of efficacy between the genetic versus pharmacological targeting of 
FAAH as a neuroprotective strategy. A novel approach to translate the ABH.FAAH-/- mouse EAE 
data into a therapy for human MS could be to target the Faah gene using gene silencing 
techniques. The gene silencing technology is progressing, with lentiviral vectors capable of 
delivering functional RNAi (interfering RNA) directly to the site of pathogenesis using 
stereotaxic injections. This has recently been deployed in other neurodegenerative diseases 
such as silencing of β-amyloid pathway in Alzheimer’s Disease (Nilsson et al., 2010) and SOD1 
mutations in motor neuron disease (Ralph et al., 2005; Ramachandran et al., 2013). Gene 
silencing technology offers a number of advantages over pharmacological treatment. Firstly, 
from our pharmacodynamic results, it appears that targeting the gene results in higher 
elevations of brain anandamide, however it would need to be experimentally determined 
whether this is indeed a developmental affect (embryonic genetic deletion), or whether this 
could be replicated in adult cell culture and then in an adult animal model using gene silencing. 
Secondly, one could specifically target the gene silencing to the target tissue (i.e. CNS neurons 
and oligodendrocytes). This would eliminate side effects arising from FAAH inhibition in other 
tissues. Of particular note is the effect of FAAH deficiency on liver function. The highest 
expression of FAAH is seen in the liver (Cravatt et al., 2001) and staining of liver tissue from 
ABH.FAAH-/- mice using Oil Red O staining has revealed a fatty liver type pathology ((Figure 
4.15). Specifically targeting the CNS regions where neurodegeneration is occurring (i.e. spinal 
cord in the EAE mouse) would reduce such side effects. This could however be achieved 
pharmacologically as well, with the intrathecal administration of a FAAH inhibitor or CB1 
receptor agonist, and could significantly increase the efficacy whilst reducing the peripheral 
side effects. A clinical example of such a treatment is the success of baclophen via an 
intrathecal pump treatment for spasticity in MS (Erwin et al., 2011). However, this technology is 
still in its infancy and much research would be required to ensure safe delivery and low side 
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effects and would certainly need to be assessed for safety and efficacy in comparison to an 
effective pharmacological agent (e.g. PF-04457845).  
 
Lipidomic and proteomic profile analysis of FAAH in EAE disease 
It is intriguing to understand why the genetic deletion of FAAH had a neuroprotective 
effect, whereas the pharmacological approach failed to show behavioural efficacy, but showed 
protection of neurofilament levels. The mean neurofilament levels in the FAAH deficient mice 
following the Relapse Phase were 5.9 ± 0.5 compared to 4.5 ± 0.4 in the wild-type, whereas in 
the PF-3845 treated mice the neurofilament was 7.8 ± 0.9 compared to 5.0 ± 0.2 in the vehicle 
treated, with both results showing significant protection of the nerve content. 
A more detailed understanding of FAAH activity in the CNS is required. Firstly, a lipidomic 
profiling analysis of FAAs during disease in wild-type, FAAH deficient and FAAH inhibitor treated 
animals could elucidate the mechanisms underlying the neuroprotective efficacy, or lack 
thereof. This approach was recently performed in a similar model focussed on the serine 
hydrolase α/β-hydrolase domain-containing (ABHD) 12 (ABHD12) enzyme. Mutations in this 
enzyme contribute to the neurodegenerative disorder PHARC (polyneuropathy, hearing loss, 
ataxia, retinosis pigmentosa, and cataract). Genetic deletion of ABHD12 in mice induced a 
PHARC phenotype, whilst an ABHD12 inhibitor failed to induce disease. An extensive lipidomic 
profiling of the ABHD12-/- mice revealed that elevated (lyso)phosphatidylserine increased 
abnormal microglial activation and neurobehavioural abnormalities (Blankman et al., 2013). A 
similar extensive lipidomic profile of FAAs is required to understand the differences between 
FAAH deletion and inhibition. Understanding the full impact of perturbing FAAH activity may 
give an understanding of the efficacy in neuroprotection, but also in predicting the off-target 
activities of all the fatty acid amides and subsequent side effect profile that such a therapeutic 
strategy may induce. 
A similar approach, but proteomically focussed analysis of FAAH in EAE diseased animals is 
also required and could reveal clues about the mechanism of action of neuroprotection in the 
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FAAH deficient mice. This could include an analysis of FAAH and CB1 receptor expression in the 
CNS. Pryce and colleagues recently showed no major changes to the CB1 receptor system in 
FAAH deficient mice (Pryce et al., 2013). If FAAH deletion causes subtle CB1 receptor changes, 
these alterations may be accentuated during a disease such as EAE. Characterising the 
expression of CB1 receptor during the EAE disease course would be of great interest, 
particularly when comparing the CNS of wild-type and FAAH deficient animals. 
The findings of Chapter 2 and Chapter 3 prompted an exploration of FAAH expression in 
the CNS of the naïve mouse using immune-staining techniques and this is the focus of Chapter 
4. An understanding of FAAH expression in the CNS, particularly in which cells FAAH activity 
may be acting is important as a basis for understanding functionally why FAAH deficiency is 
neuroprotective in EAE. 
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Chapter 4: Expression Pattern of FAAH in the Central Nervous 
System 
Fatty acid amide hydrolase (FAAH) is an integral membrane enzyme that degrades several 
lipid signalling molecules, including N-arachidonoylethanolamine (anandamide or AEA) and 
oleamide. This catabolism regulates the levels of these lipid messenger molecules in the CNS 
and therefore FAAH has a functional role in a number of neurobehavioral processes such as 
pain, anxiety and sleep in mammals (Cravatt et al., 2001; Kinsey et al., 2011). This makes FAAH 
a potentially useful therapeutic target for a number of neurological disorders. Characterising 
the expression pattern of FAAH in the central nervous system (CNS) is therefore of great 
importance understand how FAAH inhibition may affect neural processes.  
 
4.2 Aims and Objectives 
Aims: 
i) To investigate the pattern of FAAH expression in the mouse CNS.  
 
Objectives: 
i) To develop and characterise a polyclonal antibody with specific immunoreactivity 
to FAAH. 
ii) To characterise the distribution of FAAH expression in the CNS of the ABH mouse 
strain. 
iii) To characterise the cellular expression of FAAH in the spinal cord using double 
marker co-localisation. 
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4.3 Methods and Materials 
4.3.1 Development of Anti-FAAH Polyclonal Antibody 
Antigen design and immunisation method 
Antibodies to mouse FAAH were generated ‘in house’ using a synthetic peptide antigen 
(KYMREVERLMTPEKRPS) comprising of the C-terminal region of the mouse protein (underlined), 
which was custom synthesised and purified by the Advanced Biotechnology Centre at Imperial 
College London. The peptide was coupled (using the KY linker) to thyroglobulin as a carrier 
protein via the N-terminal lysine residue using glutaraldehyde. Three female New Zealand 
white rabbits were immunized with FAAH-thyroglobulin conjugate (comprising ~100 nmol 
FAAH peptide) emulsified with Freund’s complete adjuvant, followed by three monthly booster 
injections of conjugate (comprising ~50 nmol FAAH) emulsified with Freund’s incomplete 
adjuvant. A pre-immunisation bleed was taken immediately prior to injection, and bleeds were 
then taken 1 week after each of these immunisations, as denoted by rabbit number (e.g. R2) 
and bleed number (e.g. B3), therefore is ‘R2B3’. Samples of antiserum were collected 1 week 
after each booster injection. Rabbit 1 had to be culled after booster 3 due to illness; it was 
unclear whether this was related to the immunisation procedure. All procedures were 
approved by ethical review in accordance to UK Home Office project licence PPL 7007003 
(holder Professor Maurice Elphick) issued under the Animals Scientific Procedures Act 1986. 
 
Dot blot Analysis 
Antisera from each of the bleeds from the three immunized rabbits were tested for the 
presence of anti-FAAH antibodies using dot-blot assays. FAAH peptide (1 nmol) was spotted on 
to nitrocellulose strips and allowed to dry. Negative controls included spots of an unrelated 
peptide (C-terminal peptide of mouse NAPE-PLD (Egertová et al., 2008) and C-terminal peptide 
of mouse CB2 receptor) or dH2O. Nitrocellulose strips were air dried, washed in phosphate 
buffered saline (PBS) (pH 7.4) and blocked in 5 % milk powder (Marvel™, Premier International 
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Foods (UK) Ltd, Spalding, Lincs, UK) in PBS. Individual nitrocellulose strips were incubated with 
each antiserum (1:500) diluted in 1% milk powder/0.05% Tween 20 in PBS (MPBST) overnight at 
4°C. Bound antibodies were detected using alkaline phosphatase-conjugated goat anti-rabbit 
immunoglobulin (Vector Labs) diluted in MPBST, employing 5-bromo-4-chloro-3-indolyl 
phosphate/nitroblue tetrazolium (BCIP / NTP) as an alkaline phosphatase substrate (Sigma, 
Poole, UK). 
 
4.3.2 Western Blotting 
Liver and brain tissue was dissected from FAAH+/+ and FAAH-/- Biozzi ABH mice bred in 
house. The tissue was snap frozen, homogenized using glass homogenizers in 320 mM sucrose, 
2 mM Tris-EDTA, 5 mM MgCl2, and Complete Protease Inhibitors (Roche, East Sussex, UK), and 
further disrupted by repeated aspirations through a 23 gauge needle. Cell debris was pelleted 
by centrifugation at 10,000 g for 10 min. at 4° C. The supernatants were analysed for protein 
concentration using a Coomassie Plus (Bradford) Protein Assay (Thermo Scientific Pierce, 
Northumberland, UK) and standardized in concentration prior to loading on to a gel. 
Homogenate (70 μg of protein) was separated using discontinuous SDS-Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) with a 4% stacking gel followed by a 12.5 % resolving gel, under 
reducing conditions. The gels were transferred to a nitrocellulose or PVDF (Millipore, Watford, 
UK) membrane using a Transblot-Blot SD semi-dry system (Bio-Rad, Hercules, USA) at 45 mA for 
2 h. The membranes were cut into strips containing homogenates of tissue from ABH.FAAH+/+ 
or ABH.FAAH-/- mice. The strips were immunoblotted with antisera from the different bleeds 
using the same protocol as previously described for the dot blots. 
 
Pre-adsorption Western Blot 
To determine antibody specificity, antisera were pre-adsorbed by incubation with 20 μM 
FAAH peptide for 1 h prior to primary antisera staining. Bound antibodies were detected using 
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infrared IRDye®-680LT-labeled anti-rabbit antibodies, and detected on an Odyssey® Imaging 
Systems scanner (LICOR Biosciences, GmbH, Germany). 
 
4.3.3 Affinity Purification 
Antisera were selected, as determined by blotting analysis, and purified using an affinity 
purification column with FAAH peptide coupled to AminoLink Gel (Pierce, Rockford,IL, USA), 
prepared according to the  instructions of the manufacturer. Bound antibodies were eluted and 
collected separately with 15 ml of 100 mM glycine (G; pH 2.5), followed by 15 ml 100 mM 
triethylamine (T; pH 11.5), into 1.5 ml of 1 M Tris buffer (pH 8.0), followed by dialysis in PBS (pH 
7.4) overnight. 
 
4.3.4 Histology 
Table 4.1 Primary antibodies used for immunohistochemistry and immunocytochemistry 
___________________________________________________________________________ 
Antigen      Target  Species  Manufacturer Cat. No. Dilution 
___________________________________________________________________________________ 
NeuN Neurons   Mouse  Millipore MAB377  1:400 
Olig2 Oligodendrocyte cells Rabbit  Millipore AB9610  1:300 
CC-1 Mature oligodendrocytes Mouse  Millipore OP80-100UG 1:100 
Iba1 Microglia  Rabbit  Millipore MABN92 1:1000 
GFAP Astrocytes  Mouse  Sigma  G3893  1:1000 
MBP Myelin   Rat  AbD Serotec MCA409S 1:250 
FAAH FAAH   Rabbit  Gift from Ben Cravatt  1:100 
___________________________________________________________________________________ 
Antibodies used in the studies reported in this chapter 
 
Tissue fixation and preservation 
Brain and spinal cord tissue was collected from ABH mice (FAAH+/+ and FAAH-/-) bred from 
stock at Queen Mary, University of London, under conditions compliant with UK Home Office 
project licenses issued under the Animals Scientific Procedures Act 1986. Mice were 
asphyxiated with CO2 and perfused with cold PBS (pre-wash), followed by 4% PFA in PBS (pH 
7.4). The brain was removed and the spinal cord was dissected into individual segments. For 
cryo-sectioning, tissue was post-fixed in 4 % PFA for 1-4 h, cryoprotected in 20 % sucrose / PBS 
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and embedded in Optimum Cutting Temperature (O.C.T.) mounting medium (VWR, 
Lutterworth, UK). Transverse serial sections (12 μm) were cut onto Superfrost Plus slides (VWR) 
using a cryostat (CM3050S, Leica Microsystems, UK Ltd). For paraffin wax sectioning, tissue was 
post-fixed in Bouin’s fixative for 1 – 3 days, followed by dehydration and embedding in paraffin 
wax. For the brain, coronal serial sections (7 μm) were cut at 0.5 mm intervals throughout the 
brain, while transverse sections were cut from segments of spinal cord. Both tissue types were 
sectioned using a Leica RM2145 microtome (Leica, Nussloch, Germany) and mounted on 
Superfrost slides coated with 2% gelatin (w/v) in chrome alum solution. 
 
Immunohistochemistry 
Sections were thawed (from frozen) or dewaxed and hydrated using xylene and an ethanol 
series (100 % to 30 % )(paraffin wax embedded), washed in PBS and incubated with 3 % 
hydrogen peroxide for 30 min. at room temperature to quench endogenous peroxidase 
activity. After washing in PBS, sections were blocked with 5% normal goat serum (NGS) in PBS 
with 0.2% Triton X-100 (PBS-Tx) for 2 h at room temperature. Primary antibodies were applied 
overnight in PBS-Tx. A variety of primary antibodies were used in these studies as detailed in 
Table 4.1. Following washes, the appropriate species-specific secondary antibodies were 
applied and incubated for 3 h at room temperature. Secondary antibodies used were either 
horseradish peroxidase (HRP) conjugated (Jackson ImmunoResearch, West Grove, PA), or Alexa 
Fluor® dye conjugated (Molecular Probes, Invitrogen, Paisley, UK,). After washing in PBS, bound 
antibodies with HRP tags were revealed using 3,3’-diaminobenzidine (DAB) (with nickel) as a 
substrate (Vector Laboratories, Peterborough, UK) and mounted in DPX (Sigma, Poole, UK), or 
fluorescent tagged antibodies were mounted in Prolong Gold® anti-fade (Invitrogen). In 
addition, tyramide signal amplification (TSA) was used for signal amplification when deemed 
necessary. Biotinylated secondary antibodies were applied followed by addition of avidin: HRP 
complex (ABC reagent, Vectastain Elite Peroxidase kit, Vector Labs) diluted 1:5 in PBS for 1 h at 
room temperature. Following washes, the biotin linked tyramide reagent (TSA indirect kit; 
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Perkin Elmer, Beaconsfield, UK) was added to the sections for 8 min. at room temperature. 
Following washes, avidin-FITC (Invitrogen), or streptavidin-Cy3 (Jackson ImmunoResearch) was 
added at 1:500 for 2 h. Following washes, slides were mounted with glycerol / PBS (3:1) for 
FITC, or Prolong Gold® anti-fade for streptavidin. 
 
4.3.5 Microscopy and Image Analysis 
Immunostaining analysis and image capture was performed using either bright field light 
microscopy, or fluorescence microscopy using a Leica DMRA2 compound microscope (Leica, 
Nussloch, Germany) with Volocity 6.1.1 software (Perkin Elmer). Images were also captured 
using a laser scanning confocal microscope (TCS MP5, Leica SPE, Leica Microsystems, 
Cambridge, England, UK) using LAS 2.6.0 software (Leica Application Suite, Leica). The 
percentage of FAAH-positive cells co-labelled with another marker was manually counted 
during visualisation of the section using the whole focal plane to ensure accurate co-
localisation identification. The percentage of FAAH-positive and marker-positive cells was 
calculated for each section, totalled for each animal (> 3 animals per marker analysis) and 
expressed as a mean ± SEM per animal. 
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4.4 Results 
4.4.1 Development of an anti-FAAH polyclonal antibody.  
Detection of antibodies to the FAAH peptide antigen in antisera 
Dot blot analysis of the sera from the three immunised rabbits revealed the presence of 
antibodies against the FAAH peptide in at least one bleed from each rabbit (Figure 4.1). 
Antibodies were detected in bleeds 2 and 3 (R1B2 and R1B3) from Rabbit 1, in bleeds 2, 3 and 4 
(R2B2, R2B3 and R2B4) from rabbit 2, and bleed 5 (R3B5) from rabbit 3. No cross-reactivity to 
the NAPE-PLD or CB2 receptor peptide was detected in any antisera (Figure 1 and data not 
shown). 
 
Figure 4.1. Dot blot analysis of anti-FAAH peptide antisera. 
 
The antisera from Rabbit 1, 2 and 3 revealed positive staining to the FAAH peptide 
and did not detect the NAPE-PLD peptide. 
 
 
Western blot analysis of FAAH antisera 
Liver tissue was used to initially test the antisera as this tissue has the highest expression of 
FAAH (Cravatt et al., 2001). Western blot analysis of mouse liver homogenates (Figure 4.2) 
revealed staining of a band at 63 kDa, the expected molecular mass of FAAH (Cravatt et al., 
1996), and minimal cross-reactivity with other bands. The 63 kDa band was present in 
ABH.FAAH+/+ mice but not in ABH.FAAH-/- mice, demonstrating that this band is indeed FAAH. 
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Prominent staining of the 63 kDa FAAH band was observed with the R1B3, R2B2, R2B3, R2B4 
and R3B5 antisera.  
 
Figure 4.2. Western blot analysis of anti-FAAH antisera bleeds on mouse liver tissue. 
 
 
Western blot analysis on ABH.FAAH+/+ and ABH.FAAH-/- liver tissue reveals a 63 kDa band in 
wild-type tissue, while no band is observed in the FAAH-knockout tissue. This demonstrates the 
presence of antibodies reactive to FAAH in the antisera and the selective absence of FAAH in 
the knockout tissue. Minimal non-specific binding from most of the anti-sera sample can be 
observed. Each frame indicates separate gels, and membranes were cut into two lane strips. 
 
Western blot analysis of mouse brain homogenates using the same panel of antisera that 
were tested on liver homogenates revealed strong staining of a band with the expected 
molecular mass for FAAH (63 kDa), but with extensive cross-reactivity with other bands (data 
not shown). To improve the sensitivity of the Western blotting detection secondary antibodies 
with infrared dye conjugate (IRDye®-680LT, LICOR Biosciences) were used and the blots 
detected on an Odyssey® Imaging Systems scanner (LICOR Biosciences). Consistent with the dot 
blot data (Figure 4.1), Western blot analysis showed the strongest staining was using the R2B4 
and R3B5 antisera (Figure 4.3). These two antisera produced strong staining of a 63 kDa band in 
brain homogenates from ABH.FAAH+/+ mice (Figure 4.3, lanes 1 and 5, cyan arrows), which was 
absent in the ABH.FAAH-/- mice (lanes 2 and 6). However, cross-reactivity with a number of un-
identified protein bands was also observed. These bands were considered not to be associated 
with FAAH (e.g. as FAAH dimers of FAAH complexes), as these bands were also present in the 
tissue from FAAH-knockout mouse samples.  
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To further characterise the specificity of the antisera, all the antisera were pre-absorbed 
with the FAAH antigen peptide prior to Western blotting. This revealed that immunostaining of 
a subset of the bands present in wild-type brain tissue was abolished by pre-absorption (Figure 
4.3, lanes 3, 4, 7 and 8, magenta arrows), including the 63 kDa FAAH band (cyan arrows). 
Therefore, it was considered necessary to use affinity purification methods to eliminate the 
majority of non-specific antibodies and capture antibodies that bind to the FAAH peptide 
antigen.  
 
Figure 4.3. Western analysis of anti-FAAH antisera pre-absorbed with FAAH peptide on 
mouse brain tissue. 
 
Western blot analysis on FAAH+/+ and FAAH-/- brain tissue demonstrates the cross-reactivity of 
antisera to non-FAAH proteins (lanes 1 & 2, and 5 & 6). Pre-absorption of antisera with FAAH 
peptide (lanes 3 & 4, and 7 & 8) eliminates binding to FAAH (cyan arrow) and four non-specific 
bands (magenta arrow). However, immunostaining of majority of bands labelled by the antisera 
was not abolished by pre-absorption, demonstrating that labelling of these bands must be due 
to cross-reacting antibodies present in the antisera. 
 
Affinity purification and validation of antibody specificity on FAAH-/- tissue 
Antisera R2B4 and R3B5 were affinity purified against the FAAH antigen peptide, and 
polyclonal immunoglobulin (IgG) fractions were eluted using acidic glycine (G) followed by 
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fractions eluted using basic triethylamine (T). The glycine and triethylamine fractions were 
dialysed separately in PBS overnight in a 4 L volume. This yielded polyclonal antibody fractions 
in a diluted format that could be used for immunostaining. 
Affinity purified antibody fractions obtained from the R2B4 and R3B5 antisera produced 
similar staining, but with some important differences in staining observed with the glycine and 
triethylamine fractions. The glycine fractions from both antisera produced staining consistent 
with previously reported patterns of FAAH expression, but they also produced staining patterns 
with the morphological appearance of blood vessels. This was particularly noticeable in the 
FAAH-/- tissue (Figure 4.4 A), highlighting the importance of using knockout tissue in verification 
of antibodies. In contrast, the triethylamine fractions from both affinity-purified antisera 
stained FAAH moderately well, but without cross-reactivity to blood vessels, and no staining 
was observed in FAAH-knockout brain tissue (see Figure 4.4 B and Figure 4.5 A & H for 
examples from hippocampal or thalamic regions of the brain). Further optimisation of staining 
with the triethylamine fractions revealed that immunostaining obtained with the purified R3B5 
immunoglobulins was stronger than that of R2B4 (data not shown) and consequently, this 
fraction, denoted ‘R3B5-T’, was used for all subsequent analysis of FAAH expression in the CNS 
reported here. 
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Figure 4.4. Verification of the specificity of affinity purified anti-FAAH antibodies R2B4-G 
and R3B5-T. 
 
(A) Antibody R2B4-G reveals non-specific immunoreactivity with blood vessels in FAAH-/- brain 
tissue (magenta arrows). (B) In contrast, R3B5-T shows no immunoreactivity with blood vessels 
(magenta arrow), or granule cells in the dentate gyrus of FAAH-/- brain tissue (blue arrow). Scale 
bars = 50 μm in A; 25 μm in B. 
 
4.4.2 Verification of FAAH Staining Pattern in Mouse CNS Tissue with R3B5-T 
  Antibody 
Immunohistochemical analysis of brain and spinal cord sections using the R3B5-T antibody 
revealed a wide-ranging pattern of immunostaining. Prominent immunoreactivity was 
observed in the hippocampus (Hi), dentate gyrus (DG), cerebellar cortex and spinal cord. This 
staining was predominantly in neuronal stomata and their dendrites. In addition, intense 
staining was also revealed in the white matter of the brain and spinal cord in cells with 
morphology indicative of glial cells. Furthermore, intense staining was also observed in the 
ependymal cells lining the ventricles in the brain and central canal of the spinal cord. This 
staining pattern was consistent with previously reported FAAH expression patterns (Egertová et 
al., 1998, 2003; Tsou et al., 1998b). 
 
Hippocampal and dentate gyrus staining 
Neuronal FAAH staining was observed in the somata and dendrites of pyramidal cells in the 
hippocampus and granule cells in the dentate gyrus (Figure 4.5). Mild staining was also 
observed in the thalamic nuclei; see as an example the medial geniculate (MG) nucleus in 
Figure 4.5 A. 
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Figure 4.5. Localisation of FAAH staining in the Hippocampus and Dentate Gyrus. 
 
(A & G) Low magnification images showing strong hippocampal (Hi) and dentate gyrus (DG) 
staining, and mild staining of the medial geniculate (MG) region of the thalamus. (B & H) The 
hippocampal region of FAAH-/- tissue, showing an absence of staining: the magenta arrows 
indicate the position of the hippocampal formation. (C & D) FAAH staining is concentrated in 
the granule cell layer of the dentate gyrus (GrDG), but diffuse staining also exists in the 
molecular layer of the dentate gyrus (MoDG). Note also the intensely stained cells in the white 
matter fibre tracts (blue arrows), which are probably oligodendrocytes. (E & F) High 
magnification image of FAAH staining in the somata of the pyramidal cells (pink arrow). Scale 
bars = 300 μm in A, B, G, H; 100 μm in C, 50 μm in D; 25 μm in E, 12.5 μm in F. 
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Cerebellum 
FAAH immunoreactivity was observed in the somata of the Purkinjie cells, and weak 
staining was also detected in the somata of the granule cells in the cerebella cortex (Figure 6). 
No staining was detected in the dendrites of Purkinjie cells as previously reported, although the 
dendrite staining was subtle compared to expression in the somata (Egertová et al., 1998). 
Oligodendrocyte-like staining is evident in the underlying white matter layer of the cerebellum 
(Figure 4.6 B & C, blue arrows).  
 
Figure 4.6. Localisation of FAAH staining in mouse cerebellum 
 
 
 
(A) Low magnification image showing strong staining in the cerebellum (Cb). (B, C & D) At 
higher magnification it can be seen that the immunostaining is located in the cell bodies of 
Purkinjie cells (magenta arrows) and in the granule cell layer GCL). Note also the intensely 
stained cells in the white matter layer (blue arrows), which are probably oligodendrocytes. 
Scale bars = 300 μm in A; 100 μm in B, 50 μm in C; 12.5 μm in D. 
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Spinal cord 
Prominent neuronal staining was observed in the grey matter of the spinal cord, 
particularly in the large motor neuron cells and their dendrites in the ventral horn (see Figure 
4.7 C, E & F). The use of tyramide amplification revealed widespread staining of neurons in the 
grey matter (Figure 4.7 B, D & F). However, in these tissue samples, the white matter is 
degraded (a tissue processing issue), and therefore, minimal staining of oligodendrocyte 
staining was seen. In contrast, in the 3,3’-diaminobenzidine (DAB) stained tissue, the white 
matter is intact and intense staining of oligodendrocytes was revealed, particularly in the dorsal 
column (Figure 4.7 A, C & E, blue arrows). The oligodendrocyte population of the spinal cord 
was further characterized using Olig2, a nuclear marker of oligodendrocyte lineage cells (Zhou 
et al., 2000), and CC-1, a marker of mature myelinating oligodendrocytes (Huang et al., 2011). 
Both markers identify a widespread distribution of oligodendrocytes across the spinal cord 
section, with a particularly high population in the dorsal column (Figure 4.7 G & H, 
respectively). Comparing the oligodendrocyte population to the FAAH expression pattern 
(Figure 4.7 A) indicates that FAAH is expressed in oligodendrocytes. 
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Figure 4.7. Localisation of FAAH staining in the spinal cord 
 
130 
(A, C, E, G) Light microscopy with 3,3'-diaminobenzidine staining; (B, D, F, H) 
Fluorescent microscopy with tyramide amplification and Cy3 fluorescence. (A, C & 
E) Staining in all images reveals moderate staining of motor neurons and their 
dendrites (pink arrows) and intense staining of oligodendrocytes (blue arrows). 
The tyramide amplification reveals the extent of FAAH expressing neurons (B, D, 
F). (G) Olig2 staining of oligodendrocyte lineage cells. (H) CC-1 staining of mature 
oligodendrocytes. Note the intensely stained ependymal cells of the central canal 
(A & B, green arrow). Scale bars = 300 μm in A, B, G & H; 50 μm in C & D; 12.5 μm 
in E; 25 μm in F. 
 
 
Ependymal cells 
Intense FAAH staining was detected in the ependymal cells lining the 4th Ventricle (Figure 
4.8). In addition, in the spinal cord there was intense staining of the cells lining the central canal 
(Figure 7 A and B). 
 
Figure 4.8. FAAH immunoreactivity in the ependymal cells lining the ventricle. 
 
 
(A) Low magnification image showing strong staining in the ependyma of the fourth ventricle. 
(B) At higher magnification the immunostaining labels two layers of the ependymal wall, with 
immunostaining to FAAH in these cells (magenta arrows). (C) High magnification shows staining 
of ependymocytes (magenta arrows). Scale bars = 300 um in A, 100 um in B; 25 um in C. 
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4.4.3 Identification of cells expressing FAAH in the spinal cord 
Expression of FAAH in neuronal cells in the spinal cord 
Low magnification staining shows the distribution of staining for the ‘neuronal nuclei’ 
marker (NeuN) (Kim et al., 2009) in the spinal cord, with neuronal cells stained in both the 
dorsal and ventral horn (Figure 4.9 A-C). In the dorsal horn, few neuronal cells were co-labelled 
with FAAH immunoreactivity. In contrast, in the ventral horn many neurons were co-labelled 
with FAAH, with an overall mean 24.51 ± 11.39 % of NeuN+ cells showing co-expression of FAAH 
(Figure 4.9 C, Table 4.1). Of interest is the FAAH staining (NeuN negative) in cells with a circular 
morphology, and somewhat smaller than neuronal cells (Figure 4.9, white arrows). These cells, 
which are likely to be oligodendrocytes, were observed in both the grey and white matter of 
the spinal cord including the dorsal horn and ventral horn (grey matter) and in the dorsal 
funiculus, ventral funiculus and lateral funiculus (white matter).  
Higher magnification confocal images of the ventral horn show high expression of FAAH in 
the somata of the large motor neurons (Figure 4.9, D & F) that co-label with NeuN. The FAAH 
staining of these cells is cytosolic, whereas the NeuN stains both the cytosol and the nucleus. In 
these images FAAH staining can also be seen in the circular, smaller, NeuN negative cells (white 
arrows), which based on their morphology and distribution are probably oligodendrocytes. 
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Table 4.2. Percentage of cells expressing FAAH according to cell type markers. 
________________________________________________________________________ 
Marker Cell type   % ± S.E.M. of cells with   no. animals 
   FAAH co-localisation            n 
________________________________________________________________________ 
NeuN Neuron            24.5 ± 11.4 %             3 
Olig2  Oligodendrocyte lineage         73.0 ± 5.8%             5 
CC-1  Mature oligodendrocyte         92.8 ± 2.1 %             6 
________________________________________________________________________ 
 
The analysis of FAAH staining per cellular marker was performed on mouse lumbar spinal cord 
sections. Data is presented as mean percentages ± SEM. 
 
 
Expression of FAAH in cells of the oligodendroglia lineage in the spinal cord 
Oligodendrocyte precursors and oligodendrocytes are stained by antibodies to the nuclear 
marker, Olig2 (Baumann and Pham-Dinh, 2001). This marker shows a uniform distribution in 
the ventral horn of the spinal cord, with a higher density of staining in the grey matter than in 
the surrounding white matter (Figure 4.10 B). The Olig2 marker stains cells of the 
oligodendrocyte lineage from precursors to mature myelinating cells. Here we see Oligo2 
staining co-localised with FAAH staining (Figure 4.10 C, yellow arrows). This co-staining is only 
seen in the smaller cells with the characteristic oligodendrocyte morphology. The higher 
resolution confocal analysis shows FAAH staining in the cytosol, co-localised with Olig2 staining 
in the nuclei of the oligodendrocyte lineage cells (Figure 4.10 F, yellow arrows). This co-labelling 
was observed in a subset of the Olig2-positive oligodendrocyte lineage cells, with FAAH staining 
detected in 73.02 ± 5.81% of Olig2-positive cells. This indicates that a population of 
oligodendrocyte lineage cells do express FAAH, while another population are negative 
(magenta arrows). FAAH immunoreactivity is also evident in the cytosol of the large motor 
neuron cells, and, as would be expected, these cells were negative for Olig2 expression (Figure 
4.10., white arrows). 
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Expression of FAAH in mature oligodendrocytes in the spinal cord 
Low magnification images of immunostaining shows the distribution of CC-1 staining in the 
spinal cord, with mature oligodendrocytes revealed in both the white and grey matter (Figure 
4.11 B). Mature oligodendrocytes express CC-1 in the cytoplasm, whereas OPCs show no 
staining for this marker (Baumann and Pham-Dinh, 2001; Huang et al., 2011). CC-1 staining was 
co-labelled with FAAH staining with both FAAH and CC-1 immunostaining localised in the 
cytosol producing an orange-coloured cytoplasm with a DAPI stained nucleus (Figure 4.11 C, 
yellow arrows). This co-labelling was observed in the majority of the mature oligodendrocytes, 
with FAAH immunostaining observed in 92.78 ± 2.12 % of CC-1 positive cells. A small minority 
of CC-1-positive cells were negative for FAAH (magenta arrows). As observed with the previous 
staining (Fig. 4.9 – NeuN, and 4.10 – Olig2), FAAH was detected in the cytosol of the large 
motor neurons (white arrows), and these cells were negative for CC-1 (Figure 4.11 D-F). 
 
No expression of FAAH in microglia in the spinal cord 
Microglia were identified using the ionized calcium binding adaptor molecule 1 (Iba1) 
marker (Imai et al., 1996) in spinal cord sections. At low magnification, double staining 
identified labelling of Iba1 and FAAH in close proximity (Figure 4.12 C). Higher magnification 
allowed the distinction of individual cell using the DAPI nuclei stain. This showed that this close 
proximity staining to be in separate cells (Figure 4.12 D - F). FAAH stained the cytosol of cells 
(presumably oligodendrocytes – white arrows), while Iba1 stained the cytosol and extending 
processes of the microglia (magenta arrows). The processes of the microglia are indeed in close 
proximity as they almost surround the oligodendrocyte, as illustrated in Figure 4.12 F, bottom 
left. 
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Figure 4.11. Characterisation of FAAH and CC-1 positive oligodendrocytes in the m
ouse spinal cord. 
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No expression of FAAH in astrocytes in the spinal cord 
Astrocytes were identified using GFAP as a marker (Sofroniew and Vinters, 2010). The 
spinal cord sections were double labelled for GFAP and FAAH but no co-labelling was observed, 
although close proximity staining was observed in the grey matter at low resolution. Due to the 
higher expression levels of GFAP in the white matter, this was difficult to determine at low 
resolution. At higher resolution, the individual cells needed to be distinguished using the nuclei 
stain, as GFAP only stains the main stem branches of the processes, and therefore their cellular 
origin needs to be identified. Despite the close proximity of staining, there was no co-labelling 
of the same cell with GFAP and FAAH in the grey matter (Figure 4.13 D – F), or the white matter 
(data not shown). 
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Figure 4.13. FAAH is not expressed in GFAP positive astrocytes in the m
ouse spinal cord. 
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Expression of FAAH in oligodendrocytes in a mixed glia primary cell culture 
Mixed glial cell culture, sourced from rat neonatal cortices, was immunostained using the 
R3B5-T antibody and an anti-FAAH antibody provided by Professor Ben Cravatt (Scripps 
Research Institute, USA). The R3B5-T antibody did not stain cells specifically, with a low 
intensity homogenous staining of nuclei observed all cells in the culture (data not shown). 
However, the Cravatt antibody stained the cytosol of the oligodendrocytes (Figure 4.14 A and E, 
white arrow). High resolution confocal analysis of the cell cultures revealed FAAH expression 
co-localised with myelin basic protein (MBP), a marker of myelin which is only produced by 
mature oligodendrocytes (Figure 4.14 B and E). It is interesting to note that a low level of FAAH 
staining was also detected in a cell that was negative for MBP (Frame E, bottom right), 
indicating that FAAH expression may also be detected at low levels in non-myelinating 
oligodendrocytes. 
The identification of the astrocyte cell body (magenta arrow) with the GFAP stained 
processes shows no FAAH staining in the cytosol of this cell (Figure 4.14 C and E). High 
resolution was required to accurately distinguish the cells in this culture, as the 
oligodendrocytes and astrocytes grow in close proximity. 
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Figure 4.14. FAAH is expressed in MBP positive oligodendrocytes, but not GFAP positive 
astrocytes in a mixed glia primary cell culture. 
 
A mixed glia primary cell culture was stained for the expression of FAAH (A), myelin (MBP) (B) 
and GFAP (C), and DAPI nuclei stain (E). FAAH staining was observed in four different cells 
(white arrows) as identified by their nuclei. GFAP staining highlights the extended processes of 
the single astrocyte (red arrow). FAAH staining was not observed in the GFAP+ astrocyte. MBP+ 
myelin is co-localised to three FAAH+ cells indicating that these cells are mature 
oligodendrocytes. Scale bar = 11 μm 
 
The FAAH expression summary 
To further our understanding of FAAH expression in the CNS a novel polyclonal antibody 
specific for mouse FAAH was generated, purified and verified using FAAH knockout tissue. This 
novel antibody, R3B5-T showed immunoreactivity to FAAH in the hippocampus, dentate gyrus, 
cerebellar cortex, ependyma and spinal cord of the ABH mouse. An analysis of FAAH 
immunoreactivity co-localised with cellular markers in the spinal cord revealed FAAH 
expression in a subset of neuronal cells and oligodendrocytes. More specifically, the FAAH 
appears to be expressed in mature oligodendrocytes. Immunocytochemical staining of FAAH in 
vitro further supports these observations, with FAAH expression seen in myelin-producing 
oligodendrocytes. FAAH immunoreactivity was not observed in microglia in spinal cord tissue, 
or in astrocytes in spinal cord tissue or in vitro cell culture. 
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4.5 Discussion 
4.5.1. The development of a novel polyclonal antibody R3B5-T specific to 
  FAAH 
The development and characterisation of a novel polyclonal antibody that has specific 
immunoreactivity to FAAH in brain and spinal cord has been reported here. The detailed 
analysis of the different rabbit bleeds allowed the optimal antisera to be selected, and the need 
for affinity purification was identified by western blot analysis. Furthermore, verification of the 
antibody’s specificity using FAAH knockout tissue from the ABH mouse was essential to 
eliminate the antibodies from the glycine fraction due to non-specific immunoreactivity, and 
instead selecting the showing no non-specific immunoreactivity from the triethylamine 
fraction. An alternative method to remove non-specific antibodies would be to pre-absorb the 
anti-sera with CNS tissue extracts from the FAAH-knockout mouse. Antibodies non-specific to 
FAAH would be bound, with the remaining anti-FAAH antibodies eluted on a protein A/G 
column. This may have produced a higher yield of specific antibody, whereas much antibody 
was lost in the Glycine fraction from affinity purification. 
Staining with the R3B5-T polyclonal antibody has revealed a detailed analysis of the 
distribution of FAAH in the mouse CNS. This staining was consistent with the FAAH staining 
previously reported in mouse (Egertová et al., 1998, 2003; Tsou et al., 1998b) and the pattern 
of FAAH expression in rat brain (Egertová et al., 1998; Thomas et al., 1997; Tsou et al., 1998b). 
The only subtle difference was the absence of staining the Purkinjie cell dendrites in the 
cerebellum using the R3B5-T antibody, and this was probably a reflection of this novel antibody 
being a weaker antibody compared to the antibody used in the Egertová et al. (1998) study. 
FAAH staining was also observed in the ependymal cells lining the ventricles, as previously 
reported (Egertová et al., 2004; Suárez et al., 2010). In addition, the pattern of FAAH expression 
in the spinal cord was revealed for the first time, with extensive neuronal staining particularly 
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in the ventral horn, intense staining of oligodendrocytes, both the grey and white matter, and 
staining in the ependymocytes lining the central canal. 
 
4.5.2 FAAH expression is not detected in rodent astrocytes 
FAAH was reported to be expressed in astrocytes in human post-mortem tissue (Benito et 
al., 2007). This finding contrasts with observations from this study this study, using two 
different anti-FAAH antibodies, where no expression of FAAH in astrocytes in mouse spinal cord 
tissue, or in rat astrocytes in cell culture was observed. Consistent with findings from this study, 
no FAAH expression was detected by quantitative PCR or immunohistochemistry in astrocytes 
associated with the lateral ventricle in a detailed anatomical analysis FAAH expression in 
circumventricular areas of the brain in the rat (Suárez et al., 2010). There are a number of 
possible reasons for the discrepancies in FAAH detection in astrocytes. The first is the 
difference in tissue; Benito et al. (2007) analysed human tissue, and it was in pathological 
human tissue that the most striking immunoreactivity was seen. The second reason for the 
disparity may be the use of different antibodies. The polyclonal antibody used in the Benito et 
al study was generated with a C-terminal FAAH peptide (residues 561–579) from the rat 
(Romero et al., 2002; Tsou et al., 1998b). The homology between the rat and human FAAH in 
this segment is of 85%. There is the possibility that this difference in homology may cause non-
specific immunoreactivity, as was found here using the R3B5-T antibody in rat cell culture. In 
addition, the antibody was reported to have been affinity purified against the immunogenic 
peptide, in a very similar procedure to the production of the R3B5-T antibody. In our hands, 
this procedure yielded an antibody from the glycine fraction that appeared specific in CNS 
tissue. It was only in FAAH knockout tissue that non-specific immunoreactivity was detected. 
Verification on FAAH knockout tissue of the anti-FAAH antibody used in the Benito et al. (2007) 
study has not been reported to date. Confirmation of FAAH expression in astrocytes is required 
as this could have major functional implications in disease or with the treatment of FAAH 
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inhibitors. The use of additional techniques such as in situ hybridisation of CNS tissue (normal 
and disease tissue), or Western blotting of astrocyte-pure cell culture extracts is required to 
fully verify the cellular expression pattern of FAAH in the CNS. 
 
4.5.3. Functional significance of FAAH expression in the spinal cord 
The majority of FAAH expression observed in this study was neuronal. Staining is consistent 
with staining observed in dorsal root ganglia cells (co-labelled with NeuN), both in intensity, 
and in subcellular location (Lever et al., 2009). The role of FAAH expression in neurons may be 
important for endocannabinoid signalling, as degradation of anandamide by FAAH in neuronal 
cells is important to regulate the retrograde signalling of actions of this endocannabinoid in a 
localised manner, as discussed at length in the Introduction (Chapter 1 Section3.5.6). FAAH 
expression also appeared to be localised to the somata of the neurons, with very low 
expression in the dendrites (not seen with R3B5-T antibody, but previously reported by 
Egertová et al. (1998)). Since the expression is not directly localised presynaptically with CB1 
receptor, and instead highly expressed in the cytosol, this could also reflect an alternative role 
for FAAH within the cell such as lipid metabolism for processes such as maintenance of 
intracellular membranes or vesicle generation.  
The FAAH expression observed in the ependymal cells lining the central canal of the spinal 
cord has yet to be characterised functionally. FAAH could have a role in regulating FAA uptake 
from the cerebral spinal fluid (CSF), or secretion into the CSF. Oleamide, for example is elevated 
in the CSF during sleep deprivation (Cravatt et al., 1995). Anandamide levels in the CSF have 
been reported to be altered during different disease states including multiple sclerosis (Di 
Filippo et al., 2008; Jean-Gilles et al., 2009). FAAH expression in the cells controlling secretion of 
CSF and the exchange of CSF with the spinal cord tissue is critical to regulating the movement 
and actions of FAA signalling molecules.  
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The expression of FAAH in mature oligodendrocytes is an exciting observation. FAAH 
expression has also been observed in S100 positive Schwann cells in the peripheral nervous 
system (Lever et al., 2009), with a similar cytosolic pattern as observed in CNS 
oligodendrocytes. The staining observed was punctate with high intensity in the cytosol, 
indicating high expression of FAAH in oligodendrocytes. The functional role of this enzyme in 
these cells has not been determined. Fatty acid amides are not known to have a role in myelin 
synthesis directly, but FAA may have a downstream role in synthesis, or alternatively 
catabolism of lipids. Myelin is predominantly constituted of cholesterol (27.7 %) and the 
galactolipids, cerebroside and sulfatide (27.5 %). There is a significant proportion of 
ethanolamine plasmalogen (primarily ethanolamine phosphatides) that constitutes 15.6 % of 
myelin in humans (Morell and Quarles, 1999). It remains to be determined whether these pools 
of ethanolamine plasmalogen in myelin form a substrate for FAAH in the oligodendrocyte. It is 
interesting that phosphatidylethanolamine is a precursor of NAPE, which in turn is a precursor 
for AEA and thus a substrate of FAAH.  
This finding may have exciting implications related to the neuroprotective effect observed 
in the FAAH deficient mice in EAE disease (see Chapter 2). It was speculated in the discussion of 
Chapter 2 that FAAH deletion may have a developmental effect in neurogenesis. This could be 
in parallel with an alteration in the myelination of newly formed axons, or in the differentiation 
of OPCs to mature oligodendrocytes. The effect of FAAH inhibition on the differentiation of 
OPCs to mature oligodendrocytes needs to be investigated. FAAH inhibition may also have an 
effect on the major role of oligodendrocytes in affecting myelination processes, including de 
novo myelination, and the demyelination and remyelination processes in the disease state. In 
addition, the signalling effects of elevated FAAs, such as anandamide in the FAAH deficient 
mouse, may also have an effect on oligodendrocyte behaviour during development or in 
disease. However, the observation that FAAH-deficient mice may have increased free lipids in 
their liver, which is a major source for FAAH, could suggest that FAAH is important in lipid 
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metabolism and this would consistent with a high concentration of FAAH in oligodendrocytes 
as myelin is a major lipid containing structure of the nervous system (Chapter 3, Figure 4.15). 
 
Figure 4.15. Lipid deposition in the liver of FAAH-deficient mice 
 
Cryostat sections of livers were stained for neutral lipids using Oil Red O staining. 
Scale bars = 80 μm in A – C; 20 μm in D – F. This study was performed by Jia 
Newcombe and David Baker (QMUL). 
 
 
4.5.4 Future work 
It would be interesting to undertake future studies of anatomical FAAH expression with a 
focus on the changes of FAAH expression in pathology. Specifically, this could focus on 
investigating changes in expression during experimental autoimmune encephalomyelitis, the 
mouse model of multiple sclerosis. Furthermore, an analysis of sclerotic plaques in multiple 
sclerosis in both the neuronal and oligodendrocyte populations would be important to 
understand mechanisms of action if inhibition of FAAH were to be targeted therapeutically. 
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A future study on physiological roles of FAAH in oligodendrocytes would be an interesting 
avenue for investigation. The activity of FAAH may have an effect on oligodendrocytes that may 
shed light on the neuroprotective effect observed in the FAAH deficient mice during EAE 
(Chapter 2). It may also provide insight on why the pharmacological inhibition of FAAH showed 
poor efficacy in the same model of disease (Chapter 3). Further investigation of a potential role 
for FAAH in oligodendrocyte differentiation and myelination is reported in the next chapter, 
Chapter 5. 
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Chapter 5: Effects of FAAH inhibition on myelination in vitro 
5.1.1 The role of FAAH in oligodendrocytes 
The anatomical analysis of CNS tissue revealed FAAH expression in mature 
oligodendrocytes (Chapter 4). This finding may give rise to a mechanism of action for the 
neuroprotective effect observed in the FAAH deficient mouse in the EAE model (Chapter 2), as 
oligodendrocytes play a central role in EAE, with the production of the myelin sheath and 
subsequent demyelination and the loss of oligodendrocytes in disease. The neuroprotective 
effect in EAE could be driven, or partially driven, through the abolition of FAAH activity in 
oligodendrocytes. However, to date, there are no reported studies linking the metabolic 
activity of FAAH to a role in myelin metabolism. 
A role of FAAH in myelin, in particular myelin lipid, metabolism is plausible considering the 
enzymatic regulation on a range of fatty acid amide substrates and the pool of metabolites that 
are produced. A recent study examined the role of fatty acid 2-hydroxylase (FA2H), an enzyme 
critical for the production of 2-hydroxylated sphingolipids in myelin formation and function 
(Zöller et al., 2008). Examination of the FA2H deficient mouse revealed wild-type phenotypic 
behaviour and myelin formation, but only in aged animals (>18 months old) did they find 
accelerated axonal loss indicating that this impaired lipid metabolism affects axon-glial support. 
A similar finding of normal myelin with perturbed function in ageing was observed with the 
ceramide galactosyl-transferase deficient mouse (Cgt-/-) (Meixner et al., 2011). These examples 
of lipid metabolism enzymes affecting myelin function and the integrity of the ensheathed axon 
support the idea that disruption of FAAH could have a similar, albeit protective, role in a 
diseased environment. 
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5.1.2 Remyelination as a repair mechanism in EAE and MS 
In the disease state of EAE or MS, the oligodendrocytes and the myelin sheaths are the 
target of the inflammatory or neurodegenerative processes as described previously (Chapter 1, 
section 1.3). They are also the cells that can repair damage following the insult by 
remyelinating the denuded axons. This process is thought to require oligodendrocyte precursor 
cells (OPCs) to differentiate into mature myelinating oligodendrocytes (Franklin and ffrench-
Constant, 2008). It is plausible that FAAH expression may influence, or be influenced by 
oligodendrocyte differentiation as FAAH expression was only detected in CC-1-positive mature 
oligodendrocytes. 
Mature oligodendrocytes are post-mitotic and therefore do not proliferate and are not 
replaced by mature oligodendrocytes, despite being depleted during injury (Keirstead and 
Blakemore, 1999). Instead, the repair process is mediated by oligodendrocyte precursor cells 
(OPCs) located in the CNS. OPCs migrate to the site of injury, proliferate and differentiate in 
response to a demyelination. These cells can restore the myelin sheath around an axon 
(remyelination), although with a larger g-ratio (thinner sheath), and this restores saltatory 
conduction (Franklin and ffrench-Constant, 2008; Patani et al., 2007; Wolswijk, 2002b). In a 
disease setting such as MS, or EAE, the repeated demyelination injury is thought to deplete the 
endogenous pool of OPCs (Levine et al., 2001). Once this pool is exhausted, the demyelination 
persists and causes some of the clinical deficits observed in the disease (Carroll et al., 1998; 
Franklin and ffrench-Constant, 2008). A failure to remyelinate leaves the axon vulnerable to 
degeneration (Nave and Trapp, 2008). Promoting the differentiation of OPCs to mature 
oligodendrocytes is considered a viable target for therapies to promote repair in MS patients 
(Franklin and ffrench-Constant, 2008). 
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5.1.3 Differential expression of FAAH in a remyelination transcriptome 
An elegant study involving the focal demyelination of the cerebellar peduncles of the brain, 
and time point sampling of the repair process produced a remyelination transcriptome (Huang 
et al., 2011). Adult rats were demyelinated using the myelin toxin lysolecithin by stereotaxic 
injection. Following on from the induced demyelination of the axons is a spontaneous 
remyelination processes involving OPC proliferation and migration into the injured cerebellar 
peduncles, OPC differentiation into mature myelinating oligodendrocytes, and subsequent 
remyelination of the axon. The cerebellar peduncles were sampled at days 5, 14 and 28 days 
following demyelination and analysed by comparative microarray gene expression screen. This 
analysis produced a database of genes that were differentially expressed during the 
remyelination stage of repair, which was reasoned to be the period between Day 5 and Day 14. 
This analysis identified a number of candidate genes that were up-regulated, one of which 
retinoid X receptor-γ (RXR-γ) was pursued as a target to promote remyelination (Huang et al., 
2011).  
The identification of FAAH in oligodendrocytes instigated a further analysis of the data set 
and identified an up-regulation of FAAH expression at 14 day post-lesion (dpl) compared to the 
5 dpl expression. The expression differential was less than that of retinoid X receptor, but it was 
significant as assessed by mixed-model ANOVA analysis (Huang et al., 2011). Other genes of the 
cannabinoid system were also assessed including the transcripts for CB1 receptor, CB2 receptor, 
NAPE-PLD, ABHD4, ABHD6, ABHD12, DAGLα, DAGLβ and MGL with none of these cannabinoid 
genes showing any statistical difference in expression from this analysis. 
This finding of differential expression of FAAH in the remyelination process, in addition to 
the high expression in mature oligodendrocytes, gave impetus to further investigate the effect 
of FAAH activity on differentiation and myelination. 
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5.1.4 Assays to determine the influence of FAAH on myelination processes 
There are a number of different experimental avenues to explore myelination including in 
vivo rodent models, ex vivo brain slice models and in vitro cell culture systems. An in vivo 
demyelination and remyelination experiment involves the use of a neurotoxin (e.g. lysolecithin, 
ethidium bromide, or a combination of antibody and complement targeting 
galactorcerebroside), either stereotaxic injection into specific regions of the brain of gliotoxins 
or the ingestion of a systemic demyelinating toxin, such as cuprizone (van der Star et al., 
2012b). The clear advantage of using this model is the effect of the interplay of astrocytes and 
microglia in the localised environment, and the infiltration of the systemic immune system via 
the BBB can be observed in a physiological manner, and behavioural outcomes can also be 
measured. The disadvantages with this model are the inherent complexity of the processes 
described above, and the high cost of such an experiment in terms of animal welfare.  
The use of brain slice cultures allows demyelination and remyelination to occur within a 3-
dimensional structure, and is capable of monitoring how well OPCs differentiate and form de 
novo myelin sheaths around denuded axons. Maintenance of the slice cultures has been a 
technical restraint on their use for remyelination, but recent improvement now allow cultures 
to survive over 4 weeks (Jarjour et al., 2011).  
To assess myelination, it has been shown that both oligodendrocytes and neurons are 
important, with a greatly increased rate of myelin synthesis with the formation of the axon-
oligodendrocyte contact (Pfeiffer et al., 1993; Nave and Trapp, 2008). This process is regulated 
by electrical activity (Stevens et al., 2002), contact-mediated signalling (Câmara et al., 2009; 
Zonta et al., 2008) and secreted factors (Piaton et al., 2011). This is the principal reason for 
using a co-culture system combining DRGs and OPCs, instead of single OPCs, or OPCs combined 
with synthetic fibres (e.g. carbon, glass vicryl microfibers) (Jarjour et al., 2011). 
For the purposes of this study as an initial exploration of FAAH and myelination, in vitro cell 
cultures were selected for the relative technical ease of use and low impact on animal welfare. 
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Three different experiments were attempted in this chapter. The first was an attempt to 
characterise when FAAH expression was initiated during the maturation of OPCs to mature 
oligodendrocytes, and identify which sub-groups of oligodendrocyte lineage express FAAH. The 
second experiment was to see if the inhibition of FAAH has an effect on the maturation of OPCs 
to oligodendrocytes. The final experiment was to see if FAAH inhibition alters the myelination 
process in a co-culture system. 
 
 
5.2 Aims and Objectives 
Aim:  
i). To investigate the role for FAAH in oligodendrocytes using in vitro cell culture systems. 
 
Objectives: 
i). Qualitative analysis of expression of FAAH during oligodendrocyte differentiation. 
ii). Quantitative analysis of the effects of FAAH inhibition on oligodendrocyte 
differentiation. 
iii). Quantitative analysis of the effects of FAAH inhibition on myelination in a DRG-
oligodendrocyte co-culture. 
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5.3 Methods and Materials 
5.3.1 Media and solutions 
Papain 
Freshly prepared L-cysteine solution (24 mg.mL-1 in MEM/HEPES; final = 0.24 mg.mL-1). 
40 μL papain (30 U.mL-1) (Worthington, Lakewood, NJ, USA) 
10 μL L-cysteine solution (freshly prepare 24 mg/ml in MEM; final conc. = 0.24 mg.ml-1, Sigma) 
1 μL DNaseI type IV (4 mg.mL-1 in PBS then sterile filtered; final conc. = 40 μg.mL-1, Sigma) 
1 mL MEM (Invitrogen) 
Incubated at 37 °C for 10 min. to allow papain activation 
Filter sterilised papain solution through a 0.22 μm filter. 
 
DRG Media 
DMEM (Dulbecco’s Modified Eagle’s Medium, Invitrogen) 
4.5g/L glucose (Sigma) 
1% Penicillin and Streptomycin (Sigma) 
10% Foetal Bovine Serum (Invitrogen) 
100 μg / μl NGF (nerve growth factor, Abd Serotec, Düsseldorf, Germany). 
10 μM FdU (5-Fluoro-2'-deoxyuridine, Sigma) – added for first 9 days only. 
 
OPC Media 
DMEM (high glucose, Invitrogen) 
1% Penicillin and Streptomycin (Sigma) 
10% Foetal Bovine Serum (Invitrogen) 
 
OPC Proliferation Media 
Prevents differentiation with the addition of SATO and growth factors  
500 mL DMEM (high glucose, glutamine - Invitrogen) 
5 mL 100x SATO 
1% Penicillin and Streptomycin (Sigma) 
5 mL ITS supplement (conc. Sigma) 
0.5% foetal bovine serum (Invitrogen) 
10ng.ml-1 PDGF – added fresh (platelet-derived growth factor) (PeproTech, Rocky Hill, NJ, USA) 
10 ng.ml-1FGF2/bFGF - added fresh (Fibroblast Growth Factor) (PeproTech, Rocky Hill, NJ, USA) 
 
OPC Differentiation Media 
500 mL DMEM (high glucose, has glutamine - Invitrogen) 
5mL 100x SATO 
1% Penicillin and Streptomycin (Sigma) 
5 mL ITS supplement (Sigma) 
0.5% foetal bovine serum (Invitrogen) 
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Myelination medium (serum free) 
250 mL Neurobasal medium (Invitrogen) 
250 mL DMEM - high glucose (Invitrogen) 
2.5mL Glutamine (Invitrogen) 
5mL 100x SATO 
1% Penicillin and Streptomycin (Sigma) 
5 mL ITS supplement (Sigma) 
10 mL B27 (Invitrogen) Gibco 17504-044 
5 μg.ml-1 N-acetyl cysteine (Sigma) 
10 ng.ml-1 D-biotin (Sigma) 
Filter sterilise with a 0.22 μm filter.  
 
Myelination medium(low serum) 
480 ml BME 1 (Invitrogen) 
1% Penicillin and Streptomycin (Sigma) 
5 mL ITS supplement (Sigma) 
0.5% foetal bovine serum (Invitrogen) 
5mL Glutamax  
4.5 mL glucose (4.5% solution) 
0.5% Foetal Bovine Serum 
 
SATO (100x Stock) 
DMEM (Sigma) 
5000 U.ml-1 Penicillin/Streptomycin solution  
4 mM L-Glutamine (Sigma) 
16 μg.ml-1 Putrescine (Sigma) 
400 μg.ml-1 L-Thyroxine (T4, Sigma) 
400 μg.ml-1 Tri-iodothyroxine (T3, Sigma) 
60 ng.ml-1 Progesterone (Sigma) 
5 ng.ml-1 Sodium Selenite (Sigma) 
100 μg.ml-1 Bovine Serum Albumin fraction V (Sigma) 
5 μg.ml-1 Insulin (Sigma) 
50 μg.ml-1 Holo-Transferrin (human) 
 
ITS solution (Sigma) 
1.0 mg.ml-1 insulin from bovine pancreas 
0.55 mg.ml-1 human transferrin (substantially iron-free) 
0.5 μg.ml-1 sodium selenite. 
 
5.3.2 Dorsal Root Ganglion Cell Culture 
Preparation of matrigel coated coverslips 
18 mm coverslips were acid treated (incubated in 1 M HCl for 4 h to 12 h at room 
temperature), rinsed thoroughly in ultrapure H2O (MilliQ water, Merck Millipore, MA, USA) and 
soaked for 3x for 1 h. Coverslips rinsed in 70 % ethanol (immersed for few min.), transferred to 
sterile petri-dish with sterile forceps and dried. Coverslips were coated in Poly-D-Lysine (2.5 
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μg.ml-1) by adding a 0.5 ml droplet to the coverslip that forms a meniscus. The coverslips were 
washed 3 times in H2O (2 ml per well) and allowed to dry in the hood. Matrigel™ Matrix 
(Becton, Dickinson & Co., Franklin Lakes, NJ, USA) was thawed on ice and diluted 1:40 in ice 
cold sterile H2O. Diluted Matrigel™ (0.3 ml) was added to the centre of each coverslip and 
incubated at 37 °C for 2-3 h. This was very gently washed with sterile H2O and allowed to air 
dry prior to the addition of DRG cells. 
 
Dissection of rat embryo and extraction of dorsal root ganglion cells 
This culture system was performed as described (Laursen et al., 2009; Wang et al., 2007) 
with minor adaptations. The dorsal root ganglia were sourced from rat embryos. The Wistar 
rats were sourced from Biomedical Research Resources, University of Edinburgh and all work 
was carried out in accordance with the University of Edinburgh regulations under Home Office 
rules in accordance with the Animals (Scientific Procedures) Act 1986. The E15 pregnant rat 
(plug date is E0) was culled by CO2 asphyxiation. The abdomen was sprayed down with ethanol 
and the uterus dissected. The embryos were removed from the uterus and placed in cold sterile 
MEM media in a petri dish on ice. Under a dissecting microscope, the embryos were 
decapitated, and the organs and tails removed. The ventral side of the vertebrae were carefully 
severed, and the spinal cord carefully removed by pulling the rostral end. The ganglia were 
plucked off the spinal cord with fine forceps and placed in a 15 ml tube containing sterile cold 
MEM. The DRGs were pelleted by centrifugation at 500 g for 5 min. Cells were dissociated with 
incubation in 1 ml sterile filtered Papain digestion mix. DRG Media was added to the cells to 
quench papain enzymatic action. Cells were pelleted and fresh DRG media added. Cells were 
triturated (21 gauge needle) to further dissociate cells and counted in a haemocytometer.  
 
Culture of dorsal root ganglion cells 
The DRG cells were diluted to 1 x 106 cells/ml in DRG media and seeded on Matrigel™ 
coated coverslips by adding 0.2 ml per well (200,000 cells) in a single droplet in the centre of 
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the coverslip. The plate of droplets were incubated at 37 °C in 7.5 % CO2 for 24 h. 2 ml DRG 
media with added NGF was added to each well, and cells were cultured for 21 days in vitro 
(DIV).An anti-mitotic, FdU (5-Fluoro-2'-deoxyuridine, Sigma),was added to cultures to remove 
contaminating cells. The cultures were pulsed 3 times for 48 h with 10 μM FdU at 1, 4 and 7 DIV 
after seeding. 
 
5.3.3 Oligodendrocyte precursor cell culture 
Dissection of neonatal rat brain and extraction of oligodendrocyte precursor cells 
This culture system was performed as originally described (McCarthy and de Vellis, 1980; 
Syed et al., 2008) with minor adaptations. Neonatal rats (P0-P2) were sourced from Biomedical 
Research Resources, University of Edinburgh. The rats were culled by CO2 asphyxiation. The 
animals were sprayed with ethanol and all dissections were done in a primary culture 
dissection hood. The brain was dissected from the skull and transferred to cold sterile MEM in a 
petri dish. The olfactory bulb was removed and discarded. The cerebral cortices (Figure 5.1.) 
were removed and placed in cold sterile MEM. The meninges were removed with fine forceps 
under a dissecting microscope. To dissociate the cells, the cortices were minced using fine 
scissors and incubated with sterile papain digestion mixture for 1 h at 37 °C. Cells were diluted 
in 10 mL OPC medium and pelleted by centrifugation at 500 g for 5 min. Pelleted cells were 
gently triturated 10 times with a 21 gauge needle. Cells were re-suspended in OPC media at a 
concentration of 75,000 cells / ml. Cells were seeded into PDL coated T75 flasks (Falcon, BD 
Biosciences, NJ, USA) and cultured for 11 days with the medium changed every 3 days at 37 °C 
in 7.5 % CO2. The cell culture forms a monolayer of astrocytes to which the OPCs and microglia 
are loosely attached (“mixed glial culture”). These cell types can be mechanically separated by 
shaking. The flasks were agitated on 37 °C heated orbital shaker for 1 hour at 250 rpm. The 
medium was aspirated and discarded, and replaced with 10 ml fresh OPC medium. This step 
removes the loosely adherent microglia. The flasks were returned to the shaker and further 
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agitated for 18 h. The medium was removed and decanted into 10 cm bacteriologic plastic petri 
dishes (VWR) and incubated at 37 °C for 25 min. This shake off contains OPCs and the 
remaining microglia. The microglia rapidly attach to the bacteriologic plastic, whereas the OPCs 
do not easily attach. Media was collected from the petri dishes, and pelleted by centrifugation 
at 500 g for 5 min. Cells were re-suspended in OPC proliferation media and seeded at a density 
of 50,000 to 100,000 cells per ml onto PDL coated T75 flask. This technique produces a 
population of oligodendrocyte precursors cells of which ~95% will differentiate into 
oligodendrocytes (Milner and ffrench-Constant, 1994) 
 
Figure 5.1. Schematic of rodent brain dissection.  
 
 
 
 
 
 
 
 
 
 
 
The schematic shows A) the dorsal aspect and B) the ventral aspect with the mid-
brain cortices highlighted in orange. This diagram was reproduced with the kind 
permission of Dr. Marie Bechler, University of Edinburgh, UK. 
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5.3.4 Differentiation of oligodendrocyte precursor cells 
OPCs were generated as described above, and were detached from the flask with Accutase 
(Innovative Cell Technologies, CA, USA) with a 5 min. incubation at 37 °C. Cells were re-
suspended in OPC differentiation media, triturated in a 21 gauge needle and counted in a 
haemocytometer. Cells were re-suspended in OPC differentiation media and seeded at a 
density of 75,000 cells per PDL-coated coverslip. Media was changed every 3 DIV, or until the 
cells were fixed for immunocytochemical staining. 
 
5.3.5 Myelination co-cultures 
The DRGs cultures were changed into myelination medium containing NGF (100 μg.ml-1). 
OPCs, generated as described above, were detached from the flask with Accutase with 5 min. 
incubation at 37 °C. Cells were re-suspended in myelination media, triturated with a 21 gauge 
needle and counted in a haemocytometer. Cells were re-suspended in myelination media plus 
NGF and seeded at a density of 75,000 cells per coverslip containing DRGs. Co-cultures were 
incubated at 37 °C in 7.5 % CO2.Co-cultures were cultured up to 28 days, with the media 
changed every 2 to 3 days. NGF was required till the DRG cells were 21 days old. 
 
5.3.6 Treatment of co-cultures and differentiation cultures with PF-3845 
The FAAH inhibitor compound, PF-3845 (Tocris Bioscience, Bristol, UK) was dissolved in 
dimethylsulfoxide (DMSO, Thermo Fischer) at a maximum concentration of 100 μM for toxicity 
testing, and 10 μM for treatment of cells. The compound dissolved easily in warm (37 °C) 
DMSO, with mild agitation. The dissolved compound was added drop wise directly to the wells 
containing cultures every 24 h. For lower concentration treatments, the 10 μM PF-3845 was 
further diluted in MEM.  
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5.3.7 Immunocytochemistry 
Table 5.1. Primary and secondary antibodies used in immunocytochemistry 
________________________________________________________________________ 
Primary Antibodies 
Antigen   Species  Manufacturer Cat. No. Dilution 
________________________________________________________________________ 
MBP   Rat  AbD Serotec MCA409S 1:250 
NG2   Rabbit  Millipore AB5320  1:100 
NfH   Chicken  Covance PCK-592P 1:100 
FAAH   Rabbit  Gift from Ben Cravatt  1:100 
________________________________________________________________________ 
Secondary Antibodies 
Antigen   Tag   Species  Manufacturer Dilution 
________________________________________________________________________ 
Anti-Rabbit  Alexa Fluor 594  Goat  Invitrogen 1:1000 
Anti-Rat  Alexa Fluor 488  Goat  Invitrogen 1:1000 
Anti-Chicken  Alexa Fluor 488  Goat  Invitrogen 1:1000 
Anti-Rat  Alexa Fluor 555  Goat  Invitrogen 1:1000 
Anti-Rabbit  Alexa Fluor 647 Donkey  Invitrogen 1:1000 
________________________________________________________________________ 
 
 
Primary oligodendrocyte cultures and co-cultures were fixed in freshly prepared 4 % 
paraformaldehyde (Sigma) in phosphate-buffered solution (PBS) for 15 min. The coverslips 
containing the cells were permeabilised with PBS containing 0.1 % Triton X-100 for 15 min. The 
coverslips were incubated with primary antibody for 1 h at room temp. and then washed 3 
times in PBS. The coverslips were incubated in secondary antibody for 1 h at room temp., and 
then washed 3 times in PBS. The coverslips were incubated in Hoechst stain (4 mg/mL, Sigma) 
for 5 min., followed by a 3 washes in PBS. The coverslips were mounted in Fluoromount G 
(eBioscience, CA, USA), and dried for 24 h at room temp. in darkness, and then stored at 4 °C.  
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5.3.8 Analysis of assays and microscopy 
FAAH expression during differentiation of OPCs to oligodendrocytes 
OPC differentiation cell cultures were grown for Days 1 – 4 to ensure all stages of 
differentiation were captured. The differentiation status of each cell culture (coverslip with 
cells) was detailed as described above. OPC maturation and production of myelin is increased 
by the contact with other cells. Therefore, a quantitative analysis requires singular cells 
(exclusion of clumped cells > 2 nuclei), and due to the proliferative nature of the cultures 
(despite the removal of some of fibroblast and platelet-derived growth factors (FGF2 and PDGF) 
from the culture medium), this was only possibly within 48 h of culture. At this time point there 
was an inadequate level of mature MBP+ oligodendrocytes and low FAAH expression 
throughout the culture to precisely measure the correlation of FAAH expression with 
maturation. Therefore, a high magnification qualitative analysis was performed identifying co-
localisation of FAAH-immunoreactivity with the oligodendrocyte markers NG2 and MBP.  
 
Quantitative analysis of differentiation of OPCs by confocal microscopy 
The purified OPC cultures were analysed by immuno-staining for the markers NG2 
representing OPCs and mature oligodendrocytes, and MBP representing mature myelin-
producing oligodendrocytes. Images were captured by moving the field of view horizontally and 
vertically by 2 mm across the slide, with 15 field of view images captured per slide. Exposure 
and gain settings were consistent between each image, and the Autofocus function was 
enabled with the criteria of maximum contrast of NG2 staining in channel 1. These images were 
captured and analysed in a blinded manner (treatment condition was hidden from microscopy 
operator and during analysis). Images were analysed using ImageJ (Schneider et al., 2012), with 
separate channels transformed into a binary mask using the same intensity threshold value for 
each channel to exclude background values. The percentage area occupied by MBP per NG2 
area was calculated automatically for each individual image, with values detailed as mean ± 
S.E.M, and statistical analysis using a Student’s t-test. 
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Quantitative analysis of myelination in a co-culture system using fluorescence wide-field 
microscopy 
Oligodendrocytes were identified by MBP staining and neurites were identified by 
neurofilament heavy (NfH) staining, as described in the immunocytochemical protocol above. 
The neurite density affects the amount of myelination. Therefore, the density of neurites was 
qualitatively assessed to ensure the neurites were not overly dense (this usually prohibits clear 
identification of individual oligodendrocytes), or single neurites as this reduces the propensity 
to myelinate (Barateiro et al., 2012). These qualitative parameters are shown in the 
representative images displayed in Figure 5.3 (A-C). 
Oligodendrocytes were identified by MBP staining, and only oligodendrocytes attached to 
neurites were assessed. The myelination status of each oligodendrocyte was manually 
characterised based on morphology and staining as described previously (Huang et al., 2011; 
Barateiro et al., 2012): Stage 1 ‘Contacting’: MBP+ oligodendrocyte-neurite contact; Stage 2 
‘Extending’: MBP+ oligodendrocyte membrane extension along neurites; Stage 3 ‘Wrapping’: 
MBP+ membrane forming a myelin sheath around a neurite. The percentage of MBP+ 
oligodendrocytes categorised by each stage of morphology was compared between each 
treatment condition. Co-cultures were grown for 6 days (Day 0 = OPCs added to DRGs) 
following an optimisation experiment that included analysis for 3, 6, 9 and 12 days. Data was 
pooled for each repeat and displayed as mean ± S.E.M. with statistical significance determined 
using a Student’s t-test. Immunocytochemical analysis and image capture were performed 
using either wide-field microscopy with a Leica DMRA2 compound microscope (Leica, Nussloch, 
Germany) and Volocity 6.1.1 software (PerkinElmer), or using laser scanning confocal 
microscopy (TCS MP5, Leica SPE, Leica Microsystems, Cambridge, England, UK) using LAS 2.6.0 
(Leica Application Suite, Leica). 
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5.4 Results 
The results in this chapter describe the expression of FAAH in an oligodendrocyte 
differentiation culture, investigate the effect of a FAAH inhibitor treatment on the 
differentiation of OPCs to myelin-producing oligodendrocytes and examine the effect of a FAAH 
inhibitor treatment on the myelination process in DRG-oligodendrocyte co-cultures. 
 
5.4.1 Expression of FAAH in the differentiation of oligodendrocytes 
FAAH expression was identified in Olig2-positive and CC-1-positive mature 
oligodendrocytes in spinal cord tissue. To further investigate the expression of FAAH in 
oligodendrocytes during the differentiation and maturation of OPCs to myelinating 
oligodendrocytes, FAAH was qualitatively assessed in OPC differentiation cultures. High 
magnification images of purified OPCs cultured in differentiation media for 72 h showed FAAH 
expression at low levels in the cytosol of cells expressing NG2, but negative for MBP staining. In 
cells expressing MBP, and showing morphology of myelin sheets, there was a high level of 
FAAH expression with punctate staining in the cytosol. This qualitative analysis shows 
agreement with the results observed in spinal cord tissue, and suggests that FAAH expression 
substantially increases with the expression of MBP and thus the production of myelin.  
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Figure 5.2. FAAH is expressed in OPCs and oligodendrocytes  
 
Purified OPCs were cultured in differentiation media for 72 h. Qualitative analysis of cultures 
were immuno-labelled with anti-FAAH (cyan) and anti-MBP (magenta), anti-NG2 (yellow) and 
nuclei stained with Hoechst (blue) shows low expression of FAAH in MBP- NG2+ cells (red 
arrows), and high expression in MBP+ NG2+ cells (white arrows). (n = 4 rats). Scale bar =15 μm. 
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5.4.2 Inhibition of FAAH increases OPC differentiation in culture 
To determine whether FAAH inhibition effects the differentiation of OPCs, cultures were 
treated with 0.1 μM or 1 μM of PF-3845 (a selective FAAH inhibitor), or as controls DMSO 
(vehicle) or media only (untreated). Treatment was administered every 24 h, and after 72 h 
growth in differentiation medium, cultures were fixed and immuno-stained as described 
previously. Quantification of the MBP-positive staining as a percentage of the NG2-positive 
staining showed a significant (P < 0.05 - 0.01) increase in mature myelin formation in the 
cultures treated with FAAH inhibitor, when compared to the DMSO (vehicle) control (Figure 
5.3). This marked increase was in a dose-dependent manner, with 1 μM PF-3845 treatment 
inducing a greater production of MBP-positive myelin compared to the 0.1 μM PF-3845 dose. 
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Figure 5.3. Inhibition of FAAH increases oligodendrocyte differentiation. 
 
Purified OPCs were cultured for 72 h in differentiation media and treated with (A) media only, 
(B) DMSO, (C) 0.1 μm PF-3845 and (D) 1 μM PF-3845. Cultures were immuno-labelled with anti-
NG2 (yellow) and anti-MBP (magenta) and nuclei stained with Hoechst (blue). Scale bar =30 
μm. (E) Cells treated with 0.1 μM and 1 μM PF-3845 showed an increase in the percentage of 
MBP+ / NG2+ staining compared to media only and DMSO controls (n = 2 rats). Mean ± S.E.M. 
are shown (*P< 0.05, **P< 0.01; Student’s t-test.). 
E 
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5.4.3 Inhibition of FAAH shows no effect on myelination in a DRG-
oligodendrocyte co-culture. 
The observation that FAAH inhibition increased differentiation of OPCs in purified OPC 
cultures indicates that FAAH activity may have a role in promoting myelination. To investigate 
this question, DRG-oligodendrocyte co-cultures were treated from Day 1 (following addition of 
OPCs) with the FAAH inhibitor PF-3845 at 0.1 μM and 1 μM concentrations. Control cultures 
were treated with DMSO (vehicle control) and media only (untreated control). The degree of 
myelination was quantified using an established morphological classification of myelination 
(Jarjour et al., 2011; Zhang et al., 2011), with MBP+ oligodendrocytes making i) axon contact 
(Contacting), ii) oligodendrocyte membrane extension along axon (Extending), or iii) myelin 
wrapping around an axon (Wrapping) (See Figure 5.4). The treatment of the cultures with 1 μM 
PF-3845 resulted in no difference in the percentage of wrapping, extending or contacting 
compared to either of the control cultures. It should be noted that the number of 
oligodendrocytes in the 1 μM PF-3845 treated cultures were substantially lower than the other 
cultures, with 126 ± 4 (mean ± S.E.M.) oligodendrocytes per culture (coverslip), whereas a 
minimum of 200 oligodendrocytes were counted in the other three treatment conditions.  
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Figure 5.4. Inhibition of FAAH has no effect on myelination. 
 
 
DRG-Oligodendrocyte co-cultures were cultured for 6 d after addition of OPCs and immuno-
labelled with anti-NfH (red) and anti-MBP (green) and nuclei stained with Hoechst (blue). (A-C) 
Representative images of DRG and OPC co-culture showing the morphological criteria for 
assessing myelination (A) contacting, (B) extending, and (C) wrapping. Scale bar = 15 μM. (E) 
Treatment with PF-3845 resulted in no significant changes in myelination compared to controls 
(n = 4 rats). Mean ± S.E.M. are shown. 
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5.5 Discussion 
5.5.1 Differential expression of FAAH in OPCs to oligodendrocytes 
In the developing brain, the maturation of oligodendrocytes from OPCs, the generation of 
new myelin and myelination of axons is precisely coordinated in a specific window of 
development (Emery, 2010). The expression of FAAH was detected at low levels in NG2-positive 
progenitor cells which was not observed in spinal cord tissue, and at high levels in mature 
oligodendrocytes, which supports the findings observed in spinal cord tissue (Chapter 4). This 
up-regulation of FAAH expression appears to be co-ordinated with the change in the 
maturation of the cell. The role of this up-regulation during the differentiation process is still 
unclear. 
 
5.5.2 The differentiation of OPCs is increased with the inhibition of FAAH 
The treatment of differentiating OPCs in culture with the FAAH inhibitor PF-3845 caused an 
increase in differentiation, with a relative increase in the production of MBP-positive myelin. 
The data in this study suggests that inhibition of FAAH may increase the differentiation of OPCs. 
It is possible that this increased rate of differentiation exists in the CNS of FAAH deficient mice. 
The consequences of this are unknown, but may alter the myelination in the CNS in such a way 
that is more resilient during a demyelination disease insult. To further investigate these 
observations, one needs to consider whether this neuroprotective effect is due to a more 
robust de novo myelination, or whether the FAAH deficient animals are capable of a more rapid 
differentiation and repair, with this in vitro data suggesting the latter. Furthermore, the 
influence of FAAH inhibition on OPC proliferation and migration also need to be determined, 
and this may be best achieved with the use of a brain slice culture assay (Zhang et al., 2011). 
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5.5.3 The myelination process is unaffected by the inhibition of FAAH 
Treatment of the in vitro DRG-oligodendrocyte co-culture with the FAAH inhibitor, PF-3845, 
showed no significant change in myelination. However, two general observations were made: 
the first was that the cultures treated with higher dose (1 μM) of drug had a low number of 
oligodendrocytes. This may be indicative of toxicity from the compound affecting the viability 
of the oligodendrocytes in the myelination environment (myelination media), as this effect of 
reduced oligodendrocytes was observed in 4 separate studies (n = 4 rats). The second 
observation was the shift in the proportion of oligodendrocytes from contacting to more 
oligodendrocytes extending and wrapping in the lower dose (0.1 μM) drug treatment. Although 
this was statistically insignificant, one could speculate that an affect may be observed if 
conditions and dosing were further optimised. This co-culture system is an assay for de novo 
myelination, and there is a possibility that FAAH inhibition may have more influence on a 
remyelination process. This is suggestive by both the remyelination transcriptome showing an 
altered expressed of FAAH and the influence FAAH inhibition has on differentiation.  
 
5.5.4 Immunocytochemical staining of FAAH in primary rat cell cultures 
The rat OPCs were originally stained using the anti-FAAH antibody (R3B5-T) produced in-
house. However to our surprise, the staining was non-specific. The antibody stained the nuclei 
of all the OPCs and contaminating cells (astrocytes and fibroblasts), and did not stain the 
cytoplasm of the mature oligodendrocytes as observed in mouse spinal cord tissue. There were 
two probable causes for the non-specific binding. The first is that the antibody had degraded 
since defrosting the aliquot of rabbit antisera and affinity purification. This was performed 
some 15 months prior to this staining, and the purified antisera were stored at 4 °C. The other 
possible cause was the specificity of the antibody. The immunogen was a mouse C-terminal 
FAAH peptide, whereas the anti-FAAH antibody from the Cravatt laboratory was raised against 
a rat polypeptide. Within the 20 amino acid peptide, there are 3 amino acid differences 
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between mouse and rat. It is therefore possible that the anti-FAAH antibody produced in-house 
is non-specific for rat FAAH, as was the antigen target in the rat primary cell cultures. 
 
5.5.5 Advantages and limitations of the in vitro myelination assay 
The simplicity of these in vitro culture systems makes manipulation relatively easy. The 
administration of PF-3845 was simple, and the effects were relatively straightforward to 
interpret. This is because of the lack of confounding variables that one would have to consider 
in an in vivo or ex vivo model. This technique, although time consuming, uses few animals 
compared to other relevant techniques. 
Although the simplicity of the myelination assay is the key advantage, it also raises 
questions about the physiological relevance of excluding other cells that influence the process. 
Astrocytes were deliberately excluded from the assay, although small numbers are indeed 
present due the imperfect shake off method. Astrocytes are proposed to play an important role 
in remyelination (Barnett and Linington, 2012), the therefore the impact of these cells needs to 
be considered. . Furthermore, in the context of cannabinoids and remyelination, the role of 
astrocytes needs to be investigated as astrocytes were shown to express the CB1 receptor, and 
these receptors were activated by endocannabinoids secreted from neurons in a hippocampal 
slice culture model (Navarrete and Araque, 2008, 2010). Endocannabinoids were shown to 
modulate neuronal activity with synaptic inhibitory effects at short range. In astrocytes, these 
same synaptic inhibitory effects were transmitted to adjacent neurons at a longer range. 
Inhibition of FAAH in oligodendrocytes and neurons would elevate and prolong the messenger 
effects of anandamide, and this could affect the long range synaptic signalling mediated by 
astrocytes, and thus cause alterations in myelination process. 
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5.5.6 Future Experiments 
Verification of differential expression of FAAH in remyelination transcriptome 
The microarray data generated from the remyelination transcriptome would need to be 
further validated using more specific techniques such at quantitative PCR. 
 
Inhibition of FAAH specifically in oligodendrocytes in the co-culture assay 
In the co-culture experiments described, the treatment with PF-3845 inhibits FAAH in both 
the neuron and the oligodendrocyte, whereas the genetic disruption of FAAH in the co-culture 
system would model the in vivo FAAH knockout EAE data more accurately. This would provide a 
number of advantages. Firstly, this would better compare with the in vivo data generated with 
the FAAH deficient mouse in EAE as deletion of the gene has the potential to alter the 
developmental pathway of the OPCs and oligodendrocytes, and this could account for 
differences between the FAAH knockout and FAAH inhibitor EAE studies. In addition, the 
simplicity of this in vitro system would allow only the OPCs to be manipulated by using the 
ABH.FAAH-/- mice as the source of OPCs. This would define whether the effects observed in a 
myelination co-culture were due to FAAH inhibition of the OPCs specifically. Unfortunately, the 
technical aspects of culturing mouse OPCs is challenging as the cells do not proliferate in the 
same manner as OPCs from a rat. They only do so under excessive conditions containing high 
foetal calf serum (25 %) and for a maximum of 3 passages (personal communications Dr. 
Bechler, Dr. Zhang, University of Edinburgh). In addition, to produce cultures similar to the rat 
co-cultures requires a much higher number of mouse pups (>35 pups) to get a similar number 
of OPCs. However, genetic manipulation may also be possible by using siRNA silencing of 
purified rat OPCs. One could silence FAAH in a pre-conditioning experiment prior to adding the 
cells to the co-culture system. This would dissect whether the effects observed were 
oligodendrocyte FAAH-specific, or a combination of FAAH inhibition in both neurons and 
oligodendrocytes. 
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Further experiments would also include the use of an ex vivo cerebellum slice culture, 
where demyelination is induced, the slice cultures treated with FAAH inhibitor and the 
remyelination monitored. This assessment could include monitoring changes in OPC 
proliferation and migration to the site of injury, differentiation and mature oligodendrocytes 
forming myelin sheaths on denude axons. This model would provide a more phenotypic 
environment to assess the influence of FAAH activity (or lack thereof) on remyelination 
processes.  
Furthermore, in vitro and ex vivo culture systems would also provide the opportunity to 
treated with anandamide, or other substrates of FAAH, to investigate whether this signalling 
molecule is causative of the actions observed in the differentiation assay.  
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Chapter 6: Discussion and Conclusions 
6.1 Overview 
People with MS are in need for therapeutics to reduce neurodegenerative pathology. Novel 
targets and innovative therapeutic strategies are urgently required for SPMS and PPMS. The 
multiplicity of action of exogenous cannabinoids (Δ9-THC and cannabidiol) currently provides 
symptomatic relief for pain and spasticity(Baker et al., 2000; Kavia et al., 2010), and has the 
potential to reduce neurodegeneration and thus slow progressive MS (Pryce et al., 2003; 
Croxford et al., 2008). 
The innovative strategy of inhibiting FAAH to elevate anandamide as an endogenous 
agonist of the CB1 receptor has been demonstrated to be safe and relatively free of side effects 
in clinical trials (Huggins et al., 2012). Evidence has also suggested that FAAH inhibition can be 
used to relieve pain (Ahn et al., 2009b) and spasticity (Pryce et al., 2013) in disease models. It 
was the goal of this research to disrupt FAAH activity as a strategy to investigate the 
therapeutic potential of elevated anandamide as a neuroprotective therapy. 
 
Aim one: To investigate FAAH as a potential therapeutic for progressive MS by investigating 
the effect of FAAH-knockout on disease development in an EAE model. 
The first aim of this research was to investigate the effect of FAAH deficiency in an EAE 
model. FAAH deficiency was shown to have elevated anandamide levels in the CNS and showed 
a neuroprotective effect in a monophasic EAE disease (C57BL/6.FAAH-/-) and in a chronic 
relapsing EAE disease (ABH.FAAH-/-). Three salient findings from this data were that i) FAAH 
deficient mice had no significant effect on the lymphoid cell-driven immune processes of EAE 
disease; ii) FAAH deficient mice were slower to recover from the acute phase of EAE; and iii) 
FAAH deficiency improved the recovery from the relapse phase of CREAE disease with 
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improved clinical behaviour, motor control and less degeneration of nerves in the spinal cord in 
a phase of the disease model with substantial neurodegeneration.  
 
Aim two: To investigate FAAH as a potential therapeutic for progressive MS by investigating 
the effect of a FAAH inhibitor on disease development in a chronic relapsing EAE model. 
These findings promoted a more translation approach to target FAAH disruption in 
neurodegenerative model. The selective FAAH inhibitor PF-3845 was used to treat mice 
induced with CREAE disease. Despite the treatment inducing an elevation in anandamide levels, 
no improvement in neurological disease recovery was observed, although there was a small 
inhibitory effect on the amount of nerve loss. It was clear that the currently used FAAH 
inhibitor did not produce the level of augmentation of anandamide levels as found with genetic 
deletion. Further studies would require higher doses of compounds with more frequent 
administration. Unfortunately the FAAH inhibitors used in humans with longer half-lives were 
not available for study. 
 
Aim three: To identify cell types that express FAAH expression in the mouse CNS to provide a 
neuroanatomical basis for interpretation of effects of FAAH knockout and FAAH inhibition in 
mice 
We sort to develop a specific antibody to characterise the tissue distribution and cellular 
expression in the CNS. A specific polyclonal antibody was produced, with FAAH expression 
observed in the hippocampus, dentate gyrus, cerebellum, spinal cord, and ependymal cells. 
This work led to the characterisation of FAAH expression in a subset of neurons and mature 
oligodendrocytes in the spinal cord. The functional role of FAAH in oligodendrocytes is 
unknown, yet these cells are central to the pathogenesis of EAE and MS disease.  
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Aim four: To investigate the effects of FAAH inhibition on in an in vitro model of 
oligodendrocyte differentiation and myelination. 
Data from the remyelination transcriptome showed an up-regulation of FAAH expression in the 
remyelination process. This data, combined with high FAAH expression observed in mature 
oligodendrocytes led to an alternative theory, suggesting that FAAH modulates 
oligodendrocyte myelination. The OPC differentiation studies suggest that FAAH is expressed at 
low levels in OPCs, and high levels in mature oligodendrocytes. Furthermore, inhibition of FAAH 
increases the differentiation of OPCs to mature oligodendrocytes in culture, suggestive of FAAH 
activity influencing the change in cell maturation. The differentiation of OPCs to 
oligodendrocytes is a critical step in the remyelination process, and a promising therapeutic 
target for the repair of demyelinated axons in MS. Data also suggested that FAAH does not 
influence de novo myelination of neurites in co-culture.  
 
6.2 Discussion 
The results presented in this study suggest an alternative functional role of FAAH. 
Disruption of FAAH by genetic deletion or pharmacologically causes a substantial elevation of 
anandamide in the CNS in vivo. The original premise proposed that FAAH inhibition and 
consequential elevation of anandamide would infer neuroprotection in a disease state. This 
was proposed to be mediated by activation of the CB1 receptor causing tonic inhibition of Ca2+ 
channels, reducing the release of neurotransmitter from the synapse, and thus reducing the 
excessive stimulation and excitotoxic events. Support for this mechanism of action was 
observed in the CREAE model where a neuroprotective effect was observed in mice deficient of 
FAAH following severe neurological insult in the relapse phase of CREAE. However, in the acute 
phase of this disease the FAAH deficient mice fared worse than the wild-type mice, and in 
addition no substantial effect in neuroprotection was observed in wild-type mice treated with a 
potent FAAH inhibitor during the latter stages of disease. These two latter findings suggest that 
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FAAH inhibition as a treatment strategy is more complex than the proposed CB1 receptor-
mediated pathway reducing excitotoxicity. Furthermore, an in depth analysis of FAAH 
expression in the CNS revealed cytoplasmic localisation in neurons and in mature 
oligodendrocytes. One would expect expression of FAAH in the pre-synaptic axon terminals if 
the primary function of FAAH was to regulate the levels of anandamide in retrograde signalling 
pathway. Instead, FAAH expression has been observed post-synaptically in the dendritic spine; 
a localisation that is counter-intuitive to retrograde signalling particularly when compared to 
the pre-synaptic localisation of MGL in the 2-AG signalling pathway, although the anatomical 
pattern does show FAAH to be positioned in a complementary localisation to the CB1 receptor 
throughout the brain (Egertová et al., 1998). Anandamide, like FAAH, also has a somewhat 
mysterious function that has not yet been fully characterised. The role of this lipid in retrograde 
signalling is also questionable as the only convincing evidence is the agonistic binding and 
activation of CB1 receptor in a pharmacological model. The full characterisation of biosynthesis 
of anandamide and the mobility of this lipid within or between cells are yet to be elucidated 
and these processes may shed some light of the functional role of anandamide. 
The prominent expression in the cytoplasm does raise questions about the role of FAAH in 
this location. It is probable that FAAH would have roles in addition to anandamide degradation. 
Speculatively speaking, FAAH may have a role in fatty acid metabolism in both neurons and 
mature oligodendrocytes such as in vesicle formation or maintenance of intracellular 
membranes. The expression in oligodendrocytes was further explored in vitro, showing very 
low level expression in OPCs, with a substantial increase in expression just prior to maturation 
and the production of myelin sheaths. Pharmacological inhibition of FAAH appeared to 
promote this maturation step, suggestive of FAAH activity being required during the late 
differentiation phase. A key future experiment would be a detailed analysis of the 
oligodendrocytes and myelin in FAAH deficient mice to investigate whether FAAH deficiency 
causes a shift in the population of OPCs relative to population of mature oligodendrocytes, or 
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whether the myelin structure itself is comparable to that of a wild-type mouse. Since no overt 
behavioural phenotype exists in these mice the differences in oligodendrocytes and myelin may 
be subtle, but may be accentuated during development (breeding of ABH.FAAH-/- mice is 
problematic), disease (as we observed in the EAE experiments) or in ageing.  
Complete disruption of the FAAH enzyme is likely to have negative effects on the animals, 
yet little has been reported to suggest such adverse effects. As was observed in the acute 
phase of disease, the FAAH deficient mice were slower to recover than the wild-type animals 
indicating some susceptibility in the phenotype. The accumulation of fatty acid deposits in the 
liver also requires further investigation as it indicates disrupted metabolism of fatty acids, 
particularly interesting as the highest expression of FAAH in the body is observed in the liver. 
This discussion concludes that FAAH may have multiple roles in addition to anandamide 
degradation. The purpose of this research was to investigate the therapeutic potential of FAAH 
inhibition for the treatment of progressive MS. Although a translatable role of FAAH inhibition 
is not immediately apparent following the negative results of the PF-3845 treatment in the 
CREAE model, two intriguing lines of enquiry could still be pursued. The first is to understand 
the neuroprotective effect observed in the FAAH deficient mice following CREAE disease model. 
A detailed immunohistopathological analysis of the diseased tissue in the FAAH deficient mice 
compared to diseased wild-type and to naïve tissue would be a key experiment. The second 
future aim would be to investigate the function in oligodendrocytes to see if FAAH inhibition 
can promote OPC differentiation and increase remyelination in a more sophisticated model 
such as ex vivo brain slice cultures or in an in vivo remyelination model. Both the 
neuroprotective effect and the novel role in OPC differentiation following disruption of FAAH 
are relevant to therapeutics in progressive MS. 
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6.3 Conclusion 
The inhibition of FAAH has some promise as a therapeutic strategy for MS, although much 
research is still required to understand the neuroprotective effect in FAAH deficient mice 
compared to the lack of effect observed in the FAAH inhibitor treated mice. As described 
previously evidence suggests that FAAH inhibition can be used to relieve pain (Ahn et al., 
2009b) and spasticity (Pryce et al., 2013), can be neuroprotective in an EAE disease model 
(Chapter 2) and may potentially be promote differentiation as remyelination target (Chapter 5). 
However, translation of these findings can be challenging, as was demonstrated in the lack of a 
marked effect observed in the PF-3845 treated EAE mice, and in addition, the FAAH inhibitor 
PF-04457845 showed no efficacy in the treatment of pain in clinical trials. Improvement of 
disease models is constantly required to further understand the mechanisms of action of 
potential therapies. In this research, the data has shown that FAAH inhibition is a target for 
neuroprotection, although not as attractive and translatable as originally proposed. Further 
research investigating neuroprotection, and potentially remyelination could one day provide a 
multi-modal mechanism of action that may be therapeutically useful for treatment of MS. 
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